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Abstract 
 
Airway mucus protects and maintains the health of the respiratory tract. Its production 
is orchestrated by environmental cues, thus inter-individual variation in mucus 
composition, quantity and rheology is likely to confer differences in disease 
susceptibility and response, and may also result in environmental specific suitability. 
 
Glycoproteins known as mucins are considered to be the major components of mucus. 
This project is concerned with the large secreted airway mucins that are encoded by 
MUC5AC and MUC5B, with the overall aim being to study their genetic variation in 
relation to disease and demography.  
 
Using a single base extension genotyping method, this project reports for the first time, 
significant associations between five dependent allergy related respiratory outcomes, 
including asthma, and a single nucleotide polymorphism of MUC5AC in a European 
longitudinal cohort. The cause of these associations could not however be refined and 
therefore further characterisation of the MUC5AC gene is essential for understanding 
the relationship between allergic airways and MUC5AC. 
 
Variants of the MUC5B gene have also been explored in relation to asthma. Variation of 
the MUC5B upstream promoter region has been characterised in two asthmatic disease 
case-control cohorts by Sanger sequencing. Statistically significant associations are 
reported here between regulatory variants of MUC5B, whereby the ‘high’ expressing 
promoter haplotype is significantly underrepresented in a sample set of severe asthmatic 
cases as compared to their controls.  
 
To further characterise variation within these genes, the MUC5B promoter has also been 
sequenced in a sample set of eight African populations and the patterns of regulatory 
diversity have been examined in relation to population differentiation, geographic 
demarcation and species conservation profiles. We show here for the first time, a 
statistically significant overrepresentation of the ‘high’ expressing promoter haplotype 
 12 
in a collection of the Anuak peoples of Ethiopia as compared to four other Ethiopian 
sample sets of differing Ethnicity. 
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1 General Introduction 
 
This thesis is about variation within genes encoding highly glycosylated proteins known 
as mucins, which are expressed at the interface between body and the environment. The 
main focus of this general introductory section will be on mucin characterisation, 
assembly and function, with special emphasis on the large secreted respiratory mucins, 
MUC5AC and MUC5B. The potential role mucins play in inflammatory airway disease 
will also be explored and mucin gene association studies will be reviewed. Please note 
that more detailed background information is supplied at the beginning of each chapter. 
 
It is however important to firstly discuss the vast resources available to geneticists and 
start here by describing the successful completion of the human genome sequence and 
the current state of knowledge on the frequency of genetic variation.  
 
 
1.1 The Human Genome 
 
“The human genome holds an extraordinary trove of information about human 
development, physiology, medicine and evolution”  Lander 2001- Nature 
  
After a competitive race between the $3 billion government-funded project 
(international human genome sequencing consortium- IHGSC) and the privately funded 
Celera consortium project headed by Craig Venter, a rough draft of the human genome 
was announced in 2000 and published in 2001 (Lander et al. 2001; Venter et al. 2001). 
Both drafts were consensus human genome sequences composed of multiple individuals 
and were ‘completed’ in 2003. While most of the human genome has largely been read, 
gaps scatter the sequence and highly repetitive regions such as the centromeres and 
telomeres remain unsequenced or incomplete. It is very difficult to find official 
estimates of genome completion, however an unofficial source suggests that 92.3% of 
the genome has now been sequenced (Genome completion estimates – see web citations 
on page 206). 
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The compiled human genome sequence known as the golden path, is publically 
available in databases such as UCSC Genome Bioinformatics and Ensembl, where the 
sequence is both extensively annotated with genes and sequence variants, and is 
supplemented with additional information such as species comparison data. To date the 
golden path length equates to 3.1 billion nucleotides within which 23,483 protein 
coding genes are known to exist (Ensembl Assembly and Genebuild – see web citations 
on page 206). 
 
 
1.1.1 Variation of the human genome 
 
Genetic variation such as single nucleotide polymorphisms (SNP), copy number 
variants (CNV) and simple repeat sequences so called microsatellites and minsatellites, 
are wide-spread throughout the human genome. After publication of the draft sequence, 
SNP density estimates suggested that one SNP per 1.9Kb or rather 1.42 million SNPs in 
total, could be found within the human genome (Sachidanandam et al. 2001). SNP 
estimates are ever growing and the actual number of reported SNPs is close to 18 
million (Ensembl Assembly and Genebuild – see web citations on page 206), but it 
should be noted that frequency data are not available for all (some of which may be 
errors) and a variation can only strictly speaking be classed as a polymorphism if it is 
present in at least 1% of the tested population. 
 
Copy number variation (CNV) has recently gained considerable interest as a common 
genetic marker and one comprehensive genome wide CNV study has calculated that as 
much as 12% of the human genome is affected by CNV (Redon et al. 2006). 
  
A considerable fraction of the polymorphism is functional for instance those within the 
exome that result in amino acid variants or those located within the exon-intron 
boundaries that cause splice variants. Less is known about the functional significance of 
most other non-coding variation. However variants within regulatory regions, such as 
the DNA sequences where transcription factors bind, are likely to alter expression. Due 
to the degenerate nature of transcription factor binding sites, it is difficult to predict 
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sequence involved in regulation thus making it difficult to establish which non-coding 
variants are likely to be functional. Experimental procedures are required to determine 
functional regulatory variants which perhaps explains why the vast majority of genetic 
disease association studies to date have concentrated on variants that disrupt amino acid 
sequence rather than the expression levels of the protein.  
 
 
1.1.2 Blocks of linkage disequilibrium 
 
Genetic markers are said to be in linkage disequilibrium (LD) if they are found together 
in a test population more often than expected by chance. The extent of LD is variable 
across the genome and reflects past recombination events. Some sequence regions have 
undergone more of these past events than other regions and are said to be recombination 
rich or rather recombination hotspots.  
  
A haplotype is defined as a set of alleles from multiple loci that are inherited together on 
a single chromosome. It has been suggested that stretches of recombination free 
haplotype blocks are interspersed with narrow regions known as recombination hotspots 
where the majority of the recombination events take place (Daly et al. 2001; Gabriel et 
al. 2002; Jeffreys et al. 2001). The sizes of haplotype blocks vary and one has been 
shown to extend as long as 804 kb in a European population (Dawson et al. 2002).  
 
In general the patterns of LD, or rather the positions of recombination hotspots, appear 
to be similar for all populations, however the rates of LD decay vary between 
populations. African populations have been shown to have the highest rate of LD decay 
which is consistent with an ‘older’ population history and thus supports the out-of-
Africa origin of modern day humans (Ke et al. 2004). The HapMap project has built a 
genome-wide map of LD and haplotype blocks for various populations.  
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1.2 Genetic distance between populations 
 
Extensive genetic differences in allele frequencies are known to exist between 
geographically distinct populations (Li et al. 2008; Novembre et al. 2008). These spatial 
patterns of genetic variation are a result of population specific genetic drift, 
demographic history, natural selection, and new mutations. In the case of genetic drift, 
the frequency of a genetic variant can change purely as a result of random sampling 
within a population. New mutations may arise independently in geographically distinct 
populations and may remain isolated in the absence of migration and admixture. The 
demographic history of a population will imprint itself within the genetic diversity of 
contemporary populations, for example variants may reach a high frequency if a 
population has undergone a bottleneck event whereby the genetic variants that were 
available in the ancestral population are reduced to a subset of variants. Lastly, natural 
selection is likely to play an important role in population differentiation since 
geographically distinct inhabitants will be subjected to different environmental 
conditions which will each favour particular heritable phenotypes. If possessing these 
heritable traits increases an individual’s chance of survival and ability to reproduce, 
then the trait is more likely to be passed onto the next generation and is said to be more 
successful.  
 
 
1.3 Genetics and disease 
 
As discussed previously (page 14) variation within the human genome is extensive. 
Most genetic variants result in no detrimental outcome, however some variants do cause 
disorders. Monogenic diseases such as Huntingtons chorea and sickle cell anaemia are 
caused by mutations within single genes, Huntintin (HTT) (OMIM entry #143100) and 
β-globin (HBB) (OMIM entry #603903) genes respectively. There are many diseases of 
complex etiology that are in part a result of genetic variation. Such complex diseases 
can be caused by variants within multiple genes which confer susceptibility when in 
combination with each other and/or specific environmental factors. Examples of such 
complex disorders include, diabetes (OMIM entry #125853), and asthma (OMIM entry 
#600807). For OMIM reference please see web citations on page 206. 
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Various study approaches can be used to identify genetic variants that either cause or 
increase an individual’s susceptibility to disease. Family based linkage studies use 
disease pedigree genotype data to identify markers or rather areas of the genome that are 
linked with the disease in all affected indivduals. Population based association studies 
look to identify genetic variants that are significantly more common in a disease sample 
set than in a population sample of healthy controls.  
 
Many genetic disease studies seek to identify the causal or susceptibility genetic 
variants by methods which exploit LD within the genome. Markers in LD with disease 
causing alleles will pick up signals of association and help to refine the true causal 
variant. This means that in principle the whole genome can be scanned by typing a 
small number of variants since information from one genetic marker will be 
representative for all other markers it is in LD with. 
 
 
1.3.1 Association studies 
 
Population based association studies can either include case-control or longitudinal 
cohort sample sets. A case-control association study consists of approximately even 
numbers of DNA samples from individuals with a particular disorder and samples from 
healthy controls. The best case-control study involves a matched data set, whereby the 
disease samples are matched with a corresponding control sample of the same sex and 
of similar age, ancestry etc. Case-control samples are desirable since they are relatively 
easy to obtain and allow the researcher to choose the specific disease they are interested 
in. However disease description is often an issue and can lead to phenotypic 
heterogeneity. While dataset sizes are also a continuing angst, independent association 
studies involving the same disease can be accumulated in a meta analysis.  
 
Longitudinal cohorts consist of individuals often recruited from birth and followed for a 
lengthy period of time. Studies involving longitudinal cohorts benefit from hindsight 
and thus medical history and lifestyle information are often available. This allows the 
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researcher to combine genetic and non-genetic data in tests of interaction and permits 
confounder adjustments to be included in tests of association.  
 
Until recently the candidate gene approach was generally used in most genetic studies. 
This type of study is hypothesis driven and selects genes on the basis of the function of 
their proteins in health and disease. In general allelic variants that are thought to be 
functional, such as amino acid altering or regulatory variants, are selected for 
genotyping. Non functional genetic markers are nevertheless useful since they will 
highlight regions of association as a consequence of LD. This has been the basis of the 
SNP tagging approach whereby only a minimal number of SNPs are needed to obtain 
the maximum information (Chapman et al. 2003).  
 
Recent association studies often utilise genetic data that are representative of the whole 
genome, termed as genome wide association (GWA) studies. With the invention of high 
throughput technologies such as microarrays, GWA studies have become increasingly 
accessible in genetic research. By scanning the whole genome, regions significantly 
associated with disease can be identified with no prior hypotheses. However GWA 
studies suffer notably from multiple testing since genotyping platforms are now able to 
test as many as one million variants simultaneously, and this figure is forever growing. 
This increases the chance of obtaining false positive results and therefore more stringent 
significance levels are applied which in themselves increase the risk of false negatives. 
The low power of GWA studies mean only very strong association signals will be 
correctly identified which is likely to be problematic for conditions involving multiple 
genes even if their effect size is large.  
 
 
1.4 Mucus 
 
Mucus is produced at the epithelial surfaces and acts as a primary innate defence 
mechanism. It forms a protective barrier over the epithelial surface preventing cell 
desiccation and harm from environmental insults. Mucus is a complex mixture of water, 
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inorganic salts, various immunological proteins and high molecular weight 
glycoproteins known as mucins.  
 
Epithelial surfaces are in direct contact with the environment, and the epithelial cells 
produce a plethora of defence proteins. For instance lactoferrin, lysozyme and defensins 
are produced with the intention to kill bacteria and individually do so in relatively 
specific manners (Boyton and Openshaw 2002; Fokkens and Scheeren 2000). The 
mucus itself acts more crudely by entrapping contaminants and thus preventing the 
offenders from permeating through to the underlying cells.  
 
Mucins are the major component of mucus, and are responsible for its viscoelastic 
rheology. The biophysical properties of mucus vary depending upon location within the 
body. For example, the epithelia of the gastrointestinal tract must be protected from 
gastric secretions and the mucus is viscous and adherent (Allen et al. 1993). However 
the respiratory mucus is required to be ‘sticky’ and mobile in order to capture and 
remove inhaled noxious agents via mucociliary transport (Thornton et al 2008). 
Location specific properties of the mucus are the result of the differential expression 
patterns of a diverse range of mucins with varied characteristics. 
 
 
1.4.1 Mucins 
 
Mucins share the common feature of a region rich in threonine and serine, which is 
heavily glycosylated in the mature protein, and is known as the mucin domain. At 
present 18 different genes have been given the mucin symbol MUC (Hugo Gene 
Nomenclature Commitee – see web citations on page 206) and in most of these genes 
the sequence that encodes the serine/threonine rich region is tandemly repetitive. 
Although this region is extensively glycosylated in all mucins, the repeat units and their 
organisation differ from mucin to mucin. The carbohydrates attached to the mucin 
domain usually make up more than 70% (Thornton et al. 2008) of the total protein mass 
and they aid in the lubrication and hydration of the epithelium. The carbohydrates have 
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also been shown to directly interact with bacteria and thus prevent these pathogens from 
entering the epithelial cells (Linden et al. 2002; Van de Bovenkamp et al. 2003). 
 
 
1.4.1.1 Mucin glycosylation 
 
Generally the mucin carbohydrate structures are a result of O-glycosylation. During the 
initial step of O-glycosylation an N-acetylgalactosaminyl peptidyltransferase adds a N-
acetylgalactosamine (GalNac) to serine or threonine residues in the mucin protein 
backbone producing O-glycans. Elongation of the O-glycans then occurs whereby 
specific glycosyltransferases (GT) attach either a sialic acid or hexose; galactose (Gal), 
N-acetylglucosamine (GlcNAc), fucose. Studies of mucin O-glycans have identified 
four major core structures defined as follows; for core 1 and 2 O-glycans, galactose is 
transferred to C-3 of the GalNAc which is elongated in the case of core 1. With the core 
2 O-glycan branching occurs whereby the next transferase adds to the GalNAc again. In 
core 3 O-glycans a GlcNAc is added to the GalNAc, this also occurs with core 4 but is 
followed by further additions to the GalNAc (Rose and Voynow 2006).  
 
The core structures are then elongated by galactose and GlcNAc transferases to form 
Gal β1, 3/4 GlcNAc units which can be terminated by various substances e.g. fucose, 
sialic acid, sulphate and even the blood group determinants (Rose and Voynow 2006).  
 
Patterns of mucin domain glycosylation can vary from molecule to molecule in many 
different ways depending on; the precursor availability, glycosyltransferase expression 
patterns, the number of tandem repeats, differences in the sequence of tandem repeat 
units and allelic variation of the transferase as occurs in the ABO Lewis and secretor 
genes. Thus the mucin glycosylated domain provides a plethora of heterogeneity.  
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1.4.1.2 Membrane tethered and secreted 
 
There are two main types of mucin, membrane-tethered and secreted. The membrane 
tethered mucins are comprised of three regions, a short cytoplasmic tail (CT), a single 
membrane spanning region which passes through the membrane only once and a large 
extracellular domain mainly composed of the glycosylated tandem repeat region. The 
transmembrane mucin is not a continuous protein but is cleaved at a site close to the 
membrane spanning region, producing two subunits which reattach via SDS-liable 
bonds (Hattrup and Gendler 2008). 
 
The sugar chains cause the transmembrane mucins to extend into the lumen as extended 
‘bottle-brush’ structures which can stretch further than other cell receptors and 
potentially prevent pathogens from interacting with the epithelial cells (Hattrup and 
Gendler 2008).  
 
There are two types of secreted mucin, polymeric and non-polymeric. MUC7 is 
considered non-polymeric because although it is secreted it does not have the capacity 
to oligomerise. The secreted polymerising mucins have the ability to bond to each other 
via the disulphide linkages that occur between the cysteine rich regions in the amino 
and carboxyl terminal regions which flank the central glycosylated region and exhibit 
extensive homology to human von Willebrand factor (vWF) domains (see section 
1.4.2.2.2 for details). The disulphide links are very important for the mucus properties 
since they are thought to give mucus its gel-like properties (Thornton et al. 2008). 
 
 
1.4.2 Airway mucins 
 
Both secreted and membrane-tethered mucins are expressed within the airways and the 
relationship between the two mucin types is essential for a healthy respiratory tract.  
The large secreted oligomeric mucins form a viscous gel which sits on top of the 
periciliary liquid layer (PCL) where the membrane-tethered mucins reside. The ‘sticky’ 
gel layer entraps noxious agents so that they can be removed by ciliary beating within 
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the low viscosity PCL bordering the epithelial cells in a process known as the mucosal 
ciliary escalator (Curran and Cohn 2009). 
 
 
1.4.2.1 Membrane-tethered airway mucins 
 
The membrane-tethered mucins MUC1, MUC4 and MUC16 are located within the 
airway PCL, on the apical surface of the epithelial cells. MUC1 is generally localised to 
the microvilli, whereas MUC4 and MUC16 tend to be found on the cilia (Hattrup and 
Gendler 2008). 
 
The membrane-tethered mucins of the airways are not indefinitely attached to the 
epithelial cells as both MUC1 and MUC4 can be identified within mucus secretions 
(Hattrup and Gendler 2008). Tumour necrosis-α converting enzyme (TACE/ADAM17) 
has been shown to cleave MUC1 from uterine epithelia releasing the extracellular 
domain (Brayman et al. 2004), and while this is a plausible explanation for the secreted 
form of MUC1 in the airways, an alternatively spliced form of MUC1 has also been 
identified which lacks the CT and transmembrane domains (Hinojosa-Kurtzberg et al. 
2003). Since 24 different MUC4 transcripts have been identified, alternative splicing is 
also likely to result in the release of this mucin into the airway lumen (Escande et al. 
2002).  
 
MUC4 has the ability to interact with the oligomeric mucins in mucus secretions via 
disulphide linkages since it contains an extracellular vWF cysteine rich D domain. In 
some diseased airways, mucus has been seen to tether to the epithelium, making 
clearance difficult, causing the mucus to become stagnant (Thornton et al. 2008). It has 
been suggested that tethering in this instance may be a direct result of interactions 
between the D domains of MUC4 and the secreted oligomeric airway mucins (Hattrup 
and Gendler 2008).  
 
MUC1 is known to participate in cell signalling. For example the bacterial protein 
flagellin has been shown to interact with the extracellular domain of MUC1 which is 
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thought to activate signalling through phosphorylation of the conserved tyrosine 
residues in the CT. The MUC1 CT has also been localised in the nucleus where it is 
thought to directly regulate transcription. It has even been suggested that this MUC1 
signalling may upregulate the transcription of other mucin genes through NFκB and 
MAPK pathways (Hattrup and Gendler 2008). 
 
 
1.4.2.2 The secretory airway mucins 
 
MUC5AC and MUC5B are the predominantly expressed airway mucins (Kirkham et al. 
2002) accounting for more than 90% of the total mucin found in sputum (Hattrup and 
Gendler 2008), and it is therefore thought that they give respiratory mucus its 
characteristic gel-like and ‘sticky’ properties. MUC5B is primarily expressed in the 
mucous cells of the submucosal glands (Groneberg et al. 2002a) while the surface 
epithelial goblet cells are the principle secretors of MUC5AC (Groneberg et al. 2002b; 
Hovenberg et al. 1996). However during airway disease MUC5B can become aberrantly 
expressed in the goblet cells (Groneberg et al. 2002a; Kamio et al. 2005). 
 
In the airways MUC2 is expressed at only very low levels and is not easily detectable 
but may also be aberrantly expressed during disease (Hovenberg et al. 1996; Ordonez et 
al. 2001). 
 
The predicted MUC19 gene has been proposed to code for another large secreted 
oligomeric mucin (Chen et al. 2004). However there is little evidence to suggest that 
this protein is present in human respiratory mucus (Thornton et al. 2008). 
 
 
1.4.2.2.1 The glycosylated domains of the secretory mucins  
 
Mucin carbohydrate side chains are important in determining mucus biophysical 
properties since they are essential for mucin expansion when in solution, protease 
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resistance, requisition of pathogens, water holding and ion binding (Thornton et al. 
2008). Since the glycosylated central domain differs between mucins, alterations in the 
mucin composition of mucus will change its physical properties.  
 
Within the colon, the major part of MUC2 appears to occur as an insoluble form. 
(Herrmann et al. 1999). Its central region is composed of two repetitive domains 
separated by approximately 600bp. The first region mainly contains a 16 amino acid 
repeat motif (table 1.1). The second region is affected by a polymorphism known as 
variable number tandem repeat (VNTR). The repeat unit of 23 amino acids as seen in 
table 1.1, has been shown to be present any number of times between 51 to 115 
(Toribara et al. 1991), and in addition some variation occurs within the tandem repeats. 
Thus the central glycosylated domain of MUC2 varies greatly between individuals.  
 
 
Table 1.1  Amino acid repeat motif units within the central regions of MUC2, MUC5AC and 
MUC5B (Desseyn et al. 1997b; Escande et al. 2001; Toribara et al. 1991). 
 
Mucin Tandem repeat unit (amino acid) 
MUC2 PPTTTPSPPPTSTTTL (region 1) 
PTTTPITTTTTVTPTPTPTGTQT (region 2) 
MUC5AC TTSTTSAP (consensus) 
GTTPSPVP (frequently occurs) 
MUC5B ATGSTATPSSTPGTTHTPPVLTTTATTPT 
 
 
The central domains of MUC5B and MUC5AC are somewhat different from MUC2. 
While threonine and serine richness is again a prominent feature of their central 
domains, the glycosylated regions are interrupted by cysteine rich domains termed cys 
(see figures 1.1 and 1.2). Only one conserved potential O-glycosylation site is present 
within each of the cys domains meaning that these are virtually free from the constraints 
inflicted by carbohydrate structures (Desseyn et al. 1997b; Escande et al. 2001). The cys 
domains are thought to act as hinges, allowing the mucins to be flexible, a property 
essential for airway mucus whereby it is required to be easily moved via mucosal ciliary 
transport (Thornton et al. 2008). However the very fact that these domains are rich in 
cysteine implies an additional role with respect to bond interactions. In fact a study of 
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the yeast two-hybrid system has identified interactions between two of these central cys 
domains and histatin 1 (Iontcheva et al. 2000). 
 
The glycosylated central region of MUC5B is composed of 3570 amino acid residues, 
coded for by a single exon of 10.7kb. The sequencing by Desseyn et al (Desseyn et al. 
1997b) led them to describe the central region as having 19 subdomains (see figure 1.1). 
Subdomains R01, R02 and R03 have no typical repeat structure but are rich in 
threonine, serine and proline (TSP). The five subunits RI to RV are also TSP rich, but in 
addition exhibit a repeating structure composed of various numbers of the 29 amino 
acid repeat motif shown in table 1.1. The R-ends are very similar to each other and are 
again TSP rich.  
 
The glycosylated subdomains of MUC5B are interrupted by seven cys subunits (Cys1-
7). The cysteine residue positions within these domains are highly conserved when 
aligned with homologous domains from human MUC5AC, mouse Muc5ac, pig gastric 
mucin, human MUC2 and the rat Muc2 homologue (Desseyn et al. 1997b). 
 
 
 
 
 
 
 
 
Figure 1.1  MUC5B protein central region and the annotated subdomains. Deduced by Desseyn et al 
(Desseyn et al. 1997b).  
 
 
The glycosylated central region of MUC5AC is also coded for by a single exon which is 
thought to be approximately 10.5kb although it has only been partially sequenced. This 
central protein region has been deduced to include 17 subdomains (figure 1.2) (Escande 
et al. 2001). Nine of these subdomains are cysteine rich (Cys1-9) and have a high 
degree of sequence identity especially with respect to the cysteine residue locations 
which are completely conserved. Four non-repeating domains termed TSP 1-4 are rich 
in threonine, serine and proline. TSP1 and TSP3 are almost perfectly identical while 
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TSP2 and TSP4 are also completely homologous. The remaining four domains are also 
TSP rich, however they each contain various numbers of the MUC5AC repeat unit of 8 
amino acids (table 1.1). 
 
 
 
 
 
 
 
Figure 1.2  MUC5AC protein central region with annotated subdomains (Desseyn et al. 1997b; 
Escande et al. 2001). 
 
 
1.4.2.2.2 Amino and carboxyl terminal regions  
 
The amino and carboxyl terminal regions of the secreted oligomeric mucins are rich in 
cysteine residues and are therefore thought to be the main sites of oligomerisation via 
disulphide bonds which are of paramount importance for the gel-like properties of 
mucus (Desseyn et al. 1997b; Thornton et al. 2008). Both regions exhibit high sequence 
homology between the secreted mucins MUC2, MUC5AC and MUC5B, and also share 
high sequence identity with the human vWF. The most prominent conservation is seen 
with respect to the numbers and positions of the cysteine residues and also the 
intron/exon boundaries.  
 
Human vWF is a multimeric glycoprotein found in plasma. It plays an important role in 
blood clotting, acting to stabilize clotting factor VIII and mediating platelet adhesion. 
As shown in figure 1.3 the amino and carboxyl terminal regions of the oligomeric 
mucin proteins have been divided into domains based on those predefined for the 
human vWF (Buisine et al. 1998; Desseyn et al. 1997a; Desseyn et al. 1998; Escande et 
al. 2001; Gum, Jr. et al. 1992; Offner et al. 1998). 
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Figure 1.3  Major domains of the secreted oligomeric mucins and human von Willebrand Factor. a. 
represents human vWF protein divided into its major domains. b. represents the domains of a generic 
secreted oligomeric mucin (MUC2, MUC5AC and MUC5B) (Perez-Vilar and Hill 1999; Thornton et al. 
2008; Verweij et al. 1987). 
 
 
1.4.3 Mucin Assembly 
 
It is difficult to study mucin assembly because of the sheer size and complexity of the 
proteins. Mucus gel can be solubilised by agents such as 6M guanidium chloride, which 
breaks down non-covalent bonds, and it is therefore thought that the entanglement of 
mucins gives mucus its gel-like properties (Thornton and Sheehan 2004).  
 
After mucus denaturation, electron microscopy reveals mucin monomers assembled in 
linear chains held together end to end by disulphide bonds (Thornton and Sheehan 
2004). However the procedures used to extract mucins from mucus are very harsh and 
disruptive. Therefore we cannot be sure that all native state patterns of assembly have 
been identified.  
 
Protein studies of mucus generally show that samples from healthy and diseased 
airways largely differ in their mucin composition. However a single study of a mucus 
plug obtained during autopsy from the airways of a status asthmaticus patient, revealed 
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unusual mucin architecture. A low charged glycoform of MUC5B accounted for 96% of 
the total mucin content within the viscid mucus plug. Electron microscopy of the 
sample did not reveal the usual linear threads but instead entangled nodes of mucins 
with emanating linear threads (Sheehan et al. 1999). This is the only case of extensive 
branching and cross-linking identified to date, however it successfully highlights the 
severity caused by defects in mucin assembly. 
 
A recent study has attempted to characterise the dynamics of MUC5B by allowing 
intact MUC5B molecules to interact with a variety of surfaces. They have shown that 
MUC5B forms a structured and hydrated interface that ranges from 40-100nm thick. 
The regions of the mucin proteins that are not glycosylated, referred to as the naked 
protein, are responsible for attachment. The carbohydrate structures dominate the 
interface, and it is this carbohydrate richness that confers the absorptive properties of 
the interface. Keismer and Sheehan have used microbeads to show that this interface 
selects what it absorbs based on size. Beads of 60nm are allowed to enter through the 
interface, however beads of greater than 100nm in size are excluded from the layer 
(Kesimer and Sheehan 2008). 
 
 
1.5 Hypersecretory airway diseases 
 
In healthy airways the epithelial layer has adopted a homeostatic mechanism whereby 
inflammation caused by various environmental insults and pathogens results in the 
upregulation of mucin expression (Gray et al. 2004b; Gray et al. 2004a; Koo et al. 
2002) which consequently allows for greater amounts of mucus to be secreted. The 
increased airway mucus helps to exclude the noxious agent from the airways by 
entrapment and removal via the mucociliary escalator and cough. When the 
inflammatory inducer has been removed the mucosal system reverts back to its balanced 
state. However during chronic respiratory diseases such as asthma, Cystic fibrosis (CF), 
diffuse panbronchiolitis (DPB) and chronic obstructive pulmonary disease (COPD), this 
mechanism persists at a greater intensity and for a longer period of time causing this 
protective mechanism to actually exacerbate disease symptoms. In fact mucus airway 
occlusion can often be fatal and a recent study of subjects, who had died in status 
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asthmaticus, has shown that 95% of the patients had airway narrowing that ranged from 
20-100% of the airway lumen due to mucus occlusions (Kuyper et al. 2003).  
 
Although enlarged submucosal glands are evident in some respiratory diseases (Bai and 
Knight 2005; Fahy 2002; Kamio et al. 2005; Rogers 2004) the surface epithelial goblet 
cells are thought to be the principal contributors of excess mucin production during 
episodes of mucus hypersecretion because mucus occlusions have been found in parts 
of the airways where goblet cells are the only source of mucus production (Evans and 
Koo 2009; Turner and Jones 2009). Even in mild and moderate asthmatic airways, the 
mean volume of stored goblet cell mucin was three times higher in the cases than the 
controls (Ordonez et al. 2001; Turner and Jones 2009). 
 
In healthy humans goblet cells are rarely seen distal to the trachea i.e. the small airways 
(Curran and Cohn 2009; Williams et al. 2006). However during episodes of 
inflammatory disease, mucous cell numbers within these regions are dramatically 
increased (Groneberg et al. 2002b; Groneberg et al. 2002a; Kamio et al. 2005). The 
excess secretory cells are thought to be a result of goblet cell metaplasia in which pre-
existing cells adopt an alternative phenotype (Williams et al. 2006).  
 
Alteration of mucin composition within the airway mucus has been identified during 
episodes of inflammatory respiratory disease. In cases of asthma and COPD, MUC5B 
has been shown to be the primary respiratory mucin within mucus plugs and sputum 
respectively (Burgel and Nadel 2004; Groneberg et al. 2002a), although in healthy 
airways MUC5AC has been shown to predominate (Kirkham et al. 2002). 
 
 
1.6 Secretory oligomeric mucin gene complex 
 
The genes that code the secreted oligomeric mucins, MUC6, MUC2, MUC5AC and 
MUC5B are located within a 400kb region on chromosome 11p15.5. Pulse field gel 
electrophoresis was used to determine the order of these genes as MUC6-MUC2-
MUC5AC-MUC5B (see appendix 4a), in a telomeric to centromeric direction (Pigny et 
al. 1996). The human genome browser annotations for this gene complex are not correct 
since MUC5AC and MUC5B are shown to overlap on the golden path sequence, 
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implying that they are the same gene (see appendix 4b). It should also be noted here that 
due to the difficult nature of the tandemly repeated MUC5AC central region, a sequence 
gap still remains in the golden path for this gene. The gap can be partially supplemented 
by sequencing data from the literature (Escande et al. 2001) however some parts of the 
central region remain unsequenced. 
 
This secretory mucin gene complex is highly conserved and has been identified in the 
genomes of the mouse, dog, chimpanzee, rhesus monkey, cow and horse (Thornton et 
al. 2008).  
 
Extensive LD is evident within the MUC gene complex since long ranging haplotypes 
have been shown to extend from MUC2 to MUC5B (Rousseau et al. 2007). However, 
no association between MUC6 variants and any of the other mucin markers has been 
identified within the 11p15.5 MUC complex, due to a recombination hotspot located 
between MUC6 and MUC2 (Rousseau et al. 2007). 
 
 
1.6.1 Mucin gene associations with respiratory disease 
 
Significant associations have been noted between variation in MUC7 and MUC2 
VNTRs and asthma phenotypes. The MUC7 repeat domain is composed of units of 23 
amino acids which can occur 5, 6 or rarely 8 times (alleles MUC7*5, MUC7*6 and 
MUC7*8 respectively). The short allele MUC7*5 has been shown to be significantly 
underrepresented in a small asthmatic population (Kirkbride et al. 2001). This study has 
also shown that MUC7 haplotypes carrying the short length allele are significantly 
associated with better lung function (higher FEV measures and reduced FEV decline 
where FEV is defines as forced expiratory volume) (Rousseau et al. 2006). 
 
In a small matched asthmatic cohort the distributions of MUC2 VNTR allele lengths 
indicate that the larger alleles may protect atopic individuals from developing asthma 
(Vinall et al. 2000). Since the MUC2 protein has only been found at very low levels 
within the airways it was proposed that the association identified may in fact be due to a 
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linked causal polymorphism within MUC5AC or MUC5B (Rousseau et al. 2007) which 
code for the dominate airway mucins. 
 
Length variation of the threonine and serine rich central region will affect the extent of 
glycosylation and therefore VNTR polymorphisms are generally accepted as the most 
likely functional candidates with respect to disease association. However no length 
variation has been noted for MUC5B and only small differences have been identified for 
the MUC5AC tandem repeat (Escande et al. 2001; Vinall et al. 2000), thus we might 
expect any disease association involving these genes to be due to different functional 
variation. Variation in MUC5AC and MUC5B glycosylation may of course result from 
sequence variants within the central region, and polymorphisms of this kind have 
previously been identified for MUC1 (Fowler et al. 2003) and MUC2 (Toribara et al. 
1991).  
 
It is also highly plausible that variation within the regulatory regions of MUC5AC and 
MUC5B may be associated with hypersecretory respiratory diseases. During chronic 
airway disease the upregulation of mucin expression in response to insults is known to 
be exaggerated and prolonged, which could in itself be a direct consequence of 
regulatory variation. In fact polymorphisms within the MUC5B promoter have been 
shown to be significantly associated with diffuse panbronchiolitis (Kamio et al. 2005).  
 
It is clear from the high levels of sequence conservation in the amino and carboxyl 
regions that these domains are important for mucin function. We also know that the 
corresponding cysteine rich regions in human vWF are essential for its assembly and 
that mutations within these regions cause von Willebrand disease due to defects in 
oligomerisation (Michiels et al. 2006). It may therefore be proposed that missense 
mutations within the amino and carboxyl termini are likely to influence normal 
function.  
 
Recently a non-synonymous SNP (Ala497Val) located within exon 12 of the MUC5AC 
amino terminal has been shown to be significantly associated with idiopathic interstitial 
pneumonia. This SNP is located within an amino terminal D domain and it is therefore 
thought that disease susceptibility may be a result of assembly and oligomerisation 
defects of the MUC5AC protein (Burch et al. 2010). 
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ENU-induced mutant mice have also highlighted the importance of these regions. 
Missense mutations within Muc2 have been shown to cause spontaneous ulcerative 
colitis and chronic diarrhoea in mutant mice Winnie and Eeyore. A mutation resulting in 
the substitution of a cysteine to a threonine in the amino terminal D3 domain, and the 
substitution of a serine to a proline in the carboxyl D4 domain have been identified in 
Winnie and Eeyore respectively. Both mice exhibit defects in mucin oligomerisation 
and secretion, and ER stress in the goblet cells due to protein misfolding has also been 
noted (Heazlewood et al. 2008). 
 
 
1.7 Project Aims  
 
The overall aim of this thesis is to describe variation within the mucin genes expressed 
in the respiratory tract, MUC5AC and MUC5B, and to examine this variation with 
respect to disease and demography. This thesis is divided into four results sections 
which aim to examine two specific hypotheses. 
 
We firstlty hypothesise that inter-individual variability of the predominantly expressed 
respiratory mucins, MUC5AC and MUC5B, will confer differing degrees of 
suseptibility to respiratory disease. 
• Chapter three aims to explore this hypothesis by studying the genetic 
variability of MUC5AC with respect to allergy related respiratory disease. This 
results section examines associations between a single nucleotide polymorphism 
within the 3′ region of MUC5AC and various respiratory outcome data, in a 
longitudinal birth cohort. Tests of gene-gene interactions are also performed 
between the same MUC5AC variant and a variety of functional inflammatory 
markers with respect to respiratory outcome. 
• Chapter four aims to explore this hypothesis by studying both MUC5AC and 
MUC5B variability with respect to asthma. This results section describes genetic 
variation within the MUC5AC 3′ region and MUC5B regulatory regions in the 
context of asthmatic case-control association studies. MUC5AC 3′ variation has 
been explored within these sample sets in an attempt to replicate the associations 
identified in chapter 3. MUC5B regulatory variation has been studied in this 
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results section since haplotype variants have been shown to confer different 
expression levels of MUC5B in two independent studies (Kamio et al 2005, Loh 
et al 2010). Taking into account MUC5B promoter variant functional 
information, we hypothesise that the high expressing haploptype will be 
overrepresented in the asthmatic cases on the basis that asthma is a characteristic 
hypersecretory disease. 
• Chapter five aims to identify the MUC5AC genetic factor that may be 
responsible for the disease associations identified in chapter three. This results 
section introduces a sequencing strategy to identify copy number variation and 
applies this technique to MUC5AC sequence traces in order to explore the 
possibility that this gene is affected by copy number.  
 
Since mucin expression is affected by environmental cues, we finally hypothesise that 
the MUC5B promoter variants will vary between geographically distinct populations 
who have experienced different environmental pressures during their demographic 
histories. 
• Chapter six aims to explore this hypothesis by characterising genetic variation 
within the MUC5B promoter in African samples of varying geographic location. 
Promoter variants are examined with respect to population differentiation, 
diversity measures and species conservation profile.
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2 Material and Methods 
 
2.1 DNA Samples 
2.1.1 Laboratory volunteer samples 
 
These anonymous samples were donated with consent from laboratory employees and 
students. The samples are not from a single population or phenotypic group and were 
used solely for optimisation purposes. 
 
 
2.1.2 1946 longitudinal birth cohort 
 
The MRC National Survey of Health and Development longitudinal study initially 
recorded information about all United Kingdom births within the week 3-9th March 
1946. A social class stratified cohort of 5362 individuals was followed further. The 
individuals within this cohort have been studied a total of 21 times, 10 during childhood 
and 11 in adulthood. The last data collection for which we have collated information 
was carried out at age 53 years, at which time blood and buccal samples were collected 
from consenting participants. As a result, DNA is available for 2939 of these individuals 
(ethical approval reference MREC no 98/2/121). This sample is considered to be 
representative of a European population since the study began before mass immigration 
into the United Kingdom.  
 
 
2.1.3 Matched asthmatic cohort 
 
The matched asthmatic disease cohort is composed of 100 individuals; 50 clinically 
diagnosed asthmatics and 50 non-asthmatic controls, which were age and sex matched 
details for which can be found in Vinall et al 2000. Both asthmatic and control sample 
sets are composed of atopic individuals. Atopy was defined by positive skin prick tests 
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which were generally confirmed by elevated IgE levels. All individuals are British with 
northern European ancestry. DNA was extracted from blood samples collected from St 
Mary’s Hospital Chest clinic. Ethical approval has been obtained from Parkside Health 
Authority (EC no 2893). DNA extraction procedures have been described previously 
(Kirkbride et al. 2001; Vinall et al. 2000). 
 
 
2.1.4 Severe asthmatic cohort 
 
The severe asthmatic disease cohort is comprised of 177 individuals; 85 severe 
asthmatics and 92 ‘hyper’ normal non-asthmatic controls, all are thought to be of 
northern European ancestry. The asthmatic disease samples have been clinically 
diagnosed and were defined as severe if they were on step 4 or 5 of the British Thoracic 
Society’s asthma treatment guidelines. All asthmatic individuals were recruited from 
Southampton general hospital in collaboration with Dr John Holloway.  
 
The ‘hypernormal’ control sample is comprised of healthy, non-asthmatic individuals 
believed to be of northern European ancestry. All individuals are recruited blood donors 
from around the Southampton area and have reported no personal or family history of 
respiratory disease. No atopy information is available for either sample set.  
 
For both the severe and control sample sets, DNA was extracted from 10ml of blood 
using the Qiagen Genomic DNA Maxi-prep kit. Ethical approval was obtained from the 
Southampton and S. W. Hants Joint Ethics Committee. 
 
 
2.1.5 African samples 
 
Eight African sample sets obtained from The Centre for Genetic Anthropology, have 
been examined during this project; Ethiopia (n = 380), Mozambique (n = 51), Ghana   
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(n = 57), Malawi (n = 50), Cameroon Lake Chad (n = 65), Cameroon Grassfields-Somie 
(n = 65), Congo (n = 55), Sudan (n = 30). DNA was extracted from buccal swabs taken 
only from anonymous males, unrelated at the grandpaternal level. Informed consent was 
given by all participants. Social and anthropological data are available for each 
individual which include, participants first and second language, mother and fathers first 
and second language, birthplace, and self-declared cultural identification.  
 
 
2.1.6 cDNA samples  
 
The cDNA samples used during this project had been synthesised from RNA extracted 
from a variety of subclones of the HT29-MTX mucus secreting cells by Wendy Pratt. 
For the cell culture protocol refer to Lesuffleur et al (Lesuffleur et al. 1993) and for 
RNA extraction and cDNA synthesis procedures refer to Wang et al (Wang et al. 1994). 
 
 
2.2 Genotyping methods 
2.2.1 Six SNP multiplex 
 
The 1946 cohort samples were genotyped for six polymorphisms using a multiplex 
technique. Three SNPs were genotyped in MUC5B (rs2672785, rs2075853 and 
rs2075859), and one each within the genes MUC5AC, IL4 and IL13 (rs1132440, 
rs2070874 and rs1800925 respectively), the relevant details are given in Chapter 3. 
 
 
2.2.1.1 Multiplex PCR 
 
Optimal polymerase chain reaction (PCR) conditions were defined by altering thermal 
cycling and primer concentrations, and the final PCR conditions used are as follows. To 
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each 2µl DNA sample (mean concentration of 30ng/µl) the following PCR reagents 
were added: 1µl of 10X Abgene Buffer IV containing MgCl2 [750mM tris-HCl (pH8.8 
at 25°C), 200mM (NH4)2SO4, 0.1% v/v Tween 20®, 15mM MgCl2], 0.1µl of 100X 
dNTPs, 5 p moles of rs1132440, rs2070874, rs1800925, 9 p moles of rs2672785, 3.5 p 
moles of rs2075853 and 2 p moles of rs2075859 primers. Distilled water was added to 
make a final reaction volume of 10µl. Table 2.1 shows the MUC5AC primer sequences. 
Please note that primer sequences for all other SNPs can be found in Andrew Loh, PhD 
thesis (Loh  2007) and Black et al supplementary information (Black et al. 2009). 
 
Thermal cycling of the samples was initiated by denaturation at 95°C for 5 minutes, 
followed by 30 cycles of 30 seconds at 95°C, 30 seconds at annealing temperature 60°C 
and 30 seconds at 72°C. A final elongation step of 72°C for 5 minutes was added to the 
end of the thermal programme.  
 
Post optimisation, two PCR products from each plate were run on a 12% 19:1 
acrylamide gel and silver stained in order to visualise the multiplex product prior to the 
next step of PCR product treatment.   
 
4µl of each PCR product was treated, in order to remove remaining primers and residual 
dNTPs, by adding 1.33 units of Shrimp Alkaline Phosphatase (SAP) (USB Corporation) 
and 0.8 units of Exonuclease I (NEB, inc) Additions of these reagents were followed by 
1 hour incubation at 37°C and enzyme deactivation at 75°C for 15 minutes. The treated 
PCR products were held at 4°C prior to -20°C storage.  
 
 
2.2.1.2 Multiplex Single base extension (SBE) 
 
Single base extension (SBE) was the chosen genotyping method for the multiplex. To 
1µl of purified PCR product, 1.67µl of SNaPshotTM Multiplex Ready Reaction Mix was 
added along with 0.66µl of a SBE multiplex primer mix containing equal volumes of all 
six Primer Extension (PE) primers at the following concentrations: 0.75 µM rs2075853 
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PE primer, 3.6µM rs2672785 PE primer, 3µM rs2075859 PE primer, 1.8µM rs1132440 
MUC5AC forward primer, 0.2µM rs1800925 PE IL13 primer, 2.4µM rs2070874 PE IL4 
primer (see table 2.2 for details). 
 
The samples were then subjected to 25 thermal cycles of 96°C for 10 seconds, 50°C for 
5 seconds and 60°C for 30seconds, before being held at 4°C. 
 
In order to remove 5′-phosphate groups from the unincorporated ddNTPs, the SBE 
products were treated with the following mixture: 0.33 units of calf intestinal 
phosphatase (CIP), 0.43µl of 10x CIP buffer and 0.23µl of dH2O. Samples were then 
incubated at 37°C for 1 hour followed by an enzyme deactivation step of 75°C for 15 
minutes, and a final hold of 4°C.  
 
10µl of Hi-Di formamide and 0.25µl of Genescan LIZ 120 size standard was added to 
1µl of the SBE product, which were then detected via electrophoresis on the ABI 
3730xl Gene Analyzer.  
 
 
2.2.2 Basic PCR protocol 
 
The basic PCR protocol is used for each of the subsequent PCR reactions and the 
omitted details regarding annealing temperatures, cycle numbers and primer sequences 
are shown for each specific PCR reaction in table 2.1. 
 
To each 2µl DNA sample the following PCR reagents were added: 1µl of Abgene 10X 
Buffer IV containing MgCl2 [750mM tris-HCl (pH8.8 at 25°C), 200mM (NH4)2SO4, 
0.1% v/v Tween 20®, 15mM MgCl2], 1µl of 10X dNTPs, 2.5 p moles of the forward 
primer and 2.5 p moles of the reverse primer. Distilled water was added to make a final 
reaction volume of 10µl. Thermal cycling of the samples was initiated by denaturation 
at 95°C for 5 minutes, followed by cycling of 30 seconds at 95°C, 30 seconds at the 
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optimal annealing temperature and 1 minute at 72°C. A final elongation step of 72°C for 
5 minutes was added to the end of the thermal programme. All PCR products were 
visualised by agarose gel electrophoresis (1% to 3% gels as appropriate).  
 
 
2.2.3 DNA sequencing - SNP discovery and genotyping 
 
2.2.3.1 Purification of the PCR product 
 
After amplifying the fragment to be sequenced, the PCR product was purified in order 
to eliminate excess primers, dNTPs and buffer. PCR products were purified using a 
method of a home made PCR clean up solution [40% PEG-8000, 1 M NaCl, 2mM Tris-
HCl (pH 7.5), 0.2mM EDTA, 3.5mM MgCl2], ethanol wash and centrifugation on the 
ALC® PK120 (maximum RPM 4000). Subsequent purified PCR products were air dried 
and re-suspended in distilled water. 
 
 
2.2.3.2 Sequencing reactions 
 
To 4µl of purified PCR product the following reagents were added: 2.4 p moles of 
either the forward or reverse primer used in the PCR step was added to a mixture 
containing 5µl of sequencing buffer, 1µl of ABI BigDye® Terminator mix v1.1 or v3.1 
and 0.375µl of DMSO. Each reaction was made up to 15µl volume with distilled water. 
These sequencing reactions were then subjected to a programme of 98ºC for 10 minutes, 
followed by 25 cycles of 10 seconds denaturing at 98ºC, 5 seconds annealing at 50ºC 
and 4 minutes of elongation at 60ºC. 
 
The sequencing reaction products were purified in a two step isopropanol and 
centrifugation procedure (ALC® PK120 maximum RPM 4000) to remove excess 
terminator mix, primers and buffer. The resulting purified products were air dried and 
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re-suspended in 10µl of formamide. Electrophoresis of the products on the ABI Gene 
Analyzer 3730xl was used to detect the sequence results. 
 
Sequencing reactions were mostly conducted with the help of Mari-Wyn Burley at the 
Centre for Comparative Genomics.  
 
 
2.2.4 Restriction fragment length polymorphism (RFLP)  
 
2.2.4.1 Variant -614 restriction enzyme digest 
 
PCR steps were in accordance with the described basic PCR protocol and specific 
details for this assay can be found in table 2.1. To 3µl of the PCR product 2.5 units of 
BsaI enzyme (NEB, inc) plus 1.5µl of NEB buffer 3 were added and the final reaction 
volume was made up to 15µl using distilled water and incubated for 16 hours at 50°C.  
 
 
2.2.4.2 Variant -988 restriction enzyme digest 
 
Since this variant does not fall within a natural enzyme restriction site, an allele specific 
restriction site was introduced into the PCR product by engineering a site in the reverse 
primer (see details in table 2.1) in order to perform RFLP as the method of genotyping. 
The PCR step was in accordance with the basic protocol described in section 2.2.2 and 
specific details are given in table 2.1. To 3µl of the PCR product 2.5 units of HinfI 
enzyme (NEB, inc) plus 1.5µl of NEB buffer 2 were added and the final reaction 
volume was made up to 15µl using distilled water and incubated for 16 hours at 37°C.  
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2.2.4.2.1 Variant rs1132440 restriction enzyme digest 
 
All repeat typings of the MUC5AC variant rs1132440, were performed using RFLP. 
The PCR step was in accordance with the basic protocol described in section 2.2.2 and 
specific conditions are shown in table 2.1. To 3µl of the PCR product 2 units of HaeII 
NEB enzyme, 1.5µl of NEB buffer 4 and 1.5µg of BSA were added and the final 
reaction volume was made up to 15µl using distilled water and incubated for 16 hours at 
37°C. 
 
 
2.2.5 RT-PCR  
 
For each RT-PCR assay, the following reagents were added to each 2µl cDNA sample: 
1µl of Abgene 10X Buffer IV containing MgCl2 [750mM tris-HCl (pH8.8 at 25°C), 
200mM (NH4)2SO4, 0.1% v/v Tween 20®, 15mM MgCl2], 1µl of 10X dNTPs, 2.5 p 
moles of the forward primer and 2.5 p moles of the reverse primer (see table 2.1 for 
primer sequences). Distilled water was added to make a final reaction volume of 10µl. 
Thermal cycling of the samples was initiated by denaturation at 95°C for 5 minutes, 
followed by cycling of 30 seconds at 95°C, 30 seconds at the optimal annealing 
temperature and 30 seconds at 72°C. A final elongation step of 72°C for 5 minutes was 
added to the end of the thermal programme.  
 
cDNA samples were previously made in the lab by Wendy Pratt and Jo Fowler.  
 
 
2.2.6 Genotyping of non-mucin genetic markers 
 
Genotyping of genetic markers within the genes EGFR, IL13, IL1RN, IL1B and TNF 
were conducted by Lynne Vinall and details of protocols are given in the appendix 
(appendix 1). 
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Table 2.1  PCR assay conditions.  
 
Details of conditions shown include primers sequences, concentration of primers used, optimal annealing temperatures and number of cycles used during thermal cycling. 
The red underlined allele within the reverse primer used in the -988 variant validation PCR, represents an engineered site. 
 
 
 
 
 
PCR assay  Forward primer Reverse primer final conc  (p moles) 
Annealing temp 
(°C) 
thermal 
cycles 
MUC5AC rs1132440 
 
5′ACACCGAGGTGGAAGAGTGC 3′ 5′CTGGACAGGGGCACAAGTTC 3′ 5.0 60 (multiplex) 
59 (RFLP) 
30 
MUC5B promoter A 5′CCACGGAGCATTCAGGAC 3′ 5′CCCTCCCACCACTGCTTAG 3′ 5.0 65 35 
MUC5B promoter B 5′CACAAGCCACCCAGACTG 3′ 5′GAGCCAACACCAGCGTC 3′ 5.0 62 35 
MUC5B promoter A2 5′GTGCAGTCACAGCCACGA 3′ 5′ATACGGTTCAGCCGTGAAAA 3′ 5.0 56 35 
MUC5B promoter B2 5′TCTCTGCGGGTTTCATGACT 3′ 5′ACCTCAGATGCTCCCACCT 3′ 5.0 64 38 
MUC5B -614 validation 5′CCACGGAGCATTCAGGAC 3′ 5′CTCAGTCTGGGTGGCTTGTG 3′ 5.0 64 38 
MUC5B -988 validation 5′CCACGGAGCATTCAGGAC 3′ 5′ACAGCGTCATCTGCAGGAGAC 3′ 5.0 58 38 
MUC5AC 3′ exon 13 to 14 5′ATCAACGGGACCCTGTACC 3′ 5′TGCAGATCTGGGTCTCACAG 3′ 5.0 63 36 
MUC5AC 3′ exon 18 to 19 5′CGACCTGTGCTGTGTACCAT 3′ 5′GACACTGGGACGCCTCTCT 3′ 5.0 63 36 
MUC5B distal promoter to 
exon 1 (RT-PCR) 
5′ACGAGGCCACACCACCCGA 3′ 5′CTGCGGCACCACGAGCATG 3′ 5.0 65 34 
MUC5B distal promoter to 
exon 2 (RT-PCR) 
5′ACGAGGCCACACCACCCGA 3′ 5′CCGCCATCCATGGTGTGCC 3′ 5.0 65 34 
MUC5B exon 1 to exon 2 
(RT-PCR) 
5′GAGCGCGTGCCGGACGCT 3′ 5′CCGCCATCCATGGTGTGCC 3′ 5.0 64 30 
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Table 2.2  Multiplex Single Base Extension (SBE) reaction details. 
 
 
 
 
 
 
 
 
 
 
 
 
Gene SNP PCR Extension primer Extension product 
colour 
 Identifier Alleles Product length 
(bp) 
Annealing 
temp (°C) 
length  
(bp) 
Orientation  
MUC5AC rs1132440 C/G 243bp 59˚C 25bp Forward Black/Blue 
Il4 rs2070874 C/T 150bp 59˚C 21bp Reverse Blue/Green 
Il13 rs1800925 C/T 201bp 59˚C 29bp Reverse Blue/Green 
MUC5B (exon 2) rs2672785 A/G 221bp 61˚C 15bp Reverse Red/Black 
MUC5B (exon 3) rs2075853 C/T 151bp 61˚C 17bp Reverse Blue/Green 
MUC5B (exon 9) rs2075859 C/T 206bp 61˚C 17bp Forward Black/Red 
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2.3 Statistical methods 
 
2.3.1 Deviation from Hardy Weinberg Equilibrium (HWE)  
 
Tests for deviation from Hardy Weinberg Equilibrium (HWE) generate theoretical or 
expected genotype distributions from the allele frequencies determined from the 
observed genotype counts. Where p is the frequency of the common allele and 1-p = q is 
the frequency of the rare allele, the equation representing expected genotype counts is as 
follows;  
p2 + 2pq + q2 = 1 
 
In general a chi-squared test is used to compare the observed and expected genotype 
distributions. High chi-squared values and associated low p values indicate deviations 
from HWE. However in cases where expected genotype counts are less than five, chi 
squared tests are no longer sufficient and may produce spurious results. Thus 
throughout this project, an exact test is used to calculate the departure from HWE, and 
is based on that devised by Guo and Thompson (1992) and implemented in Arlequin 
version 3.1.0.2. This test is said to be analogous to a Fishers exact test however the 2 by 
2 contingency table is extended to a triangular contingency table, which is then 
examined using a Markov-chain random walk algorithm.  
 
Deviations from HWE might be explained by factors such as a non-randomly mating 
population, population stratification, presence of silent alleles, selection or technical 
error. In general, tests of deviation from HWE are used to check data for technical 
errors.  
 
 
2.3.2 Pearson’s Chi squared test (χ2) 
 
Pearson’s Chi-squared (χ2) can be used as a test for independence and goodness of fit. In 
both cases the observed data must be in the form of counts e.g. genotype numbers in 
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cases and control groups. The chi-squared values generated are evaluated for 
significance by comparing them with critical values in a chi-squared distribution. If the 
critical value falls within the 95% confidence interval, the null hypothesis is accepted- 
the two variables are independent and therefore the distribution of the observed events 
in each category is not significantly different from that expected by chance. 
 
In order to generate the chi-squared statistic, an expected distribution of the data must 
firstly be defined which is the number of expected genotypes we would expect to find in 
each category if the variables were independent. These expected values are generally 
calculated when all observed data has been entered into a contingency table using the 
formulae as follows: 
 
                                      Expected value = row total X column total 
                                                                           grand total   
 
Chi squared is essentially the sum of the squared differences between each observed and 
expected value divided by the expected value as represented by the formulae below 
where O represents the observed frequency of a genotype and E represents the expected 
frequency of a genotype. As the Chi squared value increases the chance of the null 
hypothesis being rejected also increases.  
 
χ2 = Σ(Oi – Ei)2 
     Ei 
 
P values for the appropriate number of degrees of freedom can be looked up in chi 
squared tables but have been primarily generated by SPSS software in this project. 
 
 
2.3.3 Fishers Exact Test 
 
As with Pearson’s chi-squared, the Fishers exact test is used as a test for independence. 
It can be used for analysing small datasets, and is most commonly applied to 2 by 2 
contingency tables. The test explores whether there are non-random associations 
between two categorical variables. 
 
 46 
The exact probability of obtaining the observed dataset is calculated. Probabilities are 
also calculated for all possible contingency tables with data distributions more extreme 
than the one observed. Two-tailed tests are used when there is no prior hypothesis, 
meaning that probabilities are calculated for tables more extreme than the observed in 
both directions. All calculated probability values are summed together to obtain a 
significance value for the observed data. 
 
 
2.3.4 Logistic Regression 
 
Logistic regression attempts to predict a dependent variable from a combination of 
independent variables (IV) or rather predictor factors. The dependent variable (DV) is 
usually a binary categorical variable for example affected and unaffected disease status. 
Logistic regression has been used during this project to examine the relationship 
between genetic variables (IV) and disease outcome (DV). 
 
Logistic regression uses a combination of the predictor variables to predict the 
probability of a case falling into a particular DV category known as the odds of a 
category. Any asymmetry of the odds are adjusted for by using log(odds). All logistic 
regression calculations were performed by Iman Shah. 
 
 
2.3.5 Permutation test  
 
Permutation tests have been used in this project to test the significance of the genotype 
distributions and were performed by Dr Nikolas Maniatis. Observed genotype data were 
randomized one thousand times producing a theoretical distribution of empirical data. 
These simulated genotype distribution were then ranked. The observed data were then 
compared to the ranked distributions and a probability value was assigned, indicating 
the likelihood of obtaining the observed data by chance. 
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2.3.6 Mann Whitney U and Kruskall Wallis test 
 
The Mann Whitney U and Kruskal Wallis test have been used to compare distributions 
of continuous data. Both tests are non-parametric meaning that they do not assume 
normally distributed data and make no assumption that the variances are homogenous. 
The two tests convert raw data to ranked data and sum the ranks for each population. 
While the Kruskal Wallis statistic can be used to test any number of groups the Mann 
Whitney U test can only be used to compare two groups. The Mann Whitney U test is 
favoured in the case of a two group test since it has greater power. 
 
The Mann Whitney U statistic is calculated by the following formula where n1 and n2 
are the sample sizes of group 1 and group 2 respectively and Ri refers to the rank of the 
sample: 
 
 
 
 
The Kruskall Wallis test statistic is calculated by the following formula where H is the 
test statistic, n is the total number of observations for all groups and Ri refers to the rank 
of the sample: 
 
 
 
 
 
(Formulae - see web citations on page 206 for reference).  
 
 
2.3.7 Correspondence Analysis 
 
Correspondence analysis is a statistical method used to visualise the relationships 
between the columns and the rows of a two-way contingency table that contains 
numeric data for categorical variables. Correspondence analysis is a kind of multi-
dimensional scaling since it attempts to capture the maximum extent of correspondence 
within the contingency table in as few dimensions as possible. 
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The cross tabulation of frequencies are firstly standardised. This means that the relative 
frequencies are calculated for each cell by dividing each value by the sum of all entries. 
The new table of relative frequencies is now called a matrix. The row and column totals 
within the matrix are known as the row mass and column mass respectively and the 
mass in this sense can be viewed as a ‘cloud’ of datapoints.  
 
Mass is used to estimate inertia which is the integral of mass multiplied by the squared 
distance from the centroid (the centre of the cloud). Inertia is a measure of the spread of 
points and each dimension is given an inertia percentage. The percent of inertia details 
how much of the interrelationship within the table is captured by each dimension. The 
first dimension always captures the most and all successive dimensions, orthogonal to 
the first, capture less. 
 
The main purpose of correspondence analysis is to graphically display the relationships 
or rather distances between the row and/or column points. The distances are represented 
by coordinates for each cell within the table. Distance is used to describe the difference 
between the data distribution patterns across columns for each row and vice versa. The 
coordinates are plotted onto a two dimensional map and it is usual to plot both row and 
column points on the same map. However, distances between row and column points 
may not be interpreted. Conclusions can only be drawn for distances between column 
points or distances between row points. 
 
 
2.4 Genetic Analysis software 
 
2.4.1 Arlequin version 3.1.0.2 
 
Arlequin is a population genetics software package (Excoffier et al. 2005). It enables 
the user to perform a variety of intra and inter-population tests on genetic data. During 
this project Arlequin was used to test for deviation from Hardy Weinberg equilibrium 
(HWE) by a fishers exact based method which has been discussed previously in section 
2.3.1. 
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Arlequin analysis software has also been used to estimate haplotype frequencies and to 
calculate the exact test of population differentiation (ETOPD).  
 
The ETOPD calculates pairwise measures between different populations in order to test 
whether they are significantly different from each other with respect to the distribution 
of haplotype frequencies. The ETOPD is analogous to a Fishers exact test however the 
contingency table can be bigger. The contingency table is built with haplotype 
frequencies and its significance is determined by a Markov-chain procedure as 
previously mentioned in the HWE section (Raymond and Rousset 1995). 
 
 
2.4.1.1 Haplotype inference using the Expectation-Maximisation 
Algorithm 
 
The expectation-maximisation algorithm is a two step iterative method used to infer 
haplotype frequencies from raw genotype data, which it assumes the genotypes are in 
Hardy-Weinberg equilibrium. In each step haplotype frequencies are calculated by 
assigning definite haplotypes to individuals that are unambiguous, i.e. individuals that 
are entirely homozygous or heterozygous at only one locus, and makes estimates for 
those that are ambiguous. Since the real number of haplotypes in the ambiguous class is 
not known, a variable identified as x, is incorporated into the formula, which are used to 
calculate haplotype frequencies. In this first step the algorithm estimates haplotype 
frequencies for the ambiguous category assuming random assortment and therefore no 
linkage disequilibrium between loci. Thus haplotype frequencies are dependent only on 
the allele frequencies. The overall haplotype frequencies calculated in the first step are 
then used to estimate x in a second step. This is then used to re-estimate the haplotype 
frequencies. These two steps are iterated until convergence is established, haplotype 
frequencies stabilize and likelihood is maximised. 
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2.4.2 PHASE version 2.1.1 - Bayesian haplotype reconstruction 
 
PHASE analysis software (Stephens et al. 2001; Stephens and Donnelly 2003) 
implements a statistical method to infer haplotypes from genotype data at linked loci by 
using a Bayesian algorithm. Bayes theorem is a probability theorem that takes two 
random events, in our case observed genotype and unobserved haplotype data, and 
produces a posterior probability i.e. the probability of A (haplotypes), given B 
(genotypes). Thus the posterior probability is calculated from the prior information of 
observed genotypes. 
 
This haplotype reconstruction method regards all unknown haplotypes as random 
quantities. It combines prior information with observed genotype information to 
approximate a posterior distribution using Gibbs sampling which is a type of Markov 
chain-Monte Carlo (MCMC) algorithm. Individual haplotypes are then estimated from 
the posterior distribution by looking for the most likely haplotype pairs. The haplotype 
inference method applied by PHASE differs from other Bayesian methods with regard 
to its ‘prior knowledge’. It uses an “approximate coalescent prior” to generate expected 
haplotype patterns, for the given population, based on the evolutionary assumption that 
a haplotype is more likely to occur if it can be easily generated from a known haplotype 
i.e. they are closely related. 
 
Essentially the PHASE haplotype inference programme works as follows: After 
conclusively defining unambiguous haplotypes, it randomly guesses the unknown 
haplotype pairs. These ambiguous individuals are then chosen at random and the most 
likely haplotype pair estimations are made with the assumption that all other haplotypes 
have been resolved correctly. A defined number of iterations are performed between 
these two steps producing an approximate sample of the posterior distribution, from 
which individual haplotypes are estimated.  
 
The PHASE case-control permutation test has also been used in this project. A p value 
is calculated which confirms or rejects the null hypothesis that cases and controls are 
from the same population and there is no significant difference between them in terms 
of haplotype frequencies. The PHASE case-control test has also been used in this 
project to examine haplotypic differences between different ethnic groups.  
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2.4.3 Regulatory motif prediction - rVISTA version 2.0 
 
rVISTA is a sequence analysis tool implemented via a web server 
(http://rvista.dcode.org/). It attempts to predict cis-regulatory elements within non-
coding DNA sequence by combining database searches and comparative analysis.  
Homologous sequences from two species are entered in FASTA format. The input 
sequences are firstly aligned using zPicture and the regions of high conservation are 
then scanned for sequences that correlate with transcription factor binding sites (TFBS). 
The TRANSFAC professional V10.2 library is used to search for TFBS. Regulatory 
elements are notoriously difficult to predict since their DNA sequence is degenerate. 
However, by utilising conservation information, rVISTA is able to predict biologically 
functional TFBS with a greater accuracy.  
 
 
2.4.4 Phylogenetic shadowing - eShadow 
 
eShadow is a web based tool (http://eshadow.dcode.org/) that implements a method 
known as phylogenetic shadowing, whereby multiple sequences from closely related 
species are compared and a conservation profile is created from the combination of all 
mutations. Previous methods of conservation analysis have focused on comparisons 
between distantly related species, for instance between humans and mice. Although 
such comparisons have proved invaluable for the identification of critical regions of the 
genome, they fail to identify functionally important regions between closely related 
species, for example between humans and other primates. Phylogenetic shadowing is 
able to accurately predict functionally conserved regions between closely related species 
since the multiple sequence alignments (MSA) identify an increased number of 
mutations relative to the base sequence. It can then utilise this cumulative mutation 
density to detect slowly mutating regions.  
 
eShadow implements phylogenetic shadowing in three steps. Multiple sequence 
alignments (MSA) of the closely related sequences are firstly generated by the EBI 
alignment tool ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html). These 
MSAs are then visualised by eShadow as percentage variation plots, where the x axis 
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refers to the nucleotide position of the base input sequence and the y axis refers to the 
percentage mismatched nucleotides computed as the number of reference sequence 
mismatches in a 15bps window divided by the length of the window. It should be noted 
that the percentage variation is inversely proportional to conservation thus 0% variation 
indicates complete conservation. Lastly, eShadow statistically evaluates the MSAs to 
indentify highly conserved regions. It does so by implementing two statistical methods, 
a Hidden Markov Model (HMMI) and Divergence Threshold (DT). DT utilises a sliding 
window of predefined length, and calculates the number of matches within the window. 
If the match number reaches a defined threshold, then the sequence within that window 
region is identified as being significantly conserved. The HMMI does not use a sliding 
window but rather examines the MSAs by analysing the overall match and mismatch 
distributions. 
 
 
2.4.5 Measures of sequence diversity and tests of neutrality - 
DnaSP Version 5.10.00 
 
DnaSP is a software package dedicated to analysing polymorphisms from DNA 
sequences. Input data requires full haplotype sequence data for each individual. During 
this project DnaSP has been used for measures of sequence diversity (π) and tests of 
neutrality (Tajima’s D). 
 
 
2.4.5.1 Sequence diversity - π 
 
Measures of nucleotide diversity (π) represent the probability that two copies of a 
specific nucleotide will be different if selected randomly from a population or rather a 
set of sequences (Jobling et al. 2004). Values of zero indicate that all sites are 
monomorphic. The formulae for π is as follows: 
 
π = n(Σ xixjπij)/(n-1) 
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n represents the number of sequences, xi and xj symbolise the frequencies of the ith and 
jth sequences, and πij is the proportion of nucleotide differences between the xi and xj 
sequences (Jobling et al. 2004). Plots of π have also been created in DnaSP using 
sliding windows of user defined size. A π value is calculated and plotted for the centre 
point of each window. The x axis corresponds to the nucleotide position within the input 
sequence and the y axis refers to the value of π. Peaks represent regions of high 
sequence diversity and troughs indicate regions of low sequence variation.  
 
 
2.4.5.2 Test of neutrality - Tajima’s D 
 
The expected diversity level of any stretch of sequence is defined as θ (theta). Estimates 
of θ can be calculated by several different methods which utilise different observations 
of diversity such as number of segregating sites (total number of polymorphic loci), 
number of singletons (variants found to occur only once within the population), level of 
homozygosity, number of alleles or measures of π. Under neutral evolution or rather 
neutrality, all estimates of θ should be equal. 
 
Tajima’s D (Tajima 1989) is a statistical test used to compare estimates of θ based on π 
and the number of segregating sites (S) and is essentially a measure of the difference 
between them. If neutral evolutionary forces have acted upon the sequence in question, 
Tajima’s D will be zero since π and S estimates will be equal. However significantly 
positive values of D may represent balancing selection or population subdivision, and 
significantly negative values may be indicative of positive selection or population 
growth (Jobling et al. 2004).  
 
 
2.4.6 Haplotype tree construction - Network version 4.5.0.1. 
 
The Network software has been used in this project to reconstruct phylogenetic trees, 
which are used to display the relationships between haplotypes. The nodes of the tree 
refer to a single haplotype and the node circumference is proportional to the frequency 
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of the haplotype, and the branches indicate relationships between the nodes. It should 
however be noted that phylogenetic trees constructed using recombining autosomal data 
should be viewed with caution since they do not take into account recombination 
events. 
 
 
2.4.7 Linkage Disequilibrium - Ldmax  
 
Loci are said to be in linkage disequilibrium if two alleles from the separate loci are 
present together on the same chromosome more often than expected by chance.  
 
The simplest measure of LD is a value known as D which calculates levels of LD in 
relation to allele and haplotype observed frequencies. Let us define two separate loci as 
A and B. The loci are biallelic and therefore the extent of LD between these loci can be 
examined. Under random segregation the observed frequency of the AB haplotype, 
termed as PAB, will be a product of the A and B allele frequencies, termed PA and PB 
respectively. However if the two loci are in LD, the AB haplotype will be observed 
more often than expected given the allele frequencies. Thus the calculation of D is as 
follows; 
 
D = PAB – PAPB 
 
If LD exists between the two loci then D values will be significantly different from zero 
irrespective of a positive or negative sign. It should however be noted that measures of 
D are no longer used since they are dependent on allele frequency and therefore 
independent D values can not be compared.  
 
Values of D can however be modified in order to calculate a more robust measure of LD 
known as D′, which is the measure used throughout this project. D′ is calculated by 
taking the absolute value of D and dividing by its maximum value given the frequencies 
of the alleles. Pairwise D′ values range from zero to one. A value of one indicates that 
no separation of the two loci by recombination has been noted and they are therefore 
considered to be in complete LD. Nevertheless for low frequency alleles a value of one 
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for D′ can be obtained in the absence of statistically significant association. Values less 
than one indicate that recombination has taken place between the two loci assuming the 
phase inference was correct. 
 
Ldmax (University of Michigan. Center for Statistical Genetics) has been used to 
calculate pairwise measures of LD and does so by firstly estimating haplotype 
frequencies using the EM algorithm (Excoffier and Slatkin 1995). 
 
 
2.4.8 Primer design - Primer3 
 
Primer3 is a web based tool (http://frodo.wi.mit.edu/primer3/) used to design primer 
pairs from an input DNA sequence encompassing the desired region of PCR 
amplification. Parameters taken into account for primer design such as GC content, can 
be altered manually. Generally the default parameters were deemed adequate for the 
design of all primers used in this project. 
 
 
2.5 List of web resources and tools  
 
Pubmed - http://www.ncbi.nlm.nih.gov/pubmed/  
HapMap - http://hapmap.ncbi.nlm.nih.gov/  
UCSC genome browser - http://genome.ucsc.edu/  
NCBI dbSNP - http://www.ncbi.nlm.nih.gov/projects/SNP/  
rVista 2.0 - http://rvista.dcode.org/  
eShadow - http://eshadow.dcode.org/  
Primer3 version 0.4.0 - http://frodo.wi.mit.edu/primer3/   
ClustalW2 - http://www.ebi.ac.uk/Tools/clustalw2/index.html  
Heavens above - http://www.heavens-above.com/countries.aspx   
Ethnologue -  http://www.ethnologue.com/web.asp 
World Health Organisation - http://www.who.int/en/   
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Center for Statistical Genetics, University of Michigan (Ldmax)- 
http://www.sph.umich.edu/csg/abecasis/gold/index.html  
Database of Genomic Variants (DGV)- http://projects.tcag.ca/variation/  
 
 
2.6 List of Buffers and Solutions 
 
Agarose gel loading buffer: 15% Ficoll in dH20 plus bromophenol blue and xylene 
cyanol dyes.  
 
Abgene Buffer IV (10X) containing MgCl2: 750mM Tris-HCl (pH8.8 at 25°C), 
200mM (NH4)2SO4, 0.1% v/v Tween 20®, 15mM MgCl2.  
 
TBE (5x): 0.44M Tris, 0.44M Boric Acid, 12.5mM EDTA, pH8.2-8.4.  
 
Home made PCR clean up solution: 40% PEG-8000, 1 M NaCl, 2mM Tris-HCl (pH 
7.5), 0.2mM EDTA, 3.5mM MgCl2 
 
Home made sequencing buffer: 200mM Tris HCl (pH9), 5mM MgCl2.  
 
NEB buffer 2: 10mM Tris HCl, 10mM MgCl2, 50mM NaCl, 1mM dithiothreitol (pH 
7.9 at 25ºC.  
 
NEB buffer 3: 50mM Tris-HCl, 10mM MgCl2, 100mM NaCl, 1mM dithiothreitol (pH 
7.9 at 25ºC).  
 
NEB buffer 4: 20mM Tris-acetate, 10mM magnesium acetate, 50mM potassium 
acetate 1mM dithiothreitol (pH 7.9 at 25ºC) 
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2.7 Commercial kits 
 
ABI BigDye® Terminator mix v1.1 and v3.1 
ABI Prism® SNaPshotTM Multiplex Kit: contents AmpliTaq® DNA polymerase, 
Fluorescently labelled ddNTPs, Reaction buffer.  
 
 
2.8 Suppliers 
 
New England Biolabs (NEB) 
Applied Biosystems (ABI) 
Abgene 
Sigma Aldridge (oligos) 
USB Corporation
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3 MUC5AC variation in the 1946 Cohort 
 
Allergy related respiratory disease is primarily orchestrated by Th2 cells and it is the 
pro-inflammatory cytokines secreted by these cells that coordinate inflammation (see 
sections 3.1.1.1 and 3.1.3.1). In response to airway inflammation, the body has 
developed a homeostatic defence system whereby large quantities of airway mucus are 
secreted in an effort to expel the inflammatory causing agent (see section 3.1.2.1). In 
chronic airway disease, this mechanism is intensely active for lengthy periods of time 
and actually exacerbates disease symptoms. The mucus occlusions commonly seen in 
severe asthmatic airways (Kuyper et al. 2003) are testament to the detrimental effects 
that such a defence system can have when the balance is tipped. 
 
At the cellular level, this mechanism is thought to be controlled by pro-inflammatory 
cytokines such as interleukin 13 (IL13) and tumour necrosis factor (TNF), which are 
known to upregulate MUC5AC expression (see section 3.1.3.1), and are present at high 
levels within the asthmatic airways (Bradding et al. 1994; Broide et al. 1992; Humbert 
et al. 1997; Naseer et al. 1997; Ying et al. 1997). It is thought that an increase in 
MUC5AC expression in progenitor cells results in their transdifferentiation to goblet 
cells in a process known as goblet cell metaplasia (GCM) (see section 3.1.2.3). The 
dramatic increase of goblet cells present in diseased airways results in the characteristic 
mucous phenotype. It is clear that MUC5AC plays an important role in allergy related 
disease etiology, we therefore hypothesise that genetic variation affecting the expression 
of this gene and the properties of the glycoprotein product may alter susceptibility to 
and severity of asthma and related respiratory disease. 
 
This chapter describes the use of a longitudinal birth cohort for identifying associations 
between a MUC5AC marker and various allergy related and respiratory disease 
outcomes. Associations are also tested between these same outcomes and variations in 
genes involved in the inflammatory response with a view to ascertaining possible gene-
gene interactions between MUC5AC and various inflammatory mediator genes.  
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The introductory section will discuss known etiology of allergy and asthma as well as 
MUC5AC and its relationships with various inflammatory mediators. 
 
 
3.1 Introduction 
 
3.1.1 Allergy 
 
The term ‘allergy’ was coined by Von Pirquet in 1906. Allergy comes from the Greek 
word allos meaning "other" and ergon meaning "reaction". Over time allergy has been 
used interchangeably with the term atopy which generally refers to immunoglobulin (Ig) 
E mediated disease. In definition, an allergic reaction is an unnecessary immune 
response to harmless stimuli. Gell and Coombes (1963) divided these inappropriate 
immune responses into 4 hypersensitivity reaction groups. Categories are based on the 
time between stimulus trigger and symptom manifestation and the nature of the 
response. General use of the term allergy often refers to a hypersensitivity 1 reaction. 
This type of reaction is defined as an immediate response to otherwise harmless proteins 
known as allergens. 
 
Asthma and hayfever (seasonal or perennial conjunctivorhinitis) are both 
hypersensitivity 1 allergic disorders. Other allergic disorders categorised in this way 
include; food anaphylaxis and some intolerances; allergy-related skin disorders such as 
urticaria and atopic eczema.  
 
The prevalence of allergic disease has been increasing at an alarming rate (Peat and Li 
1999) and is primarily thought to be a disorder of the westernized world (Cohn et al. 
2004). However recent epidemiological studies have highlighted a significant increase 
in prevalence of allergy in Africa (Obeng et al. 2008). This rapid increase in prevalence 
can only be explained by changing environments. 
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3.1.1.1 Cellular and Molecular Mechanisms of Allergy: The Importance of 
Cytokines.  
 
Allergic reactions begin with the processing and presenting of allergens by antigen 
presenting cells to T helper 2 (Th2) cells in the already sensitized individual. In 
response, the Th2 cells secrete a defining profile of cytokines, Interleukin (IL) 3, IL4, 
IL5, IL6, IL9, IL10, IL13 and GM-CSF, which orchestrates the allergic reaction. 
Infiltration of these Th2 cells into the affected tissue is the “immunological hallmark” of 
an atopic response (Kay 2000b). 
 
IL13 and IL4 stimulate programmed B cells to produce allergen specific antibody IgE. 
The allergen then induces cross-linking of the IgE bound to mast cells and subsequently 
causes these cells to degranulate, releasing preformed inflammatory mediators such as 
histamine which result in chronic inflammation (Beirman et al. 1996).  
 
IL3, IL5 and GM-CSF cytokines stimulate the production and maturation of eosinophil 
colonies in the bone marrow. These cytokines “prime” the eosinophils by increasing 
their metabolic activity which is characterised by cytotoxicity enhancement and 
mediator release (Beirman et al. 1996; Kay 2000a). 
 
The circulating eosinophils are attracted to the correct location by the cytokines IL3, 
IL5 and GM-CSF which are consequently known as chemoattractants. Recruitment to 
the correct location is initially achieved by adherence of the eosinophils to the 
endothelial cells near to the site of inflammation. The endothelial cells close to 
inflammation become more adhesive for the eosinophils due to the local production of 
cytokines such as IL4 and IL13, which upregulate the production of proteins responsible 
for this specific adherence (Kay 2000a). 
 
The eosinophils enter into the sites of inflammation by transendothelial migration. This 
process appears to only occur if the eosinophils have firstly been matured by the 
cytokines IL3, IL5 and GM-CSF (Moser et al. 1992).  
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The mechanisms by which the eosinophils degranulate remain uncertain. However the 
mediators released, Major Basic Protein (MBP) Eosinophil catonic protein (ECP) 
Eosinophil-derived neutrotoxin (EDN) and Eosinophil peroxidase (EPO), are cytotoxic 
to the bronchial epithelial cells and potent inflammatory substances. 
 
 
3.1.1.2 Immune system priming 
 
While allergen exposure is universal, individual immune responses to common 
allergens differ. Non-atopic individuals mount a modest T helper 1 (Th1) immune 
response to stimuli. They produce Immunoglobulin (Ig) G antibodies and interferon-γ 
(IFN-γ), a cytokine secreted by Th1 cells. Atopic individuals respond to allergens with 
an exaggerated Th2/IgE mediated immune response. 
 
The type of immune response we mount against allergens is thought to be determined 
during early childhood. In utero the T helper lymphocytes of the fetus are weakly 
primed against common allergens. As a result the newborn demonstrates a Th2 
dominated immune response. Critical immune developmental stages appear to occur 
during childhood before the age of 5 years (Kemp and Bjorksten 2003) which define 
future immune response profiles. Normally, a process known as ‘immune deviation’ 
should occur in the infant. Where the immune system deviates towards a Th1 dominated 
allergen response. One possible trigger for this deviation event is thought to be 
microbial exposure which forms the basis of the hygiene hypothesis, whereby it is 
believed that the increasing obsession of the Westernised world to prevent child contact 
with bacteria is thought to be the driving force behind increases in allergy prevalence. In 
atopic individuals, childhood ‘immune deviation’ has been averted, and their Th2 
immunity has been programmed to respond with greater zest and specificity to the 
allergens (Holt et al. 1999; Kay 2000a).  
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3.1.1.3 Environmental Factors and Allergy Development 
 
Several allergy-protective lifestyle factors and case studies have been used as proof of 
principle for the ‘hygiene hypothesis’. It has been observed in Europe that children who 
live on a farm in close proximity to animals, have a dog or have an older brother, 
achieve a greater degree of protection against atopy (Cookson 1999). Rural living 
appears to confer allergy protection in Africa as well as Europe, whereby the prevalence 
of allergic diseases is observably divided between rural and urban Africa, with a far 
greater incidence of allergy in the cities (Obeng et al. 2008). 
 
There are other environmental factors that could explain why some individuals have a 
better chance of obtaining immune deviation. The dose of the allergen and age at 
exposure could be deciding factors for an individual’s subsequent immune profile. In 
fact Scandinavian children born within three months surrounding the birch pollen 
season are more likely to become allergic to this pollen in life (Cookson 1999).  
 
 
3.1.1.4 Genetic Variation and Allergy Development 
 
In concert with environmental factors, genetic variation is also likely to play a pivotal 
role in the development of allergy. It is therefore important to study polymorphisms in 
genes known to be upregulated or altered in expression during allergic episodes.  
 
Inflammation is the defining symptom of allergy and therefore pro-inflammatory 
substances will obviously play an important role in allergic disease etiology. In fact, 
variation in a range of pro-inflammatory cytokine genes has previously been shown to 
be associated with allergic disease (Albuquerque et al. 1998; Apter et al. 2008; Black et 
al. 2009; Choi et al. 2009b).  
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It is also important to look at proteins that are upregulated by pro-inflammatory 
cytokines or are involved in the inflammatory pathway (Tamura et al. 2001). Thus 
MUC5AC is a good candidate gene for studies of respiratory allergic diseases such as 
asthma, since its expression is upregulated in the airways during inflammation. Thus the 
next part of this introductory section will focus on asthma and the role MUC5AC plays 
in asthmatic pathology. 
 
 
3.1.2 Asthma 
 
Asthma is a chronic inflammatory disease of the airways. Periodic bronchoconstriction, 
inflammation and mucus hypersecretion are all factors which lead to tightening of the 
airways and reduced airflow. Symptoms include wheezing, breathlessness and 
coughing. Such intermittent inflammatory episodes are known as asthma attacks. These 
attacks can be very short and last for just minutes, but some last for hours and even 
days. Long severe attacks are consistent with a life-threatening condition known as 
status asthmaticus, which can be characterised by mucus plugging and rupturing of the 
alveoli. 
 
Stimuli such as respiratory viral infection, exercise, emotional stress, air pollutants and 
ozone are known to trigger asthma attacks. However it has been suggested that 80-90% 
of cases are allergy related and triggered by a variety of common allergens such as those 
from the house dust mite, grass pollen and animal danders (Cohn et al. 1998; Cookson 
2002). When inhaled, the airborne allergens evoke a biphasic allergic reaction in the 
sensitized asthmatic airways. During the initial acute-phase, allergens induce an 
inappropriate Th2/IgE mediated immune response, ultimately leading to chronic airway 
inflammation (Holt et al. 1999). In the late-phase of the attack, the Th2 cytokines 
activate and recruit eosinophils. Mucus plugging and perivascular oedema are also 
conditions characteristic of the late-phase (Holt et al. 1999). 
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3.1.2.1 Mucus Hypersecretion in Asthmatic Airways 
 
Mucus airway occlusion can often be fatal and a recent study of subjects who had died 
in status asthmaticus, showed that 95% of the patients had airway narrowing that 
ranged from 20-100% of the airway lumen due to mucus occlusions (Kuyper et al. 
2003). Mucus plugging is thought to be a marker of asthmatic severity, and it is 
therefore essential to understand the process of mucus production in both healthy and 
diseased airways.  
 
 
3.1.2.2 Cellular Source of Mucus Hypersecretion 
 
MUC5AC and MUC5B are the major secretory mucins expressed in the airways 
(Kirkham et al. 2002). They give the respiratory mucus its characteristic gel-like and 
sticky properties. MUC5B is primarily expressed in the submucosal glands (Groneberg 
et al. 2002a) while the surface epithelial goblet cells are the principal secretors of 
MUC5AC (Groneberg et al. 2002b; Hovenberg et al. 1996). However during airway 
disease MUC5B can become aberrantly expressed in the goblet cells. 
 
Although enlarged submucosal glands are evident in some respiratory diseases (Bai and 
Knight 2005; Fahy 2002; Kamio et al. 2005; Rogers 2004) the surface epithelium goblet 
cells are thought to be the principal contributor of excess mucin production during 
episodes of mucus hypersecretion. This is supported by the fact that the small and 
medium airways of status asthmaticus specimens have been shown to be occluded by 
mucus (Evans and Koo 2009), and within these regions, goblet cells are the only source 
of mucin production (Turner and Jones 2009). Even in mild and moderate asthmatic 
airways, the mean volume of stored goblet cell mucin was three times higher in the 
cases than the controls (Ordonez et al. 2001).  
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3.1.2.3 The Mucous Phenotype 
 
In healthy human and murine airways, goblet cells are rarely seen distal to the trachea/in 
small airways (Curran and Cohn 2009; Williams et al. 2006). However during episodes 
of inflammatory disease, mucous cell numbers within these regions are dramatically 
increased. Abnormally large numbers of goblet cells within the small and medium 
airways is the defining characteristic of a ‘mucous phenotype’. This condition could be 
ascribed to either goblet cell ‘hyperplasia’, defined by proliferative events, or goblet cell 
‘metaplasia’ in which pre-existing cells adopt an alternative phenotype (Williams et al. 
2006). 
 
Mouse models of airway inflammation have been extensively used to attempt to solve 
the conundrum of ‘hyperplasia’ or ‘metaplasia’. Evidence at present appears to favour 
goblet cell metaplasia (GCM) as the primary cause of the mucous phenotype. Epithelial 
proliferation is not significantly increased in allergen challenged mice at the point in 
which excessive numbers of goblet cells first appear, suggesting that no increase in cell 
number is taking place and mucin production has therefore been initiated in resident 
cells (Evans et al. 2004). A mouse study has also reported that the mucous phenotype 
following sensitization could not be explained by an increase in epithelial cell numbers 
since the number of cells per unit surface remained constant. This expansion in mucous 
cell number could be entirely compensated for by the dramatic decrease in Clara and 
ciliated cells (Reader et al. 2003), implying a process of ‘transdifferentiation’, whereby 
the Clara and ciliated cells have assumed a goblet-like phenotype. The idea of Clara 
progenitor cells has also been demonstrated in human smokers. Smoker airways have 
shown an increase of mucous cell number in locations usually occupied by Clara cells 
(Lumsden et al. 1984). 
 
Both clara and ciliated cells have been implicated as progenitor cells in mouse airways 
with mucous phenotypes. Direct evidence of airway epithelial cell transdifferentiation 
has been obtained by ultrastructural analysis of allergen challenged mice, whereby cells 
exhibit both Clara and goblet characteristics. Co-localization of the ciliated cell marker 
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beta-tubulin and MUC5AC has also been seen in mice infected by the Sendai virus 
(Turner and Jones 2009).  
 
Cells staining positive for MUC5AC are defined as mucous cells, and therefore 
increased expression of MUC5AC is the marker of GCM and transdifferentiation (Fahy 
2002). MUC5AC has been shown to be the mucin most upregulated in the asthmatic 
airways of both humans and animals (Kirkham et al. 2002; Ordonez et al. 2001; Young 
et al. 2007) and it is therefore important to understand why MUC5AC becomes 
aberrantly expressed in progenitor cells.  
 
As mucins give mucus its rheological properties, alterations in the MUC5AC expression 
patterns are likely to change the consistency, viscosity and stickiness of the mucus. 
Therefore any genetic variation that affects MUC5AC expression or protein structure is 
likely to be functional.  
 
 
3.1.3 Mediators of GCM and MUC5AC Expression 
 
3.1.3.1 Th2 cells mediate GCM 
 
Th2 cells mediate inflammation and are also known to mediate mucus 
hypersecretion/GCM. A mucous phenotype results when Th2 cells are transferred into 
the lungs of naïve mice (Cohn et al. 1997; Cohn et al. 1998). Thus Th2 mediated GCM 
in humans is likely to have a profound effect in asthmatic airways where a significant 
enrichment of Th2 cells has been noted in bronchoalveolar lavage fluid (BALF) 
(Robinson et al. 1992).  
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3.1.3.2 Th2 cytokines regulate MUC5AC expression 
 
Various pro-inflammatory cytokines such as, IL1B, IL4 and IL13 have been shown to 
upregulate MUC5AC expression (Gray et al. 2004b; Gray et al. 2004a; Koo et al. 2002) 
and GCM. A mouse study has suggested that IL-13 may be the only cytokine essential 
for allergy mediated GCM. Whittaker et al administered IL-13 +/+ or IL-13 -/- Th2 cells 
to both IL13 wild type and IL13 knock out mice, followed by antigen challenge. Only 
the mice with a complete IL13 blockade showed no epithelial cell mucus staining in 
their otherwise inflamed airways. Increased mucus production was evident after antigen 
challenge in all mice that were either IL13 wildtype or had been administered IL13 
positive Th2 cells (Whittaker et al. 2002). Thus the elevated IL13 levels seen in human 
asthmatic lungs (Humbert et al. 1997; Naseer et al. 1997; Ying et al. 1997) are likely to 
exacerbate mucus production. 
 
 
3.1.3.3 IL13 signalling  
 
IL13 and IL4 transduce their signals through a common receptor which is a heterodimer 
composed of the chains IL4 Receptor α (IL4Rα) and IL13 Receptor α1 (IL13Rα1). 
When cytokine attachment occurs the chain associated signalling intermediates Janus 
kinase (JAK) 1 and Tyrosine kinase (TYK) 2, are phosphorylated and subsequently 
activated. Phosphorylation of other tyrosine residues located within the intracellular 
domain of IL4Rα occurs allowing Insulin receptor substrate (IRS) and Signal transducer 
and activator of transcription 6 (STAT6) to associate at these sites. IRS and STAT6 
themselves become phosphorylated leading to the activation of further downstream 
signalling pathways. IRS activates the phosphatidylinositol 3 kinase (PI3K) and 
Ras/MAPK pathways important for cell survival/proliferation and transcriptional 
regulation respectively. Phosphorylated STAT6 also activates transcription but does so 
directly by firstly dimerising and then translocating to the nucleus (Hershey 2003; 
Kasaian and Miller 2008). 
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The IL13Rα1 60 amino acid intracellular domain does not appear to play a very 
important role in IL13 signal transduction, however this region in highly conserved with 
98% amino acid sequence homology between humans and mice and is therefore likely 
to be of functional importance (Hershey 2003).  
 
IL13 also interacts with another receptor, IL13 Receptor α2 (IL13Rα2), which is 37% 
homologous to IL13Rα1. IL13Rα2 binds IL13 with a much greater affinity than 
IL13Rα1 and it appears that it does not require the aid of another chain for efficient 
cytokine attachment, although this remains to be proved (Hershey 2003).  
 
IL13Rα2 has no obvious role in signal transduction and has therefore been proposed as 
a decoy receptor, acting to absorb excess IL13 without inducing changes within the cell. 
A mouse study has shown that in the absence of functional IL13Rα2, IL13-mediated 
inflammation, mucus cell metaplasia and mucin gene expression are increased (Zheng et 
al. 2008). This supports the idea that the IL13Rα2 acts as a sink for excess IL13, and in 
its absence IL13 induces pathways that increase the expression of inflammatory 
response genes such as mucins.  
 
A recent study has however suggested that IL13Rα2 could mediate signalling through 
AP1 (Fichtner-Feigl et al. 2006). An AP-1 binding site has been noted in the MUC5AC 
promoter region between nucleotides -3576/3570 which is known to be involved in the 
upregulation of MUC5AC transcription during Haemophilus influenzae (NTHi) 
infection (Chen et al. 2004).  
 
This AP-1 binding site is also thought to mediate MUC5AC transcriptional upregulation 
in response to cigarette smoke. Gensch et al have shown that the increased mucus 
production in the lungs of smokers is paralleled by elevated MUC5AC mRNA levels 
(Gensch et al. 2004). Using a luciferase reporter gene attached to 3700 nucleotides of 
the immediate upstream MUC5AC sequence, Gensch and colleagues were able to show 
that MUC5AC promoter activity is significantly increased by cigarette smoke. A major 
smoke response element was subsequently identified at -3700/-3337 nucleotides relative 
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to the transcription start site and mutagenesis of all transcription factor binding sites 
within this refined region identified AP-1 as the smoke response element (Gensch et al. 
2004). 
 
Interestingly it has been implicated that AP-1 along with the glucocorticoid response 
element (GRE) and nuclear factor kappa B (NFκB) binding motifs are the sites at which 
glucocorticoids/receptor complexes bind to suppress gene expression. As all three 
motifs have been identified in the MUC5AC regulatory region (Gensch et al. 2004; Li et 
al. 1998), so inhaled glucocorticoid treatment could directly repress MUC5AC 
production. 
 
Large intracellular pools of IL13Rα2 have been identified within a small subset of cells 
including respiratory epithelial cells. The intracellular IL13Rα2 is able to mobilise to 
the cell surface after treatment with the Th1 defining cytokine IFN-γ (Daines and 
Hershey 2002). 
 
Cell surface mobilisation has also been noted in the presence of IL4 and IL13 at high 
concentrations (Yoshikawa et al. 2003). This could possibly explain why bronchial 
epithelial cell cultures grown at air liquid interface (ALI), exhibit increased goblet cell 
density (GCD) when exposed to low concentrations but not higher concentrations of 
IL13 (Atherton et al. 2003). 
 
 
3.1.3.4 Pathways involved in IL13 mediated MUC5AC upregulation- MAPK 
 
Subject to IL13 binding to its receptor located on the respiratory epithelial cells, the 
exact mechanisms by which IL13 induces MUC5AC gene expression and subsequent 
GCM remain unclear. However much evidence suggests that the MAPK pathway plays 
a pivotal role.  By inhibiting key components in the MAPK and PI3K pathways (the 
IRS activated pathways) in human bronchial epithelial ALI cultures during IL13 
treatment, GCD in these cultures was significantly reduced (Atherton et al. 2003). A 
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similar result was obtained by inhibiting the p38 MAPK pathway in mouse ALI culture 
cells (Fujisawa et al. 2008). Using western blotting Fujisawa et al show that STAT6 is 
phosphorylated during the first 20 minutes after IL13 treatment and lasts for 48 hours. 
However p38 MAPK phosphorylation is delayed and does not occur until 36-48 hours 
post treatment. The upregulation of MUC5AC gene expression was also delayed with a 
significant increase in transcription not occurring until 48 hours post IL13 treatment. 
The synchronisation of p38 MAPK activation and MUC5AC upregulation identifies a 
potential direct link between the p38 MAPK pathway and MUC5AC transcriptional 
regulation (Fujisawa et al. 2008). 
 
It has been suggested that STAT6 may directly mediate IL13-induced MUC5AC gene 
expression. This notion is supported by the fact that STAT6 deficient mice who 
overexpressed IL13 did not possess a mucous phenotype (Kuperman et al. 2002), and  a 
knockdown of STAT6 expression in human ALI culture cells prevented IL13 from 
inducing GCM (Turner and Jones 2009). However STAT6 does not appear to bind 
directly to the MUC5AC promoter because there is no STAT6 binding motif within the 
MUC5AC immediate promoter (Li et al. 1998) and no conserved STAT6 motifs could 
be located within the whole MUC2-MUC5AC intergenic region (Young et al. 2007). 
Why therefore is IL-13 unable to induce GCM in STAT6 knock out mice? In an attempt 
to answer this problem, Fujisawa and colleagues have suggested that in order for 
MUC5AC gene expression to be upregulated by IL13, STAT6 activation must initially 
occur which is followed by de novo protein synthesis of an unknown protein which 
results in p38 MAPK activation (Fujisawa et al. 2008). This hypothesis is supported by 
the timing of pathway activation whereby STAT6 is immediately activated by IL13 
followed by a delay in p38 MAPK activation and MUC5AC transcriptional 
upregulation.  
 
 
3.1.3.5 Other pathways involved in MUC5AC regulation- EGFR 
 
Exogenous stimuli such as cigarette smoke, and internal mediators such as the pro-
inflammatory cytokines IL13 and TNF (Schmiegel et al. 1993; Takeyama et al. 1999), 
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have been shown to increase the expression of specific Epidermal growth factor 
receptor (EGFR) ligands. Thus one may expect significantly elevated EGFR levels in 
the lungs of smoke-induced COPD sufferers and in allergic asthmatic airways where 
IL13 and TNF are thought to be in abundance (Bradding et al. 1994; Broide et al. 1992; 
Humbert et al. 1997; Naseer et al. 1997; Ying et al. 1997).  
 
EGFR is a  membrane glycoprotein that plays a pivotal role in airway epithelial cell 
repair and differentiation (Curran and Cohn 2009) EGFR and its ligands, Epidermal 
Growth Factor (EGF) and Transforming Growth Factor alpha (TGF-α), are scarcely 
found in the adult respiratory epithelium, however they have been shown to be more 
abundantly present in asthmatic airways (Amishima et al. 1998). EGFR activation by its 
ligands has been shown to stimulate MUC5AC gene expression and MUC5AC protein 
production in human epithelial cell cultures (Takeyama et al. 1999). This has been 
supported in an in vivo study in which EGFR and a homologous transmembrane 
receptor ErbB3, were shown to be significantly upregulated along with MUC5AC in the 
epithelial cells of smokers compared with non-smokers (O'Donnell et al. 2004). 
 
 
3.1.4 MUC Asthma Association 
 
There is previous reported evidence of association between the MUC2 tandem repeat 
polymorphism and asthma. In a small asthmatic cohort (n = 100) atopic individuals with 
longer length alleles appeared to be at lower risk of developing asthma (Vinall et al. 
2000). Biologically this association appears to be rather unlikely since MUC2 is found 
at extremely low levels in the airways. MUC2 gene expression does appear to be 
upregulated in asthmatic airways although mRNA levels are still 20-fold less than that 
of MUC5AC (Evans and Koo 2009). MUC2 is not easily detectable at protein level 
(Hovenberg et al. 1996; Ordonez et al. 2001).  
 
The MUC5AC gene is located directly adjacent to MUC2 on chromosome 11. Linkage 
disequilibrium has been shown to extend from MUC2 to MUC5B in the 11p15.5 mucin 
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gene complex (Rousseau et al. 2007). Thus the association seen between MUC2 and 
asthma could in fact be a consequence of linkage disequilibrium between the MUC2 TR 
and a causative allele in MUC5AC.  
 
 
3.1.5 Inflammatory Mediators – Polymorphisms and asthma 
association 
 
Several inflammatory response proteins, for example the Th2 cytokines and EGFR, are 
known to upregulate MUC5AC. Therefore risk polymorphisms within these 
inflammatory mediators may act in combination with MUC5AC variation to enhance 
disease risk and/or severity. The final part of this introductory section will therefore 
explore previously identified genetic associations between asthma and other 
inflammatory response genes.  
 
 
3.1.5.1 IL13  
 
Two IL13 SNPs have been extensively studied with respect to inflammatory disease. 
IL13 rs1800925 is located within the promoter (-1024C>T) and IL13 rs20541 is a non-
synonymous SNP located within exon 4 (Arg110Gln). Although a high level of LD 
(Black et al. 2009) has been reported between these SNPs, in general the exonic SNP 
has been shown to exhibit a greater degree of association with inflammatory diseases. 
 
The IL13 exonic SNP alters an amino acid and therefore an arginine or glutamine can be 
present at position 110. Computer modelling suggests that this amino acid substitution 
is likely to be functional as the amino acid at position 110 appears to be important for 
IL13 tertiary structure. Modelling also shows that the residue at this position directly 
interacts with the IL13 receptor, and it is thought that a glutamine at this position would 
enhance binding (Heinzmann et al. 2000). Functional studies have confirmed glutamine 
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enhanced binding by showing that having a glutamine at position 110 is significantly 
more active in inducing STAT6 phosphorylation when compared to the ‘wild type’ 
IL13 (Vladich et al. 2005). 
 
The IL13 exonic SNP is significantly associated with IgE serum levels and 
homozygosity of the glutamine allele results in the highest total IgE levels (Graves et al. 
2000; Leung et al. 2001; Maier et al. 2006; Wang et al. 2003). As previously 
mentioned, enhanced IgE levels are characteristic of asthmatic airways, it is therefore 
not surprising that the glutamine allele confers increased risk of asthma (Black et al. 
2009; Heinzmann et al. 2000).  
 
In a Dutch study, significant association was shown between the IL13 promoter SNP (-
1024C>T) and asthma, however the Arg110Gln SNP did not show association (Howard 
et al. 2001). The rare TT promoter homozygote has been acknowledged as the risk 
genotype for allergic asthma. The potential functionality of this promoter SNP has also 
been highlighted in a study of T cells. The cells were firstly stimulated to produce high 
amounts of IL13 and then anti-CD2 was added to inhibit this production. Treated T cells 
from TT homozygote individuals, significantly resisted this inhibition compared to the 
CT and CC cells (van der Pouw Kraan TC et al. 1999). This indicates that the IL13 
promoter SNP is located within a functionally important site and the risk genotype TT 
somehow results in a more robust expression pattern. 
 
 
3.1.5.2 EGFR 
  
A CA microsatellite is located within the CpG rich intron 1 of EGFR. Repeat numbers 
range from 8 to 30, and the transcriptional activity of EGFR appears to decline with 
increasing numbers of repeats. In fact the presence of 21 CA repeats has been 
demonstrated to reduce EGFR transcription by 80% (Gebhardt et al. 1999).  
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The shorter alleles (≤ 16 repeats) have been identified as risk factors in Japanese 
asthmatics and in particular severe asthmatics (Wang et al. 2006).  
 
The EGFR extracellular region is functionally important because this is where binding 
of the ligands, EGF and TGF-a, occurs. A SNP (rs2227983) at codon position 521 
results in an arginine to lysine substitution located within the extracellular subdomain 
IV. Functional studies have shown that the presence of the lysine allele weakens EGFR 
growth response to its ligands (Moriai et al. 1994). 
 
 
3.1.5.3 TNF 
 
TNF is a pro-inflammatory cytokine and its gene is located within the class III region of 
the Major Histocompatibility Complex (MHC) on chromosome 6p21.  
 
The TNF promoter SNP rs1800629, more commonly referred to as -308 in the literature, 
is biallelic with alleles frequently termed TNF1 (common G) and TNF2 (rare A). Many 
studies of various ethnic groups, have noted that the TNF2 allele confers asthmatic risk 
and the TNF1 allele is protective (Chagani et al. 1999; Gupta et al. 2005; Shin et al. 
2004; Wang et al. 2004; Witte et al. 2002; Wu et al. 2007b), and this has been 
confirmed in a meta-analysis (Gao et al. 2006). In one study the TNF11 genotype is 
shown to be significantly protective of wheeze as well as asthma (Li et al. 2006), and 
the TNF2 allele has also been identified as a risk allele with respect to chronic 
bronchitis (Huang et al. 1997). This pattern of association is not however universal and 
in a study of Australian Caucasian children TNF1 was identified as the risk allele 
(Albuquerque et al. 1998). 
 
In a study of Mexican children TNF2 was again shown to be significantly associated 
with asthma, however this association was only apparent in the subgroup of cases that 
did not have parents who smoked (RR = 2.06 p = 0.0097) (Wu et al. 2007b). This 
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finding interestingly highlights the fact that environmental exposures such as cigarette 
smoke have a profound effect on the outcome of susceptibility polymorphisms. 
 
 
3.1.5.4 IL1RN and IL1B 
 
The IL1 cytokines, IL1A, IL1B and IL1Ra (Interleukin 1 receptor antagonist) are 
produced by cells such as monocytes and macrophages and their genes are located in a 
cluster on chromosome 2q14.2. IL1a and b are pro-inflammatory cytokines, which bind 
to IL1 receptor 1 (IL1R1) located on target cells and induce signal transduction. IL1Ra, 
coded for by the IL1RN gene, also binds to IL1R1. However IL1Ra is an anti-
inflammatory cytokine and on binding to its receptor does not induce a signal and 
therefore behaves as a natural antagonist of the IL1 pro-inflammatory cytokines, by 
competitive inhibition. Achieving an optimal ratio of pro and anti- inflammatory 
cytokines is likely to be of the great importance within the airways and it seems 
probable that during respiratory disease the delicate balance has been tipped in favour of 
the pro-inflammatory cytokines. The elevated IL1Ra serum levels seen during asthma 
attacks (Yoshida et al. 1996) are thus likely to be a natural response to inflammation.  
 
An 86 base pair VNTR has been identified within intron 2 of the IL1RN gene. In 
Europeans the repeat commonly occurs four times, however five alleles have been 
identified ranging in size from 2-6 repeats (see table 3.1 for allele nomenclature). This 
polymorphism is a good candidate for functional significance as it contains predicted 
protein binding sites for an α-interferon silencer, a β-interferon silencer and an acute 
phase response element (Tarlow et al. 1993).  
 
The IL1RN VNTR has been shown to be significantly associated with asthma. The 
IL1RN*2 allele is significantly associated with non-atopic asthma in a Japanese adult 
population (OR = 5.71 p = 0.0018). This study also identifies a significant association 
between IL1RN*2 and lower IL1Ra serum levels in atopic and non-atopic asthmatics 
(Mao et al. 2000). However studies of healthy IL1Ra serum levels have shown the 
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opposite effect, that is the IL1RN*2 allele is associated with significantly higher levels 
of IL1Ra (Danis et al. 1995; Hurme and Santtila 1998). These discrepancies may be 
explained by the fact that the IL1RN*2 allele only appears to confer a plasma level 
enhancing affect if it is in combination with the rare allele of the IL1B -511 promoter 
SNP (rs16944) (Hurme and Santtila 1998), or by different interactions of trans 
activators/inhibitors in asthma and non-asthma. 
 
The importance of IL1RN and IL1B haplotypes has also been noted in a study of smoker 
lung function. The IL1RN VNTR was not shown to be independently associated with a 
decline in lung function, but when combined as IL1RN VNTR/ IL1B -511 haplotypes, 
associations were noted. The IL1RN*1/IL1B -511T was significantly increased in the 
smokers with rapid decline in lung function, while there was a significant decrease of 
the IL1RN*2/IL1B -511T haplotype in this group (Joos et al. 2001). 
 
The IL1RN VNTR and IL1B -511 SNP have been shown to be independently associated 
with asthma in a study of childhood asthma in a Turkish population (Zeyrek et al. 
2008). However the VNTR genotype A1A1 was identified as the risk genotype whereas 
the A1A2 genotype was shown to be protective and the same result was seen in an 
Egyptian population (Settin et al. 2008). 
 
 
Table 3.1  IL1RN intron 2 VNTR allele nomenclature and frequencies.  
 
Allele Name Alternative  Name # of Repeats 
PCR Product 
(bp) Frequency 
IL1RN*1 A1 4 410 0.736 
IL1RN*2 A2 2 240 0.214 
IL1RN*3 A3 5 500 0.036 
IL1RN*4 A4 3 325 0.007 
IL1RN*5 A5 6 595 0.007 
 
Adapted from (Tarlow et al. 1993)
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3.2 Hypothesis and Aims 
 
Since inflammatory mediators abundant during allergy related respiratory disease have 
been shown to alter MUC5AC expression (see section 3.1.3), the general aim of this 
chapter is to investigate the relationship between MUC5AC variation and allergy related 
outcomes in a European longitudinal birth cohort. 
 
We hypothesise that MUC5AC variants will respond differently within allergic airways 
and therefore propose that functionally significant MUC5AC genetic variants might 
confer altered susceptibility to or severity of allergy and respiratory disease phenotypes.  
 
This chapter focuses on a single MUC5AC SNP, typed in the 1946 birth longitudinal 
cohort and studied in relation to allergy and respiratory outcomes. This SNP was 
choosen since it has a high minor allele frequency and was one of the few well 
established SNPs at the start of the study. Gene-gene interactions are also explored to 
further characterise the relationship between inflammatory markers and MUC5AC with 
respect to these same disease outcomes. 
 
 
3.3 Results 
 
3.3.1 MUC5AC data 
 
In order to investigate the relationship between MUC5AC variation and allergic 
respiratory disease, 2 polymorphisms have been typed within this gene in the 1946 
Longitudinal Birth Cohort; the MUC5AC VNTR, previously typed by Southern blotting 
and a synonymous SNP located in exon 19 of the 3′ region (rs1132440). As described in 
the main introduction of this thesis, it is already known that there is variation in the 
tandem repeat region of MUC5AC which is thought to affect the length of the 
glycosylated domain (VNTR). However even now in 2010 the human genome sequence 
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is not complete for MUC5AC, and due to a paucity of SNP data at the outset of this 
project, a single SNP (rs1132440) was selected for analysis. MUC5AC rs1132440 does 
not cause an amino acid substitution, thus we do not anticipate functionality. However 
this SNP was chosen because of its high minor allele frequency and since it is not in 
complete linkage disequilibrium with the VNTR polymorphism it was predicted to 
capture more of the overall MUC5AC diversity. Genotyping was performed during this 
project as part of a single base extension (SBE) multiplex assay (see figures 3.1 and 3.2) 
and genotypes were inferred from observed phenotypes (G, GC and C were interpreted 
as GG, GC and CC respectively).  
 
 
3.3.2 Other mucin data within the 11p15.5 gene complex 
 
The cohort has also been typed for other polymorphisms within the 11p15.5 gene 
complex; MUC2 VNTR was genotyped by Southern blotting; three exonic MUC5B 
SNPs (rs2672785, rs2075853 and rs2075859) genotyped as part of the SBE multiplex. 
The MUC5B data has been used as part of a previous PhD project from the laboratory 
(Loh  2007) and will therefore only be discussed briefly.  
 
 
Figure 3.1  Silver stained 12% acrylamide gel, used to visualise PCR multiplex. 1.5µl of multiplex 
PCR product loaded. Corresponding PCR products for each polymorphism are labelled. Each lane 
corresponds to the multiplexed PCR products of one individual. 
 
 
MUC5B rs2075859 (206bp) 
MUC5B rs2075853 (151bp) 
MUC5B rs2672785 (221bp) 
IL4 rs2070874 (150bp) 
IL13 rs1800925 (201bp) 
MUC5AC  rs1132440 (243bp) 
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Figure 3.2  Typical chromatogram showing SBE results for the multiplex (genotype data for six 
SNPs). The sample represented in this figure is heterozygous for all six SNPs.  
 
 
 
3.3.2.1 Allele Frequencies: 11p15.5 polymorphisms 
 
A minor allele frequency (MAF) of 0.42 (G) (see table 3.2) was obtained for MUC5AC 
rs1132440 in the Cohort sample. This frequency is similar to European CEPH data 
submitted to the NCBI SNP database which reports a MAF of 0.39.There was no 
significant deviation of observed genotype frequencies from those expected under 
Hardy Weinberg Equilibrium (HWE).  
 
Table 3.2  Minor Allele Frequencies (MAF) for the MUC5AC and MUC5B polymorphisms typed on 
the 1946 cohort. 
 
Gene SNP location SNP ID MAF Total 
MUC5AC exon 19 (3′ region) rs1132440 0.42 (G) 2910 
MUC5B exon 2 (5′ region) rs2672785 0.20 (G) 2800 
MUC5B exon 3 (5′ region) rs2075853 0.07 (T) 2801 
MUC5B exon 9 (5′ region) rs2075859 0.38 (T) 2797 
 
rs1800925 
T allele 
rs2672785 
A allele 
rs1800925 
C allele 
rs2070874 
C allele 
rs2672785 
G allele 
rs1132440 
G allele 
rs1132440 
C allele 
rs2075853 
T allele 
rs2075853 
C allele 
rs2075859 
T allele 
rs2075859 
C allele 
rs2070874 
T allele 
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The MUC5AC VNTR has two common alleles (a and b), and several rare length alleles 
(termed c-k) which are both longer and shorter than the common repeat lengths. To 
simplify analysis a triallelic model was established for the tandem repeat genotypes: a, b 
and r with allele frequencies of 0.77, 0.22 and 0.01 respectively, where r includes all 
rare alleles. 
 
Three MUC5B exonic SNPs were genotyped on the cohort as part of the SBE multiplex. 
SNPs in exons 2 (rs2672785) and 3 (rs2075853) are non-synonymous causing amino 
acid changes glutamic acid to glycine and arginine to tryptophan respectively. The 
minor allele frequencies obtained in this cohort for all three SNPs are in good 
accordance with the HapMap CEPH frequencies. 
 
The MUC2 VNTR has many alleles ranging from 3.21 to 11.64 Kb in this data set with 
mean and mode lengths of 7.33 and 7.61 Kb respectively. This was therefore treated as 
a continuous variable. The allele length data is non-normally distributed thus non-
parametric analyses will be performed on this variable.  
 
 
3.3.2.2 LD within the 11p15.5 complex  
 
Pairwise LD measures were determined for the two MUC5AC and three MUC5B 
markers and are presented in the table 3.3 as D′ and chi squared p values. As reported 
previously adjacent SNPs are in tight LD and for the purpose of this study it should be 
noted that highly significant LD exists within the MUC5AC gene and only a small 
amount of recombination seems to have occurred between the tandem repeat and 
rs1132440 SNP (D′ of 0.941).  
 
LD also extends across the two MUC5 genes as MUC5AC rs1132440 and the furthest 
MUC5B SNP in exon 9 rs2075859 are significantly associated (p = 0.009). However, 
the very small D′ value (0.071) indicates that considerable recombination has occurred 
between these two markers.
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Table 3.3  Pairwise linkage disequilibrium (LD) for MUC5AC and MUC5B markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LD measures were calculated by LDmax using the 1946 cohort data (n = 2920). Significance of 
association is shown in figure a, as chi squared p values. Measures of recombination are shown as D′ 
values in figure b. Where 5ACTR refers to the MUC5AC VNTR. SNP rs1132440 is located within 
MUC5AC. SNPs rs2672785 and rs2075853 are located within MUC5B. 
 
 
3.3.2.3 LD between the MUC5AC and MUC2  
 
This dataset was also used to examine LD between the MUC2 VNTR and both 
MUC5AC markers. Because of the multiallelic nature of the MUC2 TR lengths, LD 
analysis could not be performed with the Ldmax software. Therefore the MUC2 TR 
allele distributions were compared between MUC5AC rs1132440 genotype groups and 
between MUC5AC VNTR genotype groups (see figure 3.3 not shown for VNTR). A 
Kruskal-Wallis test was used to compare the medians of the different distributions. 
Using the binned MUC2 VNTR data, as seen in figure 3.3, a significant association with 
MUC5AC rs1132440 was identified (p = 0.013), although significance was not reached 
when the MUC2 VNTR was treated as raw data (p = 0.084). Statistically significant 
association was however noted between the MUC2 TR and the MUC5AC TR markers 
tested as raw data. Thus a general pattern of association can be seen to extend from 
MUC2 to MUC5AC, which is supported by a previous study from our group (Rousseau 
et al. 2007). 
 
 
a  rs1132440 0.000    
rs2672785 0.751 0.000   
rs2075853 0.047 0.264 0.000  
rs2075859 0.803 0.009 0.968 0.000 
  5ACTR rs1132440 rs2672785 rs2075853 
 
 rs1132440 0.941    
rs2672785 0.014 0.198   
rs2075853 0.065 0.062 0.910  
rs2075859 0.016 0.071 0.001 0.950 
  5ACTR rs1132440 rs2672785 rs2075853 
 
b 
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Figure 3.3  Bar chart to show the distribution of MUC2 TR binned allele lengths with respect to 
MUC5AC rs1132440 genotypes. The medians of the three distributions (one for each MUC5AC 
genotype group) were shown to be significantly different with a p value of 0.013 (Kruskal-Wallis test). 
This shows that markers MUC2 TR and MUC5AC rs1132440 are significantly associated which is 
reflective of linkage disequilibrium.  
 
 
3.3.3 Respiratory Measures and Outcomes 
 
Respiratory outcomes and measures available as 1946 birth cohort data are detailed in 
table 1 shown in appendix 2. The MUC5B SNP data had been previously analysed in 
the cohort for association with respiratory outcomes. Associations of marginal 
significance were observed with hayfever, allergy and wheeze (Loh  2007). However in 
this project the recoded ‘ever’ and ‘never’ respiratory variables, taken from Black et al, 
were used and none of the MUC5B associations remain statistically significant.  
 
The MUC2 VNTR data set was analysed using a Mann-Whitney test for association 
with bronchitis, wheeze, hayfever, allergy and asthma outcomes. The data are shown in 
histogram form in figure 3.4. It is noteworthy that although significance is not reached 
in any comparisons, there is a trend towards longer MUC2 TR alleles in the asthma and 
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wheeze affected groups, which is not in agreement with a previous study whereby the 
longer alleles were shown to confer protection against asthma in an atopic sample set. 
 
Thus all further association analyses detailed in this chapter will concern MUC5AC 
variation, and in particular MUC5AC rs1132440. All tested phenotypic variables were 
non-independent and concerned solely with respiratory disease, function and allergy.  
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Figure 3.4  Histograms of MUC2 TR allele lengths in the affected and unaffected groups of the five 
outcomes, bronchitis (bron89r), wheeze (wzy89c), asthma (evasthm), hayfever (evhay) and allergy 
(evallerg). The distributions of MUC2 TR allele lengths in affected and unaffected groups have been 
analysed using a Mann-Whitney U test of association. Significance was not reached for any outcome.  
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3.3.3.1 Contingency tables - goodness of fit test 
 
Contingency tables were constructed in order to compare the distribution of genotypes 
between the; ‘affected’ and ‘unaffected’ groups with respect to disease variables, and 
‘yes’ or ‘no’ groups for the confounder variables. 
 
As shown in table 3.4 MUC5AC rs1132440 genotypes counts (coded as M5ACX) show 
statistically significant association with bronchitis (bron89r), wheeze (wzy89c), 
hayfever (evhay) and allergy (evallerg), and is marginally associated with asthma 
(evasthm) (Pearsons Chi squared). However MUC5AC rs1132440 allele counts were 
only shown to be significantly associated with bronchitis and wheeze (p = 0.026), with 
an underrepresentation of the rarer allele (G) in the ‘affected’ groups. No significant 
associations were identified between rs1132440 and lung functions measures such as 
FEV.  
 
The MUC5AC TR genotype variable (coded as M5ACTRY) only shows marginally 
significant association with the hayfever outcome. It must be noted that the MUC5AC 
TR data set is smaller than the rs1132440 data set. The discrepancy in n values is due to 
the fact that the Southern blot method used to genotype the VNTR requires good quality 
DNA and therefore blood DNA had to be used, whereas the SNP could be genotyped 
with standard buccal DNA. Fewer participants gave permission for the usage of blood 
and thus the VNTR sample size is substantially smaller. 
 
The two MUC5AC markers (TR and rs1132440) are in LD, and we might therefore 
expect the significant rs1132440 associations to be reflected by the TR variable, which 
is not the case (see table 3.4). Therefore analysis of rs1132440 was repeated on the 
smaller VNTR data set in order to assess whether the association remained significant 
on the smaller dataset. All outcomes previously shown to be significantly associated 
with rs1132440 in the full data set were indeed still statistically significant in the 
reduced set. MUC5AC rs1132440 appears therefore to show stronger association and 
thus by inference greater power to detect the putative real functional variant. Therefore 
MUC5AC rs1132440 will be the only mucin variable considered from this point on. 
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Table 3.4  Tests of association between MUC5AC variables and respiratory outcomes 
 
Outcome Outcome code MUC5AC rs1132440 MUC5AC TR 
  p value n  p value n  
Bronchitis Bron89r 0.016 2733 0.377 2517 
LRTI Lripy 0.859 2700 0.555 2482 
Wheeze Wzy89c 0.019 2641 0.216 2433 
Bronchitis Bronc 0.111 2909 0.909 2673 
Wheeze Wzyc 0.178 2909 0.321 2673 
Asthma Evasthm 0.061 2734 0.583 2518 
Hayfever Evhay 0.003 2729 0.044 2515 
Allergy Evallerg 0.006 2720 0.445 2505 
 
Pearson Chi squared p values are shown for association tests between MUC5AC rs1132440 genotypes 
(M5ACX) and the MUC5AC TR genotypes (M5ACTRY) and various respiratory outcomes. Significant 
results are indicated in bold and identify statistically significant differences in genotype distribution 
between ‘affected’ and ‘unaffected’ groups. For outcome details please refer to table 1 in appendix 2. 
Where LRTI refers to lower respiratory tract infection.  
 
 
3.3.3.2 Permutation test of association 
 
Since in genetic studies of this kind there is an issue of multiple testing, another 
approach was used to test the significance of the genotype distributions. This was a 
permutation test in which the observed genotype data are randomized one thousand 
times producing a theoretical distribution of empirical data. The observed data were 
then compared to the ranked ‘simulated’ genotype distributions and a probability value 
was assigned, indicating the likelihood of obtaining the observed data by chance. 
 
All outcomes shown to be significantly associated with rs1132440 as defined by the 
contingency table test remained associated, the empirical chi squared p values being 
very similar to the chi squared nominal p values (see table 3.5). 
 
 
 
 
 
 89 
Table 3.5  Permutation tests of association between MUC5AC rs1132440 genotypes (M5ACX) and 
respiratory outcomes. 
 
Outcome Outcome code Nominal p value 
Empirical 
p value 
Bronchitis Bron89r 0.016 0.020 
Wheeze Wzy89c 0.019 0.017 
Asthma Evasthm 0.061 0.066 
Hayfever Evhay 0.003 0.003 
Allergy Evallerg 0.006 0.007 
 
Permutation tests were used as an independent means to confirm the significant association results 
between the M5ACX variable and respiratory outcomes previously identified by chi squared testing of 
contingency table data.  
 
 
3.3.3.3 Logistic Regression: Adjusting for Confounders and risk 
genotypes 
 
Confounders are defined as any factors which could account for, or dilute the 
association observed between the genetic marker and phenotypic outcome. In this study 
the potential confounders were chosen on the basis that they were significantly 
associated with one or more of the outcome variables or considered to be of biological 
relevance. In addition, region of birth was used to adjust for geographical and 
population stratification. Table 3.6 shows each of these potential confounders tested 
against rs1132440, note the significant association between MUC5AC rs1132440 and 
father’s social class. In order to adjust for confounders and verify the robustness of 
previously identified associations between rs1132440 and respiratory outcomes, a 
model of multiple logistic regression was applied to these data. Crucially, as seen in 
table 3.7, all previously identified associations remain significant after adjustments for 
potential confounders. 
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Table 3.6  Tests of association between MUC5AC rs1132440 genotypes (M5ACX) and potential 
confounders. 
 
Confounder Confounder 
code p value n  
Cigarette smoker Cig89cr 0.687 2730 
Cigarette smoker Cig99cr 0.848 2909 
Father’s social class Fsc50r 0.031 2672 
Region of birth Reg46ar 0.896 2910 
Own social class Scl89r 0.667 2570 
Own social class Scl99r 0.647 2618 
Sex Sexxr 0.341 2910 
 
Pearson chi squared p values are shown for tests of association between the M5ACX variable and various 
confounder variables. Significant result shown in bold signifies non-independent distributions of 
genotypes amongst confounder categories. 
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Table 3.7  Tests of association between MUC5AC rs1132440 genotypes (M5ACX) and respiratory outcomes before and after confounder adjustment. 
 
Outcome Genotypes (CC versus) Before adjustments After adjustments n  
  OR (95% CI) p value OR (95% CI) p value  
GC 1.042 (0.83-1.30) 0.717 1.033 (0.83-1.29) 0.779 Bronchitis 
GG 0.689 (0.50-0.94) 0.019 0.683 (0.50-0.93) 0.017 
2361 
GC 0.938 (0.64-1.37) 0.739 0.898 (0.61-1.32) 0.582 Wheeze 
GG 0.382 (0.20-0.74) 0.005 0.372 (0.19-0.73) 0.004 
2285 
GC 1.220 (0.99-1.51) 0.068 1.242 (1.00-1.54) 0.049 Hayfever 
GG 0.930 (0.70-1.23) 0.614 0.949 (0.71-1.26) 0.721 
2357 
GC 1.277 (1.05-1.56) 0.016 1.290 (1.06-1.58) 0.013 Allergy 
GG 0.971 (0.75-1.26) 0.826 0.977 (0.75-1.27) 0.863 
2351 
GC 0.975 (0.73-1.31) 0.865 0.979 (0.73-1.31) 0.887 Asthma 
GG 0.614 (0.40-0.94) 0.025 0.615 (0.40-0.94) 0.026 
2362 
 
Logistic regression odds ratios (OR) and p values are shown for tests of association between MUC5AC rs1132440 genotypes (M5ACX) and respiratory outcomes both before 
and after adjusting for the possible confounders; smoking status, region of birth, father’s social class, own social class, sex. Significant associations are shown in bold and OR 
95% confidence intervals are in parentheses. 
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Logistic regression was used to calculate odds ratios (OR) by comparing each genotypic 
variable separately with the reference genotype, in this case the common homozygote. 
An OR significantly less than 1 implies that the variable in question confers protection 
from the outcome being tested, in comparison to the common homozygote. While an 
OR significantly greater than 1 suggests an increased risk of having the disease if you 
carry the genotype in question as compared to the common homozygote. Thus while 
multiple logistic regression has primarily been used here to adjust for possible 
confounders, it has also facilitated in identifying protective and risk genotypes.  
 
As seen in table 3.7 the bronchitis (bron89r), wheeze (wzy89c) and asthma (evasthm) 
rare homozygote genotypes appear to confer protection against the tested outcomes with 
an OR significantly less than 1 (OR =  0.689, 0.382 and 0.614 respectively, p values ≤ 
0.025). This is reflected by the fact that there were significantly less rare alleles in the 
bronchitis and wheeze ‘affected’ groups, a pattern mirrored in the asthmatic allele count 
data, but statistical significance was not reached.   
 
The hayfever (evhay) and allergy (evallerg) logistic regression results (table 3.7) show 
that the heterozygote genotype confers risk. No rs1132440 allelic association was 
identified with either of these outcomes and therefore the logistic regression confirms 
that any association is due to genotype alone, in this case heterozygosity. This result is 
unexpected as in a model of disease association we would usually expect the risk allele 
to confer a dominant or additive effect.  
 
It appears from the logistic regression results that the patterns of genotypic association 
differ between the bronchitis/wheeze/asthma outcomes and the hayfever/allergy 
outcomes. However as seen in bar charts of the genotype contingency tables (figure 3.5) 
there is always an overrepresentation of heterozygotes and an underrepresentation of 
rare homozygotes in the ‘affected’ groups for all five outcomes.  
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Figure 3.5  Graphical display of MUC5AC rs1132440 genotypes (M5ACX) among affected and 
unaffected groups. The distribution of the rs1132440 genotypes amongst the affected and unaffected 
groups are shown here as bar charts for outcomes bronchitis (Bron89r), wheeze (Wzy89c), asthma 
(Evasthm), allergy (Evallerg). Numbers above the CG and GG genotype bars represent the odds ratio for 
either the CG heterozygote or the GG rare homozygote as compared to the common CC homozygote. * 
represents significant p values for the corresponding OR.  
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3.3.3.4 Unexpected heterozygote distribution  
 
Because of the unusual heterozygote association with allergy and hayfever, HWE 
calculations were performed for the ‘affected’ and ‘unaffected’ groups separately. 
Although no significant deviation from HWE was observed for the MUC5AC 
rs1132440 cohort data as a whole, deviation was observed for the segregated affected 
and unaffected allergy (Evallerg) and hayfever (Evhay) samples (table 3.8). For both 
outcomes the rs1132440 heterozygotes are significantly overrepresented in the affected 
groups, whereas the unaffected group has a deficit of heterozygotes, and results are 
shown in detail in table 3.9 a and b. 
 
 
 
Table 3.8  HWE p values when considering affected and unaffected groups separately for all five 
outcomes previously shown to be associated with MUC5AC rs1132440 (M5ACX) 
 
Outcome Outcome 
code 
Affected & 
Unaffected Affected Unaffected 
Bronchitis Bron89r 0.40 0.20 0.10 
Wheeze Whzy89c 0.50 0.07 0.30 
Asthma Evasthm 0.40 0.10 0.15 
Hayfever Evhay 0.40 0.01 0.01 
Allergy Evallerg 0.50 0.03 0.02 
 
Bold font signifies significant deviation in genotype distribution from that expected under HWE at the 
95% confidence level. 
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Table 3.9  Comparison of observed and expected MUC5AC rs1132440 genotype counts for 
‘affected’ and ‘Unaffected’ groups with respect to a. Hayfever (Evhay) and b. Allergy (Evallerg).  
 
Genotypes Hayfever Affected Hayfever Unaffected 
 Observed Expected Observed Expected 
CC 201 216.99 718 690.84 
CG 352 320.02 958 1012.31 
GG 102 117.99 398 370.84 
Total 655 655.00 2074 2073.90 
 
Genotypes Allergy Affected Allergy Unaffected 
 Observed Expected Observed Expected 
CC 259 274.38 650 625.57 
CG 449 418.24 862 910.86 
GG 144 159.38 356 331.57 
Total 852 852.00 1868 1868.00 
 
 
In order to exclude the possibility that the difference in the pattern of association 
observed for the non-independent outcomes was not attributable to the exclusion of 
different people in the analysis sets because of incomplete outcome data, the regression 
analyses were repeated on a specific set of individuals who provided data for all five 
significantly associated outcomes (n = 2263). The results in table 3.10 show that the 
genotype association patterns remain, although the bronchitis variable (Bron89r) no 
longer reaches statistical significance (p = 0.065), probably due to the reduced power of 
the smaller sample size.  
 
a. 
b. 
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Table 3.10  Tests of association between the MUC5AC rs1132440 genotype (M5ACX) variable and respiratory outcomes only on samples with full data, before and 
after confounder adjustment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Logistic regression odds ratios (OR) and p values are shown for tests of association between MUC5AC rs1132440 genotypes and respiratory outcomes both before and after 
adjusting for possible confounders. The same set of individuals with full data has been tested for each outcome, thus all n values = 2263. Significant associations are shown in 
bold and OR 95% confidence intervals in parentheses. 
  
Variable Genotypes (CC versus) before adjustment after adjustment 
  OR (95% CI) p value OR (95% CI) p value 
GC 1.081 (0.86-1.36) 0.508 1.07 (0.85-1.35) 0.551 Bron89r 
GG 0.742 (0.54-1.02) 0.065 0.737 (0.54-1.01) 0.060 
GC 0.947 (0.65-1.39) 0.781 0.912 (0.62-1.34) 0.638 Wzy89c 
GG 0.386 (0.20-0.75) 0.005 0.379 (0.19-0.74) 0.004 
GC 1.233 (0.99-1.54) 0.062 1.249 (1.00-1.56) 0.049 Evhay 
GG 0.962 (0.72-1.29) 0.792 0.978 (0.73-1.31) 0.881 
GC 1.268 (1.04-1.55) 0.021 1.282 (1.05-1.57) 0.017 Evallerg 
GG 0.957 (0.73-1.25) 0.747 0.961 (0.74-1.26) 0.772 
GC 0.978 (0.73-1.32) 0.881 0.982 (0.73-1.32) 0.903 Evasthm 
GG 0.642 (0.42-0.99) 0.044 0.642 (0.42-0.99) 0.044 
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3.3.4 Inflammatory Mediators, MUC5AC and possible gene-gene 
interactions.  
 
The next step was to consider the role of other genes. As outlined in the introduction, a 
variety of proteins have been shown to regulate MUC5AC expression via allergy 
mediated pathways, and others have been suggested to play a functional role within the 
inflamed airways that result from these allergic events. 
 
The particular polymorphic markers typed were selected because they had been 
significantly associated with allergic respiratory disease in previous studies and/or have 
been shown to have a direct functional effect (see section 3.1.5). Typing had been done 
previously by a variety of methods mainly by Lynne Vinall (see appendix 1 for details 
and acknowledgments). Data were available for seven polymorphic markers within, or 
in the regulatory regions of, five inflammatory response genes; EGFR, 1L13, IL1B, 
IL1RN and TNF (see table 3.11 for marker details). 
 
 
3.3.4.1 Allele and genotype data  
 
The MAFs for the seven inflammatory response markers range from 0.17 to 0.49 (table 
3.11) and genotype distributions were in accordance with HWE, with the exception of 
IL1B rs16944 (p ~ 0.01). 
 
It should be noted that the EGFR microsatellite and IL1RN VNTR are multiallelic. In 
each case, to simplify analysis, the allelic data were binned into 2 appropriate 
categories. Derived variable categories were defined by reviewing the literature for 
allelic functional relevance. With respect to the EGFR microsatellite, repeat numbers 
were defined as either short (S) or long (L). S refers to repeat numbers between 8-18 
and repeats of 20 or greater have been denoted as L. The IL1RN tandem repeat lengths 
were categorised as 2 or X; 2 referring to the IL1RN*2 allele and X includes all other 
 98 
alleles (IL1RN*1,3,4 and 5). This categorisation was chosen because previous studies 
have identified IL1RN*2 as the risk allele. 
 
Table 3.11  Details of inflammatory mediator markers. 
 
Polymorphism Location Marker Nomenclature Alleles MAF 
EGFR Microsatellite Intron 1 none L>S § 0.49 (S) 
EGFR rs2227983 Exon 13 R497K, R521K G>A 0.26 (A) 
IL13 rs1800925 Promoter C-1024T, C-1111T 
C-1112T, C-1055T † 
C>T 0.18 (T) 
IL13 rs20541 Exon 4 R110Q, R130Q G>A 0.17 (A) 
IL1B rs16944 Promoter G-511A G>A 0.34 (A) 
IL1RN VNTR Intron 2 none X>2‡ 0.29 (2) 
TNF rs1800629 Promoter G-308A, G-488A G>A 0.19 (A) 
 
Note that the marker names refer to physical positions within the gene or its regulatory sequence (for 
references see introduction).
 † rs1800925 is a promoter SNP and therefore various notations have been 
used to describe the believed start of transcription. ‡ X represents alleles IL1RN*1,3,4 and 5. Please note 
that the EGFR SNP ID rs2227983 was previously rs11543848 in accordance with the NBCI SNP 
database.
 § S represents repeat lengths of 8-18 and L refers to lengths of 20-30 repeats. N values range 
from 2788-2918.  
 
 
3.3.4.1.1 Allelic association 
 
Prior to investigating gene-gene interactions, all inflammatory mediator gene 
polymorphisms were tested for association with the outcomes previously shown to be 
significantly associated with MUC5AC rs1132440; bronchitis, wheeze, asthma, 
hayfever and allergy (bron89r, wzy89c, evasthm, evhay and evallerg respectively). 
 
2 by 2 contingency tables of allele counts were generated for each polymorphism in 
combination with each of the five outcomes. The chi squared tests performed for each 
table identified significantly different allelic distributions between the affected and 
unaffected groups for; the IL13 promoter SNP (rs1800925) in asthma and allergy (p = 
0.038 and 0.024); the IL13 exonic SNP (rs20541) in asthma and allergy (p = 0.0007 and 
0.0104); the EGFR SNP (rs2227983) in bronchitis (p = 0.007). Please note that the 
associations between both IL13 SNPs and the asthma and allergy outcomes on this data 
set have been observed previously and are published (Black et al. 2009).  
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For both IL13 SNPs the rare allele confers risk and is therefore overrepresented in the 
asthma and allergy affected groups. In contrast, the rare EGFR SNP allele is 
significantly underrepresented in the affected bronchitis group, which implies a 
protective property, and is shown for the first time. 
 
 
3.3.4.1.2 Logistic Regression: Genotypic association and confounder 
adjustment 
 
Logistic regression analysis was performed using genotypes. As seen in table 3.12 all 
significant associations identified between markers and outcomes with respect to allele 
counts are also shown to be significantly associated with respect to genotype 
distribution.  
 
All significant results remain significant after adjusting for confounders in a multiple 
logistic regression. The confounders used in these adjustments were the same as those 
used in the MUC5AC analysis (table 3.6).
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Table 3.12  Tests of association between inflammatory mediator markers and the five respiratory outcomes previously shown to be associated with MUC5AC 
rs1132440.  
 
 
ORs from logistic regression analysis represent the level of outcome risk associated with each genotype. The common homozygote has been used as the reference genotype in 
all cases. 1 refers to common homozygote versus heterozygotes. 2 refers to common homozygotes versus rare homozygotes. Bold font indicates significant ORs and 95% 
confidence intervals are in parentheses. Adjustments were performed using all confounders previously used for adjustment in M5ACX variable multiple logistic regressions. 
N values range from 2526-2733. 
 
Variable EGFR (L and S) 
EGFR 
(rs11543848) 
IL13 
(rs1800925) 
IL13 
(rs20541) 
IL1B 
(rs16944) 
IL1RN 
(TR) 2 and X 
TNF 
(rs1800629) 
 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
Bron89r 0.96 
(0.77-
1.21) 
0.99 
(0.76-
1.29) 
0.86 
(0.70-
1.04) 
0.55* 
(0.35-
0.86) 
1.19 
(0.97-
1.47) 
0.85 
(0.48-
1.49) 
1.10 
(0.89-
1.35) 
1.04 
(0.60-
1.83) 
0.98 
(0.80-
1.19) 
0.97 
(0.70-
1.34) 
1.09 
(0.90-
1.32) 
1.02 
(0.72-
1.44) 
0.91 
(0.74-
1.12) 
0.98 
(0.59-
1.62) 
Whzy89c 1.03 
(0.69-
1.52) 
0.86 
(0.53-
1.40) 
0.74 
(0.52-
1.05) 
1.03 
(0.55-
1.93) 
0.98 
(0.68-
1.41) 
0.79 
(0.29-
2.21) 
0.78 
(0.54-
1.16) 
1.08 
(0.43-
2.73) 
1.06 
(0.75-
1.50) 
1.21 
(0.71-
2.08) 
1.13 
(0.80-
1.60) 
1.55 
(0.90-
2.64) 
0.87 
(0.61-
1.26) 
1.65 
(0.81-
3.37) 
Evasthm 1.09 
(0.81-
1.48) 
1.01 
(0.71-
1.45) 
0.89 
(0.68-
1.16) 
1.02 
(0.61-
1.68) 
1.49* 
(1.14-
1.95) 
0.89 
(0.40-
1.96) 
1.55* 
(1.19-
2.03) 
1.73 
(0.70-
3.34) 
1.23 
(0.94-
1.60) 
1.42 
(0.94-
2.14) 
1.17 
(0.90-
1.53) 
1.39 
(0.904-
2.13) 
0.97 
(0.74-
1.28) 
1.51 
(0.84-
2.71) 
Evhay 1.02 
(0.83-
1.27) 
0.96 
(0.75-
1.23) 
1.17 
(0.97-
1.41) 
1.05 
(0.73-
1.52) 
1.17 
(0.96-
1.42) 
1.20 
(0.73-
1.95) 
1.07 
(0.88-
1.30) 
1.48 
(0.90-
2.43) 
1.18 
(0.98-
1.43) 
0.96 
(0.70-
1.31) 
1.05 
(0.87-
1.26) 
1.06 
(0.77-
1.47) 
0.85 
(0.70-
1.03) 
1.25 
(0.80-
1.97) 
Evallerg 1.06 
(0.87-
1.30) 
1.16 
(0.92-
1.47) 
0.96 
(0.80-
1.14) 
0.97 
(0.69-
1.36) 
1.25* 
(1.05-
1.50) 
1.19 
(0.75-
1.89) 
1.29* 
(1.08-
1.55) 
1.21 
(0.75-
1.97) 
1.00 
(0.84-
1.18) 
1.24 
(0.94-
1.63) 
0.94 
(0.79-
1.11) 
1.18 
(0.88-
1.59) 
0.88 
(0.74-
1.06) 
1.34 
(0.88-
2.04) 
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3.3.4.2 Tests for gene-gene interactions 
 
Since there are potential biological interactions between the inflammatory mediators 
typed and MUC5AC gene expression, we tested for statistical interactions between each 
of the inflammatory loci and MUC5AC rs1132440. It was hypothesised that the 
functional variants of the inflammatory mediators may interact with MUC5AC to 
enhance disease association by a combinatorial effect. The possible interactions were 
tested using the likelihood ratio test with logistic regression.  
 
As can be seen in table 3.13 EGFR rs2227983, IL1RN VNTR and TNF rs1800629 show 
significant interactions with MUC5AC rs1132440 with respect to bronchitis (p = 0.019, 
0.009 and 0.046 respectively).  
 
When one displays the data as bar charts (see figure 3.6) we can see that the usual 
pattern of MUC5AC rs1132440 association with bronchitis is only apparent in the 
sample set of non-carriers for the IL1RN*2 risk allele. This suggests that the IL1RN*2 
risk allele abolishes any affect MUC5AC may have on the bronchitis outcome. 
Although the IL1RN*2 allele has been shown to be significantly associated with asthma 
(Mao et al. 2000), the functional consequences of this allele on the plasma levels of the 
protein it codes for (IL1Ra) appear to be complicated. The IL1RN*2 allele has been 
associated with both elevated and decreased serum levels of IL1Ra (Danis et al. 1995; 
Hurme and Santtila 1998; Mao et al. 2000). The Hurme and Santtila study has also 
suggested that the IL1RN*2 allele only appears to have a plasma level enhancing affect 
if in combination with the IL1B promoter variant (-511). It is however clear that an 
increase in IL1Ra serum levels will be beneficial since this protein is an anti-
inflammatory cytokine. Thus we might expect any affect of MUC5AC on bronchitis to 
be more detrimental within airways that contain less of this natural antagonist to 
inflammation. With this in mind, one might propose the IL1RN*2 allele to be associated 
with increased IL1Ra serum levels in this data set, since the MUC5AC affect on 
bronchitis is only apparent in the IL1RN*2 non-carriers.  
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The bar chart in figure 3.7 shows that the patterns of association seen between 
MUC5AC rs1132440 and bronchitis (bron89r) are only apparent when in combination 
with the EGFR rs2227983 genotype that does not contain the rare allele (GG). The rare 
EGFR allele codes for a lysine which has been shown by a previous study to weaken 
EGFR response to its ligands. Therefore we might expect this weakened response to 
reduce inflammatory responses and therefore reduce susceptibility to respiratory 
disease. The MUC5AC/EGFR interaction pattern appears to support this functional 
study by showing that the association between MUC5AC rs1132440 and bronchitis only 
exists if the EGFR rare allele is not present. The EGFR allele that codes for lysine, 
apparently dampens any effect of MUC5AC variants in relation to bronchitis. 
 
A statistically significant result was also obtained for an interaction between MUC5AC 
rs1132440 and the IL13 promoter SNP rs1800925 with respect to the wheeze outcome 
(p = 0.013). By plotting the IL13 promoter risk allele carriers and non-carriers 
separately (figure 3.8) it can be seen that the MUC5AC pattern of association with 
wheeze (wzy89c) is evident when in combination with both IL13 rs1800925 risk allele 
carriers and non-carriers. This is stronger when in combination with the IL13 rs1800925 
risk allele but is not statistically significant.  
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Table 3.13  Possible interactions between MUC5AC rs1132440 and various polymorphisms found in inflammatory response genes. 
 
 
All p values in bold font indicate a statistically significant gene-gene interaction with respect to outcome tested. 
 
 
 
 
Outcome 
MUC5AC &  
EGFR  
(L&S) 
MUC5AC &  
EGFR 
rs2227983 
MUC5AC & 
IL13 
rs1800925 
MUC5AC & 
IL13  
rs20541 
MUC5AC & 
IL1B  
rs16944 
MUC5AC & 
IL1RN 
MUC5AC & 
TNF 
rs1800629 
Bronchitis 0.582 0.019* 0.333 0.273 0.909 0.009* 0.046* 
Wheeze 0.335 0.244 0.013* 0.099 0.324 0.983 0.519 
Asthma 0.385 0.592 0.781 0.933 0.346 0.637 0.495 
Hayfever 0.459 0.476 0.933 0.587 0.052 0.246 0.397 
Allergy 0.671 0.562 0.663 0.608 0.340 0.872 0.935 
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Figure 3.6  Bar charts showing the interaction between IL1RN VNTR and MUC5AC rs1132440, 
with respect to Bronchitis (Bron89r). Both show unaffected (NO) and affected (YES) bron89r outcome 
clusters defined by MUC5AC rs1132440 genotypes. Graph a only includes the results from non-carriers 
of the IL1RN risk allele (34, 44, 45, 46, 55). Graph b only includes the results from carriers of the IL1RN 
risk allele (22, 23, 24, 25, 26). Cross tabulations constructed for each data set (with respect to MUC5AC 
rs1132440 genotypes) and tested using Pearson chi squared, show that the distribution of unaffected and 
affected cases is only significantly different in the non-carriers of the IL1RN*2 allele (p = 0.004). This 
gene-gene interaction is confirmed in a formal test for interactions (see table 3.13). NS refers to not 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Bar charts showing the interaction between EGFR rs2227983 and MUC5AC rs1132440, 
with respect to Bronchitis (Bron89r). Both show unaffected (NO) and affected (YES) bron89r outcome 
clusters defined by MUC5AC rs1132440 genotypes. Graph a only includes the results from carriers of the 
rare EGFR allele (AA and AG). Graph b only includes the results from non-carriers of the EGFR rare 
allele (GG). Cross tabulations constructed for each data set (with respect to MUC5AC rs1132440 
genotypes) and tested using Pearson chi squared, show that the distribution of unaffected and affected 
cases is only significantly different in the EGFR GG homozygotes (p = < 0.001). This gene-gene 
interaction is confirmed in a formal test for interactions (see table 3.13). NS refers to not significant. 
 
p = 0.004         NS 
            NS p < 0.001 
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Figure 3.8  Bar charts showing the  interaction between IL13 promoter rs1800925 and MUC5AC 
rs1132440, with respect to wheeze (wzy89c). Both show unaffected (NO) and affected (YES) wzy89c 
outcome clusters defined by MUC5AC rs1132440 genotypes. Graph a only includes the results from non-
carriers of the IL13 rs1800925 risk allele (CC). Graph b only includes results from carriers of the IL13 
rs1800925 risk allele (CT and TT). In neither case were the distribution statistically significant (p = 0.254 
p = 0.102 for a and b respectively). NS refers to not significant. 
 
 
            NS             NS 
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3.4 Discussion 
 
In this study of a longitudinal birth cohort we have indentified statistically significant 
associations between a MUC5AC SNP (rs1132440) and five non-independent 
respiratory/allergy related outcomes; asthma, allergy, wheeze, hayfever and bronchitis. 
In order to safeguard against type I errors (false positives) we have utilised two 
independent goodness-of-fit tests using contingency tables and permutation testing. In 
both cases the null hypothesis could be rejected with more than 95% certainty showing 
that the rs1132440 genotypic distributions are significantly different between affected 
and unaffected groups.  
 
Confounders are also a source of type 1 error because there is the possibility that 
environmental, population or lifestyle factors are the true cause of the association rather 
than the genetic variable. Therefore all initial significant associations between 
rs1132440 and outcome were retested using a model of multiple logistic regression 
which incorporated confounder adjustment. All associations previously shown to be 
statistically significant remained so after adjusting for confounders. 
 
The associations identified between MUC5AC and the respiratory/allergy related 
outcomes appear to be robust. Although LD has been shown to span from MUC2 to 
MUC5B, the MUC5AC marker rs1132440 is the only one to show significant 
association with the five non-independent respiratory and allergy related outcomes. The 
previously identified MUC2 TR association with asthma (Vinall et al. 2000) was not 
replicated in this study, however it must be noted that in this case, tests for association 
only took into account those affected by asthma versus those unaffected. No atopic 
information was incorporated and therefore the association seen in the small asthmatic 
cohort could be in direct relation to asthmatic protection in atopic individuals only. 
 
Although MUC5AC rs1132440 has been shown to significantly associate with various 
respiratory and allergy related outcomes, we do not anticipate that this is a causal SNP 
as it does not alter an amino acid residue. It seems likely that this SNP is in very high 
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LD with the causal genetic factor. What this factor may be is not obvious because of the 
unusual excess of heterozygotes, seen in all affected groups but exaggerated with 
respect to the hayfever and allergy outcomes. One possible explanation for this pattern 
of heterozygote association might be copy number variation (CNV), which will be 
explored in chapter 5.  
 
Statistically significant associations have been recently noted between two non-
synonymous MUC5AC SNPs and the respiratory diseases familial interstitial pneumonia 
(FIP) and idiopathic pulmonary fibrosis (IPF) (Burch et al. 2010). Burch et al 
hypothesise that these common variants lead to diminished MUC5AC function which 
leads to an increased susceptibility to FIP and IPF. Both variants result in an amino acid 
change, Ala497Val and Ala4729Lys. The Ala497Val variant is located within exon 12 
of the amino terminal in a vWF-like D domain, and could therefore play an important 
role in the oligomerisation of MUC5AC. This SNP had not been identified at the outset 
of this study but is certainly an attractive candidate for future studies involving the 1946 
cohort. 
 
The 11p15 chromosome has also been significantly linked to asthma in a genome wide 
linkage study of Caucasian families (CSGA 1997). While this result has not been 
replicated in any asthmatic genome wide association studies (GWAS), methods used to 
analyse GWAS data are notoriously conservative and therefore type II errors are likely 
to be extensive. The conservative approach taken by the standard analyses is essential 
because of multiple testing, but it should be recognised that many important genes will 
be missed as a result of this low sensitivity especially with respect to complex diseases 
where many genes are thought to be involved in susceptibility and etiology. The 
extensive data obtained from GWAS are a goldmine of information and it is therefore 
important that we adopt more sensitive analyses, such as linkage disequilibrium unit 
(LDU) maps (Andrew et al. 2008).  
 
Perhaps one of the most interesting findings reported in this results chapter is the 
evidence of interactions between MUC5AC and various inflammatory functional 
variants. Although these interactions are not enormously strong, they are consistent with 
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what is known about MUC5AC expression during inflammation and its regulation by 
the inflammatory mediators studied. There is some uncertainty as to whether the IL13 
promoter SNP (rs1800925) is actually functional or whether significant association 
between this SNP and asthma are in fact due to this marker being in LD with the non-
synonymous IL13 exonic SNP (rs20541) which is considered to be a significant 
asthmatic risk factor (Black et al. 2009). There is however some evidence of interaction 
between the IL13 promoter SNP and smoking status with respect to the allergy outcome 
in this 1946 birth cohort (Black et al. 2009). These two interactions involving the IL13 
promoter SNP, be it gene-gene or gene-environment, point to a functional role for this 
variant which could impact upon MUC5AC expression. It is noteworthy that IL13 may 
be acting in two different ways, firstly to increase IgE levels and subsequently enhance 
allergy risk, and secondly to increase MUC5AC expression.  
 
The newly described interaction between the EGFR SNP and MUC5AC rs1132440 is of 
particular interest. The MUC5AC association is only apparent if the EGFR variation 
favours a stronger response to its ligands which will subsequently cause enhanced levels 
of inflammation. It makes biological sense to suggest that bronchitis associated 
MUC5AC variants will have a more detrimental affect on respiratory disease 
susceptibility and/or severity if present within inflamed airways.  
 
Although the function of the IL1RN*2 genetic risk allele on the serum levels of its 
encoded protein appears to be complicated, we do know from this study that the 
MUC5AC effect on bronchitis is only apparent in the group of IL1RN*2 non-carriers. If 
we suggest that the basis of this interaction is biologically similar to MUC5AC/EGFR 
interaction, then we might predict that the non-carriers of the IL1RN*2 allele have 
increased levels of airway inflammation. Thus by extrapolation, this would suggest that 
the IL1RN*2 allele is associated with higher levels of the IL1Ra protein in this sample 
set, since the carriers of this genetic variant would have reduced levels of inflammation 
due to an increased abundance of this anti-inflammatory cytokine. 
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4 MUC5AC and MUC5B variation in asthmatic 
case-control cohorts 
 
In the previous chapter a MUC5AC SNP (rs1132440) located within the 3′ region was 
shown to be significantly associated with asthma in a longitudinal birth cohort. Here 
MUC5AC rs1132440 and other SNPs within close proximity have been typed in two 
small asthmatic disease cohorts collected in a clinical setting, in an effort to replicate 
this association and to further characterise MUC5AC variation.  
 
Since MUC5B is also a prominent airway mucin like MUC5AC, it is also an attractive 
candidate gene for respiratory disease association studies. In the second part of this 
chapter, variation within the MUC5B promoter will be described in these same disease 
cohorts. Studies have shown MUC5B expression to be up-regulated at the mRNA and 
protein levels during chronic respiratory disease (Burgel et al. 2007; Caramori et al. 
2004; Groneberg et al. 2002a; Kamio et al. 2005; Kirkham et al. 2002). We therefore 
hypothesise that MUC5B regulatory variation, and in this case specifically within the 
immediate promoter, will result in altered inter-individual susceptibility to and severity 
of respiratory disease. This hypothesis is supported by a study on the hypersecretory 
disease diffuse panbronchiolitis (DPB) in which significant association has been 
identified between MUC5B promoter variation and the disease in a Japanese population 
(Kamio et al 2005).  
 
Since the relationship between MUC5AC and asthma has already been explored in 
detail in chapter 3 this short introductory section will focus on gene regulatory regions 
and more specifically the MUC5B promoter with respect to hypersecretory airway 
disease. 
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4.1 Introduction 
 
4.1.1 MUC5B expression in hypersecretory airway disease 
 
MUC5B has been shown to be significantly up-regulated at mRNA and protein levels in 
asthmatic, COPD, CF and DPB airways (Burgel et al. 2007; Caramori et al. 2004; 
Groneberg et al. 2002a; Kamio et al. 2005; Kirkham et al. 2002). In sputum obtained 
from COPD airways, the abundance of MUC5B exceeds that of MUC5AC, a pattern 
which is reversed in healthy airways (Kirkham et al. 2008). In the case of asthma and 
COPD, MUC5B has been shown to be the primary respiratory mucin within mucus 
plugs and sputum respectively (Burgel and Nadel 2004; Groneberg et al. 2002a). It is 
therefore important to understand the patterns and mechanisms of MUC5B expression. 
 
MUC5AC and MUC5B are the predominant mucins found in the respiratory mucus 
(Kirkham et al. 2002). In healthy airways the MUC5 mucins are expressed in different 
cells, MUC5AC in surface epithelial goblet cells (Groneberg et al. 2002b; Hovenberg et 
al. 1996) and MUC5B in the mucous cells of the submucosal glands (Groneberg et al. 
2002a). However during hypersecretory respiratory disease MUC5B is expressed in the 
goblet cells as well as the submucosal glands (Groneberg et al. 2002a; Kamio et al. 
2005). This aberrant expression coincides with goblet cell metaplasia (GCM) and 
submucosal gland hypertrophy but the mechanisms by which ectopic MUC5B goblet 
cell expression occurs remains unknown. We do however know that the pattern of 
mucin expression seen in diseased airways mirrors that of human tracheobronchial 
epithelial cells cultured at air liquid interface and is also reminiscent of the patterns of 
expression in fetal airways at 13 weeks of gestation (Buisine et al. 1999).  
 
There is however the possibility that MUC5B protein production occurs at baseline 
levels in the goblet cells but can only be identified in the cells when expression levels 
exceed secretion. A mouse mutant has been identified that has a defect in the mucin 
secretion pathway. Examination of this mouse has identified MUC5B protein in the 
Clara cells where it was thought previously not to be expressed. The study concludes 
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that this is not aberrant expression but rather MUC5B had not been previously detected 
because it is secreted as fast as it is made (Zhu et al. 2008). 
 
 
4.1.2 Gene promoters 
 
Since this chapter includes characterisation of MUC5B promoter genetic variants, it is 
appropriate to discuss here the properties and mechanisms of human gene promoters 
and regulatory regions.  
 
The Promoter of a gene describes a region of DNA containing the cis-acting regulatory 
motifs needed for the gene to be transcribed. RNA polymerase II is the enzyme that 
transcribes all protein coding genes. In order to initiate and maintain transcription at a 
basal level, RNA polymerase II and a variety of general transcription factors bind to 
DNA motifs upstream of the gene and within close proximity to the transcription start 
site (TSS).  
 
Basal promoter sequence motifs such as the TATA box and the initiator element (INR) 
have been shown to be essential for transcription. The TATA box is located 25-30 
nucleotides upstream of the TSS. The exact number of gene promoters that contain a 
TATA box is not known however estimates range from 11% (Bajic et al. 2004) to 32% 
(Suzuki et al. 2001). Estimations are difficult to make since many promoters have not 
been experimentally defined and bioinformatics methods for motif predictions are not 
altogether reliable since the motif sequences are degenerate. It is however known that 
the TATA box is sufficient for the initiation of transcription. The initiator motif (INR) is 
also sufficient for transcriptional activation. It spans across the TSS and can act 
independently to initiate transcription, or in concert with the downstream core promoter 
element (DPE) located at +28/+32bp relative to the TSS, providing that the space 
between the two elements is optimal.  
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While the basal promoter is essential for gene transcription it confers low transcriptional 
activity and therefore regulatory regions are needed for adequate expression. Upstream 
regulatory elements (UREs) and enhancer sequence motifs, located approximately 100-
200 nucleotides and up to thousands of nucleotides upstream of the TSS respectively, 
provide the binding sites for the transcription factors required to stimulate expression 
levels. UREs and enhancer motifs often overlap (Turner et al. 2000). 
 
 
4.1.3 MUC5B Promoters: proximal and distal 
 
The basal promoter of a gene ensures baseline expression, while the URE’s and 
enhancer elements respond to challenges causing fluctuations in expression levels. For 
example, a Creb response element (CRE) located in the 5′ upstream region of MUC5B 
at -956 relative to transcription start site, has been shown to respond to the E2 sex 
hormone causing the upregulation of MUC5B expression (Choi et al. 2009a). Thus we 
would expect MUC5B expression to be higher in cells expressing E2 or within 
hormonal rich microenvironments. As opposed to hormonal challenge, diseased airways 
will be subjected to inflammatory challenge and therefore any MUC5B regulatory 
inflammatory response elements will cause MUC5B expression levels to increase during 
disease. It can also be proposed that genetic variation within the MUC5B inflammatory 
response elements could result in aberrant expression of the gene and may therefore be 
associated with increased disease susceptibility and/or severity.  
 
Genetic variation within the one kilobase sequence immediately upstream of the 
MUC5B TSS, referred to as the MUC5B proximal promoter from now on, has been 
shown to be significantly associated with diffuse panbronchiolitis (DPB). DPB is a 
predominantly Asian hypersecretory disease which is symptomatically similar to CF but 
does not appear to have the same genetic cause. Three MUC5B polymorphisms located 
within the proximal promoter region were shown to be significantly associated with 
DPB. This variation is likely to be functional since different MUC5B proximal promoter 
haplotypes which include these three associated polymorphisms, have been shown to 
confer varied expression levels in vitro (Kamio et al. 2005) and in vivo (Loh  et al. 
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2010). The low expressing haplotype shows significant negative association with DPB 
and the high expressing haplotype is overrepresented in the disease group, although 
statistical significance is not reached in this case. 
 
Much of the literature refers to a single MUC5B promoter, which we call here the 
proximal promoter, however a study by Perrais et al (Perrais et al. 2001) has identified a 
second promoter which is very active in a gastric cancer cell line. This additional 
promoter is located directly upstream of the proximal promoter and is referred to as the 
distal promoter. Using a primer extension method, RNA transcripts corresponding to the 
distal TATA box were identified abundantly in the gastric cancer cell line and were also 
shown to be present in human trachea indicating that this is an active promoter (Perrais 
et al. 2001). 
 
 
4.2 Hypothesis and Aims 
 
The first aim of this chapter was to replicate the findings of significant association seen 
between the MUC5AC 3′ SNP and asthma identified in the longitudinal birth cohort 
(chapter 3). We aim to do this by initially characterising 3′ MUC5AC variation by 
Sanger sequencing in two asthmatic case-control disease cohorts.  
 
Since GCM is characteristic of asthma and MUC5AC is a marker of GCM (see chapter 
3) it could be hypothesised that MUC5AC variation leads to alter susceptibility to 
asthma and/or may result in varied asthmatic severity.  
 
The second aim of this chapter is to explore the relationship between MUC5B 
regulatory variants and asthma. MUC5B regulatory variants have been shown to be 
significantly associated with the hypersecretory airway disease DPB (Kamio et al 2005) 
and promoter haplotype variants have been shown to confer different gene expression 
levels by two independent studies (Kamio et al 2005; Loh et al 2010). We therefore 
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hypothesise that the high expressing haplotype will be overrepresented in the asthmatic 
case sample set since asthma is a characteristic hypersecretory disease.  
 
 
4.3 Results 
 
The results section will be divided into three parts; analysis of variation within the 3′ 
end of MUC5AC; MUC5B proximal promoter variation and an account of the 
preliminary findings with regard to the putative MUC5B distal promoter. Note that all 
sections report data from asthmatic disease cohorts.  
 
 
4.3.1 MUC5AC genetic variation 
 
In chapter 3 a statistically significant association between MUC5AC rs1132440 and 
various allergy related respiratory outcomes in a longitudinal birth cohort is reported. 
Here we describe this SNP and others located within close proximity in the 3′ end of 
MUC5AC in two small asthmatic disease cohorts referred to as the matched and severe 
asthmatic cohorts. The first sample set known as the matched asthmatic cohort (n = 
100), is composed of clinically diagnosed atopic asthmatic individuals accompanied by 
sex and age matched atopic non-asthmatic controls. The second sample set will be 
referred to as the severe asthmatic cohort (n = 176) and consists of individuals with 
clinically diagnosed severe asthma (n = 84), and hypernormal controls with no personal 
or family history of respiratory disease (n = 92). It should be noted that no atopy data is 
available for the severe cohort. The two cohorts have been treated separately for all 
analyses in this chapter unless otherwise stated (refer to materials and methods section 
for sample details). 
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4.3.1.1 Allelic data and analysis 
 
Sequence was obtained for two MUC5AC 3′ end regions: fragments spanning from exon 
13 to 14 and exon 19 to 20, the previously tested rs1132440 being located within exon 
19. Because of the unusual patterns of association and deviations from HWE seen with 
rs1132440 in the 1946 cohort (chapter 3), these two neighbouring fragments where 
chosen in order to investigate whether SNPs within close proximity also exhibited 
similar patterns of association  
 
In total, 7 polymorphisms were identified within the region spanning exon 13 to 14 and 
8 SNPs were noted within the exon 18 to 19 region (see figures 4.1 and 4.2 for 
annotated sequences) in the two asthmatic cohorts, several of these SNPs have been 
reported previously. Details and MAFs for all identified SNPs are shown in table 4.1, 
All MAFs are evidently similar for both the matched and severe cohorts. 
 
Table 4.1  Details of the MUC5AC 3′ end SNPs typed in the matched and severe asthmatic cohorts, 
including  minor allele frequencies. 
 
  Matched Cohort Severe Cohort 
SNP ID SNP location MAF n MAF n 
novel 116 Intron 13 0.01 (T) 88 0.03 (T) 161 
rs2075843 Intron 13 0.20 (A) 89 0.22 (A) 164 
10bp VNTR Intron 13 0.03 (3) 88 0.06 (3) 161 
novel 245 Intron 13 0.01 (T) 88 0.01 (T) 161 
rs34666042 Intron 13 0.16 (T) 88 0.12 (T) 161 
novel 287 Intron 13 0.03 (G) 88  0.05 (G) 161 
rs34831688 Exon  14 0.17 (T) 83 0.13 (T) 140 
rs35968147 Intron 18 0.19 (C) 88 0.18 (C) 169 
rs2075844 Intron 18 0.40 (G) 87  0.41 (G) 170 
novel 420 Intron 18 0.01 (T) 88   0.00 (T) 170 
novel 422 Intron 18 0.01 (A) 88 0.00 (A) 170 
rs28728088 Intron 18 0.19 (T) 88 0.18 (T) 170 
novel 514 Intron 18  0.00 (T) 88 0.01 (T) 170 
novel 527 Intron 18 0.00 (T) 88 0.003 (T) 170 
rs1132440 Exon  19 0.38 (G) 99 0.41 (G) 170 
 
MAF refers to minor allele frequency and SNP location details the intron/exon location of the SNP. Both 
exonic SNPs are synonymous and thus do not alter an amino acid. N = number of individuals from whom 
data was obtained. The SNPs reported previously have a rs identifier number. The novel polymorphisms 
discovered during this project have not been previously reported and therefore have no existing 
identifiers, thus each has been assigned a number in relation to the location within the PCR fragment. 
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None of the SNPs in table 4.1 are represented in the HapMap project. The MAF of 
rs1132440 in the larger of the two cohorts (severe cohort), is in good agreement with 
that of the 1946 cohort sample set (chapter 3). 
 
All polymorphic markers identified in these sample sets are annotated in figures 4.1 and 
4.2 and the novel variants, which have no rs identifiers, have been assigned numbers in 
accordance with their nucleotide position within the PCR fragment. Three novel SNPs 
and a 10bp VNTR were identified within intron 13. SNP 116, SNP 245 and the VNTR 
were confirmed by sequencing in both orientations. SNP 287 was specific to samples 
typed as heterozygotes for the tandem repeat and it was not therefore possible to 
confirm this SNP in the forward orientation due to the overlapping peaks generated by 
the insertion of an extra 10 base pairs.  
 
Four novel SNPs were also identified within intron 18 and confirmed by sequencing in 
both orientations, however all but one are represented on only one chromosome 
(singletons). All confirmed novel polymorphisms are at low frequencies (table 4.1) and 
only two genotypes were identified for each (common homozygote and heterozygote). 
The intron 13 VNTR is the most frequent of the novel polymorphisms with MAFs of 
0.03 and 0.05 (3 repeats) in the matched asthmatic and severe asthmatic cohorts 
respectively, and is therefore the only novel polymorphism included in the MUC5AC 3′ 
haplotypes subsequently generated in this chapter. 
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GGGCAGGCTGGACAGTGTGCAGC[ATCAACGGGACCCTGTACCAGGTAAGAGCCACGGAG 
 
CTCAGACCCCCTCAGCCATAGGGACGGAGCTTCCCACTGACCCTGAGGCCCAGGTAGACT 
 
TTGGAGCAACTGCCAACTCYGGCCGRGGCCAGGGACTCGAGTCTCTGCAGACACAGCCCA 
                   116   rs2075843  
CTATCAAGTGTGGCTGAGGCCCGAGGTCGGCCCCAGGTCCCGGAAATATGGACATCTACA 
               10bp tandem repeat 
CCCTGGCCTGCCTGGCTCCGGGGGGCTCYGGGGGACTTTGCCTCTCYTGGCACCACAGCA 
                            245               rs34666042 
CAGCCAGGCCKGGATCCCACGGCTCTGTCCTGAGCCGGCTGAGTATGTGGCCCTGCAGAG 
          287 
TGTGTGGCCTTGTTGGGCACCCCATCCAAGGGGGTGCAGCGTGGGGCTCTGCTCTAGGGA 
 
TGGGGACCCTGGGCTGTGGCCTCTGCACCAAGAGGTGCCACCACGAGTCACCCCAGGGGT 
 
GCAACTCGGCCTGGTAGGAAGCGGCCTGGAGGGGGATGTCTGGGAAGTTGGGGGCAGCAA 
 
GCCAGTGGGGAGGCAGGGGCGGGTCTCCCCAGGGCCCAAGCTCATGAGTGTCTGCTGCCC 
 
TGGCTCTCCCCAGCCCGGCGCCGTGGTCTCCTCGAGCCTGTGCGAAACCTGCAGGTGTGA 
 
GCTGCCGGGTGGCCCCCCATCGGAYGCGTTTGTGGTCAGCTGTGAGACCCAGATCTGCA] 
                        rs34831688 
ACACACACTGCCCTGTG 
 
 
Figure 4.1  Nucleotide sequence of the MUC5AC 3′ terminal region spanning from exon 13 to exon 14. 
Exons are highlighted in grey. Square brackets define PCR fragment boundaries. Yellow highlight shows 
positions of novel polymorphisms and the number identifiers for these polymorphisms are defined relative 
to the start of the PCR fragment. Green highlight represents locations of previously reported SNPs. Note that 
all polymorphisms annotated in this sequence have been confirmed in this study. Nucleotide abbreviations; 
K = G/T; R = A/G; Y = C/T.  
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TGGGCTGGTCCTAAACCCTGTGTTCCTCTCCAGAGT[CGACCTGTGCTGTGTACCATAGG 
 
AGCCTGATCATCCAGCAGCAGGGCTGCAGCTCCTCGGAGCCCGTGCGCCTGGCTTACTGC    
 
CGGGGGAACTGTGGGGACAGCTCTTCCATGTACGTGCCTGGGCAGCAGGCAGGGAGACGC 
 
GATTGGCTGTGGGGTGCAGTCAGGGCCCCCAGGGCTCYAGGTGCCAGATAGACGAGGGGC 
                                     rs35968147 
AGGACCATGAGGGGCCAGRCAAAGGGCTCTGAGGGTGAGGCGGGAAAGGGGTCCTGAGAT 
                  rs2075844 
GGCAAGGGTGGGGCTGGGGTAACTACATCCCCAGAGCCTGTGTCGGCATCACGCTCTCCT 
 
GTTTACTGAGCTCCGCCAGGAACTTGCCGCAGCCGCCCCGAGTCTCCCTCCCTCCCATCA 
                                      422 
GCACGGAGCCGGGGTCGGCCCTGGTGGGACTGTTGGYGMCTGGGGAACTGGCAAAGGAGA 
                                    420 
GCTGGTTGTCAGACACTGGCAGCATGCCTCCAGGAGCAGGGAACACGATGAGGCCGCCCA 
          514 
GAGCTYGGCAYGGCGCCGGCTTAYGGCAGGAGGCTGGGGTGGCGCAGCAGCTGGTGCTGA 
     rs28728088        527 
GCAGCCCCTGCCCACAGGTACTCGCTCGAGGGCAACACGGTGGAGCACAGGTGCCAGTGC    
 
TGCCAGGAGCTGCGGACCTCGCTGAGGAATGTGACCCTGCACTGCACCGACGGCTCCAGC  
 
CGGGCCTTCAGCTACACCGAGGTGGAAGAGTGCGGCTGCATGGGCCGGCGSTGCCCTGCG  
                                                  rs1132440                                                                               
CCGGGCGACACCCAGCACTCGGAGGAGGCGGAACCCGAGCCCAGCCAGGAGGCAGAGAGT 
                      
GGGAGCTGGGAGAGAGGCGTCCCAGTGTC]CCCCATGCACTGA 
 
 
Figure 4.2  Nucleotide sequence of the MUC5AC 3′ terminal region spanning from exon 18 to exon 19. 
Exons are highlighted in grey. Square brackets define PCR fragment boundaries. Yellow highlight shows 
positions of novel polymorphisms and the number identifiers for these polymorphisms are defined relative 
to the start of the PCR fragment. Green highlight represents locations of previously reported SNPs. Note that 
all polymorphisms annotated in this sequence have been confirmed in this study. Nucleotide abbreviations; 
K = G/T; M = A/C; R = A/G; S = C/G; Y = C/T.  
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4.3.1.2  Data analysis 
 
The allelic distribution of all SNPs was compared between the cases and controls in 
both disease cohorts. 2 by 2 contingency tables were constructed and examined using 
chi squared tests. No statistically significant difference between cases and controls was 
noted for any SNP in either cohort. 
 
Because of low expected cell counts, genotype distributions were analysed in two 
separate ways; by grouping genotypes into common homozygotes versus the 
heterozygotes and rare homozygotes; by combining the two cohorts in order to increase 
expected cell counts to sufficient numbers in order to perform chi squared tests. No 
statistically significant difference in genotype distribution was observed between the 
cases and controls in either of the analyses performed. 
 
The only significant difference noted between the cases and controls with respect to 
genotype counts were deviations from HWE for two SNPs rs34666042 and rs34831688 
(p = 0.01 and 0.02 respectively) in the asthmatic sample set of the severe cohort; no 
deviation from HWE is noted within the hypernormal controls. Marginal significant 
deviation (p = 0.05) from HWE equilibrium was also noted for rs34666042 in the 
asthmatic sample set of the matched cohort and once again no significant deviation was 
seen for any SNPs in the matched controls. However in contrast to the observations in 
the 1946 cohort (chapter 3), there are less heterozygotes than expected in this disease 
sample. Genotype distributions for all other SNPs are not shown to deviate from those 
expected under HWE.  
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4.3.1.3 Measures of linkage disequilibrium 
 
 
 
Table 4.2  D′ measures of pairwise LD for polymorphisms within the MUC5AC 3′ end region 
spanning from exon 13 to exon 19 in asthmatic a. cases and b. controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only polymorphisms with a frequency greater than 10% have been included in these LD analyses.  a. 
Cases include asthmatic samples from both the matched and severe cohorts. b. Controls include control 
samples from both matched and severe cohorts.  
 
 
In order to study the patterns of LD across this 3′ end region, Ldmax was used to 
compute pairwise measures of LD for cases and controls separately. The two disease 
cohorts were combined in order to amalgamate cases and controls; cases include the 
matched asthmatic samples plus the severe asthmatics, while the controls are 
represented by the matched atopics plus the hypernormal controls from the severe 
cohort. As shown in table 4.2 a and b there is almost complete LD across this region as 
all pairwise associations are statistically significant ( with p values of < 0.05 as tested 
by chi squared) and nearly all have D′ values of 1. The patterns of LD between cases 
and controls are almost identical except for the D′ values between SNPs rs2075843 and 
rs1132440, where there appears to have been a small amount of recombination in only 
the sample set of cases. 
 
 
 
 
 
        
 
rs34666042 1.000       
 
rs34831688 1.000 1.000      
 
rs35968147 1.000 1.000 1.000     
 
rs2075844 1.000 1.000 1.000 1.000    
 
rs28728088 1.000 1.000 1.000 1.000 1.000   
 
rs1132440 0.914 1.000 1.000 1.000 1.000 1.000  
 
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088  
         
         
 
a.  
 
  
      
 
 
rs34666042 1.000      
 
 
rs34831688 1.000 1.000     
 
 
rs35968147 1.000 1.000 1.000    
 
 
rs2075844 1.000 1.000 1.000 1.000   
 
 
rs28728088 1.000 1.000 1.000 1.000 1.000  
 
 
rs1132440 1.000 1.000 1.000 1.000 1.000 1.000 
 
 
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088 
 
         
         
 
b.  
 122 
4.3.1.4 Haplotypes inference and analysis 
 
Haplotypes were inferred by PHASE with a certainty of 0.99 or greater for the 
MUC5AC 3′ terminal region spanning from exon 13 to exon 19 using the genotype data 
for 6 of the previously described SNPs and the novel intron 13 VNTR. Data for SNP 
rs34831688 has been removed from the haplotypic analysis since this marker could not 
be typed in the individuals who were heterozygotes for the intron 13 TR which could 
result in uneven dropout due to the complete linkage noted within this region. The 
inferred MUC5AC 3′ region haplotypes are detailed in table 4.3. There are four major 
haplotypes (HA-HD) which account for all haplotypes identified in the severe asthmatic 
cohort and 98 per cent of the matched asthmatic haplotypes. The rare haplotypes (HE-
HG) appear to be recombinants of the common haplotypes. Please note that the 
haplotype frequencies obtained from Arlequin (not shown) are almost identical to the 
PHASE results shown in table 4.3. 
 
The rare novel alleles were assigned to a haplotypic background by firstly identifying a 
carrier of the novel allele who was also homozygous for a particular haplotype. It was 
subsequently assumed that the rare allele was only present on this haplotype since it is 
unlikely that the mutation will have occurred independently more than once. Novel 
SNPs 287 and 245 are exclusive to the HD haplotype. SNP 287 is always present on the 
HD haplotype while 245 is present occasionally. Novel alleles 116 and 514 only occur 
on the most frequent haplotype HA. The other novel alleles cannot be assigned to 
haplotypic backgrounds since they have only been identified on a single chromosome.  
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Table 4.3  Details and frequencies of the MUC5AC 3′ region haplotypes for all case and controls 
sample sets. 
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HA G 2 C T A C C 0.59 0.62 0.57 0.63 
HB A 2 C T G C G 0.16 0.21 0.23 0.22 
HC G 2 T C G T G 0.19 0.13 0.16 0.09 
HD G 3 C C G T G 0.03 0.02 0.04 0.06 
HE A 2 C T G C C 0.02 0.00 0.00 0.00 
HF G 2 C T G C C 0.01 0.00 0.00 0.00 
HG G 2 C T A C G 0.00 0.01 0.00 0.00 
 
SNP rs34831688 has been removed from haplotype analysis because we were unable to type this variant 
in the heterozygous intron 13 TR individuals. The shading in this table indicates likely recombination 
events that may have occurred to produce the rarer haplotypes.  
 
 
Haplotype frequencies are shown in table 4.3, and they show that the rare recombinant 
haplotypes have only been identified in the matched asthmatic cohort and are found in 
both the cases and controls. It is noteworthy that the rare allele of the SNP showing 
significant deviation from HWE in the cases (rs34666042), is only found on the HC 
haplotypic background. Haplotype distribution between cases and controls are 
represented graphically in figure 4.3 for both the severe and matched asthmatic cohorts. 
The distributions of haplotypes with respect to disease status, are fairly similar for both 
asthmatic cohorts. Notably the controls have a greater percentage of HA and the cases 
have a greater percentage of HC.  
 
The differences in haplotype distributions between cases and controls were tested three 
separate ways, chi squared test, PHASE case-control analysis and the exact test of 
population differentiation (ETOPD) implemented by Arlequin. A significant difference 
was noted between the haplotype frequencies of the severe cohort case and control 
sample sets (p = 0.021) when examined with the ETOPD. However the PHASE case-
control analysis and a chi squared test indicated that the difference was not statistically 
significant. No statistically significant difference in haplotype distributions could be 
identified in the matched asthmatic cohort. 
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Figure 4.3  Bar chart representing the distribution of MUC5AC 3′ region haplotypes between cases 
and controls of the a. severe asthmatic cohort b. matched asthmatic cohort. 
 
 
4.3.2 MUC5B proximal promoter 
 
As discussed in the introductory section of this chapter, variation in the MUC5B 
immediate promoter region appears to be of functional importance in the hypersecretory 
disease DPB. Therefore the MUC5B proximal promoter (+97 to -1097 with respect to 
the TSS) was sequenced in our two small asthmatic disease cohorts with a view to 
examining the corresponding Kamio haplotypes (Kamio et al. 2005). We hypothesised 
that the high expressing H1 haplotype would be overrepresented in the asthmatic 
populations based on the notion that like DPB, asthma is a hypersecretory disease of the 
airways.  
 
 
4.3.2.1 Allelic data 
 
Six polymorphic SNPs were identified (see figure 4.4) and typed by sequencing in the 
matched asthmatic and severe asthmatic disease cohorts. Minor allele frequencies 
(MAF) range from 0.05 to 0.24, all shown in table 4.4. Only two of these SNPs are 
included in the HapMap project, rs885454 and rs7118568, and the MAFs identified for 
 
 
a. b
. 
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these two European disease cohorts are in good accordance with the HapMap CEPH 
dataset. It should be noted that the proximal promoter indel (rs17235353) which defines 
the low expressing H2 haplotype is monomorphic within this European sample, with 
only the insertion allele being represented.  
 
Table 4.4  Details of the MUC5B proximal promoter SNPs typed in the matched and severe 
asthmatic cohorts, including minor allele frequencies (MAF). 
 
Matched Cohort Severe Cohort SNP  
ID 
SNP  
location MAF n MAF n 
rs885455 -919 0.19 (G) 96 0.19 (G) 135 
rs885454 -906 0.05 (A) 96 0.06 (A) 136 
rs7115457 -237 0.09 (A) 96 0.09 (A) 156 
rs7118568 -217 0.09 (G) 96 0.09 (G) 156 
rs56235854 -100 0.05 (A) 96 0.05 (A) 154 
rs2735738 -78 0.21 (C) 96 0.24 (C) 155 
 
SNP location refers to base position relative to transcription start site and n refers to number of 
individuals. 
 
In order to compare allelic distributions between cases and controls within each cohort, 
2 by 2 contingency tables of allele counts were constructed and tested with chi squared 
or Fishers exact tests under the null hypothesis that asthmatic and control samples come 
from the same population and are therefore not significantly different with respect to 
MUC5B promoter allele counts.  
 
Analysis of the severe asthmatic cohort identified statistically significant associations 
between the two SNPs rs7115457 and rs7118568 and severe asthma with a chi squared 
p value of 0.015 for both. It should be noted that these SNPs are completely linked and 
therefore any significance is due to the same association. For both SNPs the rare alleles 
are underrepresented in the asthmatic disease group, and it should be noted that these 
rare alleles define the high expressing H1 haplotype. 
 
This association could not be confirmed at the 95% confidence level in the matched 
asthmatic cohort however rs56235854 showed marginal significance with a p value of 
0.054.  
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-1097 
CCACGGAGCATTCAGGACGCTGGTGACCAGGGAGCCAGGAGGTGGGAGCATCTGAGGTGCA 
 
GGTCACACGGGCAGGAGGTGTTTGCAAGAGGTATTGCAGCGCGGACGGAGTGTCCTGCAGA 
                                                        -919 
TGACGCTGTCTGTCCTGTAGATGACGCTCGTCAAGGAGGTTTACCACATAGCCCCCRGGAA 
        -906                                         rs885455 
GCCCACCCRACACCAGCCGGAGGTGCTAGGCTTCTGCGGCTCCCACCTGGGGCAGGCGGAG 
        rs885454 
GACCCCGGGCAGGTCCAGGACCCCCCGGAGCAGCTGCTTCCTCAACCCTGCCAGGGTTAAT 
 
GAGGAGGCCCCAGAGTGAGGTGGAGGCCAAATGGGACTCAGGGCCGGAGCCTCTGGCCTGG 
 
CTGGATCAGGGCTGGCATTGGACAAGCGCAGCTGACTCCCGATGTGCATGGCCAGGAGACA 
          -659/660 
CTCTGGGCCTCAGTTTCCCCTTGAATGTGAACCTTGAAACAGATCAGCCCAGAGACCTCCC 
          rs17235353 
ACGGTCTTCAAGGGGCTCTGGTCAGCTGGGCTGGGGTCTCTGGAAATAGAGCCTCCTCCAG 
 
GGACCCCCACAAGCCACCCAGACTGAGCATCCTGGCCATGTGCATGCCTGAGCTCAGCAGG 
 
AGCCTCCCGGcCTCCCCGTGGGCTAAGCAGTGGTGGGAGGGGAGCTCCAGCCTCGTGGGCC 
 
CTCCCCGGGCCTCGGGGACCCATGGTCAGTGGCTGGGGGTGCTGCCCAGAGGCTGGGATTC 
 
CCTTCCAGCAGGAGCCGCAGTGGGGCTGAGTGTGAGGCAGGCTGGCTGACCACTGTTTCCA 
 
TGGACCCTGCGTCCAAGGCCAGCCCTGCCTTCCAGCGGCTTTGCCATCTAGGACGGGTGCC 
      -237                -217 
AGGTGGRGTAGGCCCTTCTCTCCCTTSCGATTCTCAGAAGCTGCTGGGGGTGGGGGCGTCC 
      rs7115457           rs7118568 
TGGGCCTCAGGGCACAGAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCC 
                     -100                  -78 
CCTCCCCGAGAGCAAACACACRTGGCTGGAGCGGGGAAGAGCAYGGTGCCCTGCGTGGCCT 
                     rs56235854            rs2735738 
GGCCTGGCTTGGGGCCAAGGCTCCCTGCTACATAAGCTGGGGCCCCCAGGGGAGCAAGCA▌ 
+1                     PROXIMAL TATA BOX 
CCCGGCCCGGCTCCCTCCCTGCCCGTCCCCGTCCCCCCACCCGTGCCAGCCCCCAGGATGG 
TSS                                +97 
GTGCCCCGAGCGCGTGCCGGACGCTGGTGTTGGCTC 
 
Figure 4.4  Annotated sequence corresponding to the MUC5B proximal promoter. Grey highlight 
indicates forward and reverse primers for the fragment A. Pink highlight indicates forward and reverse primers 
for fragment B. All SNPs typed in the two asthmatics cohorts are highlighted in green, note that all are 
polymorphic within these sample sets with the exception of the indel rs17235353. Transcription start site is 
indicated by ▌. The TATA box is highlighted in yellow and the start of translation codon (ATG) is underlined 
and in bold
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4.3.3 Allelic variants and transcription factor binding sites 
 
Figure 4.5 shows predicted transcription factor binding sites (TFBS) within the MUC5B 
proximal promoter most of which have been previously described in the literature (Chen 
et al. 2001; Wu et al. 2007a). Only the two Sp1 TFBS have been experimentally 
determined (Wu et al. 2007a). Wu et al have shown that binding of the transcription 
factor Sp1 to the binding sites located in the MUC5B promoter region, is induced by 
phorbol 12-myristate 13-acetate (PMA). PMA is used to model inflammation and it is 
therefore proposed that the Sp1 TFBS might play an important role during airway 
inflammatory disease. It should be noted that all other TFBS reported by Chen et al and 
Wu et al have only been predicted using the TRANSFAC database and are thus 
considered to be putative. Three additional predicted binding sites (STAT -919/-912, 
HNF4 and AP2α) were identified during this project using the web based tool rVista 
(see materials and methods for details and web address), which predicts cis-regulatory 
elements by combining TFBS database searches (TRANSFAC professional V10.2 
library) with comparative sequence analysis. In this instance the mouse homologous 
MUC5B promoter sequence was used as the comparison sequence. The rodent promoter 
sequence was chosen as opposed to a primate sequence since the human and mouse are 
more distantly related and therefore high conservation between these species is likely to 
be indicative of function. In order to maximise the stringency of the predictions, the 
matrix similarity was set at 90% and only high-specificity matrices were selected. The 
rVista tool was also able to predict the MYC (-106/-95) and Sp1 (-124/-114) TFBS that 
had previously been identified in the literature (Wu et al. 2007a).  
 
On examining SNP positions with respect to predicted TFBS, SNPs rs56235854, 
rs7115457 and rs885455 were shown to fall within MYC, NFκB and STAT binding 
sites respectively (see figure 4.5).  
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Figure 4.5  Diagrammatic representation of the MUC5B proximal promoter with annotated 
transcription factor binding sites (TFBS) and identified allele variants. The annotated binding sites 
are located at the following positions relative to the transcription start site; STAT -919/-912, HNFα -866/-
861, AP1 -500/-493, NFκB -373/-364, NFκB -238/-229, STAT -213/-205, Sp1 -196/-185, Sp1 -124/-114, 
MYC -106/-95, TATA -32/-26, AP2α +49/+57. Note that STAT -919/-912, HNF4 and AP2α binding sites 
were identified during this project with rVista using the human and mouse conservation profile. All other 
TFBS had been previously identified by either Chen et al or Wu et al (Chen et al. 2001; Wu et al. 2007a). 
SP1 TATAMYCSP1STATNFκβNFκβAP-1HNFαSTAT
EXON 1TSS
AP2-α
rs7115457
(-237) rs56235854(-100)
+1
rs7118568
(-217)
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(-78)
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4.3.3.1 Genotypic data 
 
Because of the small size of the data sets, the genotypes for all SNPs were grouped into 
two categories, common homozygotes and carriers of the rare allele (heterozygotes and 
rare homozygotes). In the severe asthmatic cohort the SNPs shown to significantly 
associated with asthma at the allelic level, also show statistically significant association 
with respect to the grouped genotypes. In fact the significance is increased with a chi 
squared p value of 0.008 for both rs7115457 and rs7118568 and as can be seen in the 
bar charts in figure 4.6 the severe asthmatic cases show an underrepresentation of the 
genotypes carrying the rare allele and have a greater proportion of common 
homozygotes as compared to the hypernormal control sample set. This pattern of 
association suggests that the rarer alleles confer protection irrespective of genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6  Grouped genotype distributions for rs7115457 and rs7118568 between cases and 
controls in the severe asthmatic cohort. Significant association has been noted for the combined 
genotypes of both SNPs with a p value of 0.008 for both (2-tail Pearsons chi squared).  
 
 
In the matched asthmatic cohort the SNP exhibiting borderline significance with respect 
to allelic distributions rs56235854, is shown to be significantly associated with asthma 
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in this sample set when analysed as grouped genotypes with a chi squared p value of 
0.038. It is noteworthy that the pattern of association for the genotype distributions of 
rs56235854 are very similar to rs7115457 and rs7118568 (figure 4.7) in the severe 
cohort, in which the common homozygotes are overrepresented in the cases and the 
heterozygotes/rare homozygotes are underrepresented in the disease sample set.  
 
 
 
 
 
 
 
 
    
 
 
 
 
4.3.3.2 Haplotypic data   
 
MUC5B proximal promoter haplotypes for both disease cohorts were constructed using 
the haplotype inference software PHASE. Haplotypes were assigned identifiers in 
accordance with those previously identified by Kamio et al. A total of 8 proximal 
promoter haplotypes were identified in the matched asthmatic cohort and 7 in the severe 
asthmatic cohort (see table 4.5).  
 Figure 4.7  Grouped genotype 
distribution for rs56235854 
between cases and controls in 
the matched asthmatic cohort  
The grouped gentotype 
distributions are significantly 
associated with the asthmatic 
phenotype with a a p value of 
0.038 (Pearsons 2 tail chi 
squared).  
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Table 4.5  MUC5B proximal promoter haplotype details and frequencies in the matched and severe 
asthmatic cohorts. 
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H3 A G I G C G T 0.74 0.66 0.67 0.67 
H1 G G I A G G C 0.07 0.11 0.05 0.13 
H8 A G I G C G C 0.07 0.04 0.09 0.10 
H4 G A I G C G C 0.03 0.06 0.07 0.04 
H3a A G I G C A T 0.02 0.09 0.07 0.02 
H6 G G I G C G T 0.03 0.02 0.04 0.04 
H5 G G I G C G C 0.03 0.01 0.00 0.00 
H9 G A I G C G T 0.00 0.01 0.00 0.00 
? A A I G C G T 0.00 0.00 0.009 0.00 
 
Haplotype IDs are in accordance with the Kamio haplotypes (Kamio 2005). H3a is a novel haplotype as it 
includes the rare allele of the SNP rs56235854 which was not identified in the Japanese population. Note 
that the rs56235854 rare allele only occurs on the H3 haplotypic background. A severe asthmatic sample 
SA053 also contains a novel haplotype not previously identified. SNPs in bold have been shown to be 
significantly associated with asthma in either the severe or matched asthmatic cohorts. 
 
 
It has previously been shown in vitro by reporter construct assays, that H1 haplotype 
confers the highest expressional activity of the three haplotypes H1, H2 and H3 (H2 not 
identified in this population), which has been supported by an in vivo study (Loh  et al. 
2010). Thus our prior hypothesis was that the H1 haplotype would be overrepresented 
in the asthmatic samples and therefore all haplotypes were grouped into two categories; 
H1 or not H1. 2 by 2 contingency tables were constructed in order to compare haplotype 
counts in asthmatic and control samples and chi squared test were used to test the tables 
for deviations in haplotype count distributions. Statistical significance was noted in the 
severe asthmatic cohort with a p value of 0.03 (2 tailed) whereby there is a decrease of 
H1 haplotypes in the asthmatic sample compared with their controls (see figure 4.8). A 
similar pattern can be seen in the matched asthmatic cohort where the H1 haplotype 
frequency is greater in the atopic controls (0.11) than in the asthmatic cases (0.07), 
though statistical significance is not reached. Thus a significant association between the 
H1 haplotype and asthma has been noted although the identified pattern of association is 
opposite from that which we had hypothesised. 
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Figure 4.8  Bar charts showing the distribution of H1 and non H1 haplotypes between the cases and 
controls of the a. severe asthmatic cohort b. matched asthmatic cohort. The distribution depicted in 
chart a was shown to be statistically significant with a p value of 0.03 (2 tail Pearsons chi squared). The 
distribution shown in chart b was not shown to be significantly different.  
 
 
4.3.4 MUC5B distal promoter 
 
A preliminary study of the MUC5B putative distal promoter (-2268 to -986 relative to 
the TSS) reported by Perrais et al (Perrais et al. 2001) has been conducted during this 
project.  
 
Within this region 24 SNPs have been reported to the NCBI SNP database, however 
only 9 of these SNPs are accompanied by supporting polymorphic data within a 
European population. The aim of this preliminary study was to characterise all sequence 
variants within the putative distal promoter region in both asthmatic cohorts. However 
due to limited DNA supply only the matched asthmatic cohort has been included in this 
preliminary study. RT-PCR was also used to evaluate the validity of this region as an 
active promoter, since this promoter has been reported only once in the literature and 
therefore little functional information is available. 
 
a. 
 
 
b. 
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4.3.4.1 Allelic data 
 
Within the putative distal promoter region 7 polymorphic SNPs were identified in the 
matched asthmatic sample set (see appendix 3 for annotated sequence), all of which 
correspond to previously reported SNPs. Allele frequencies range from 0.006 to 0.49 
(table 4.6) and only rs868903 is represented in the HapMap project for which the MAF 
for the CEPH sample is in good agreement with the disease cohort reported here. All 
genotypic distributions were in accordance with those expected under HWE.  
 
 
Table 4.6  Details of the MUC5B SNPs located within the putative distal promoter. 
 
SNP ID SNP Location MAF 
rs11042646 -2019 0.16 (T) 
rs55974837 -2002 0.03 (T) 
rs35619543 -1996 0.26 (T) 
rs12804004 -1947 0.44 (T) 
rs868902 -1738 0.45 (A) 
rs868903 -1556 0.49 (T) 
rs868904 -1437 0.006 (T) 
 
MAF is minor allele frequency, minor alleles are in parentheses, SNP location refers to base position 
relative to transcription start site. Data for 186 chromosomes were available for rs11042646, rs55974837, 
rs35619543, rs12804004 and rs868902. Data for 174 chromosomes were available for rs868903 and 
rs868904. 
 
 
2 by 2 contingency tables of allele counts were constructed to compare allelic 
distributions between asthmatic and atopic control samples and tables were tested using 
a Fishers exact test. No statistically significant associations could be identified between 
allelic counts and asthma. 
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4.3.5 Looking for the putative MUC5B distal promoter: RT PCR 
 
A previous study has identified active MUC5B distal promoter activity in the Kato III 
gastric carcinoma cell line and has also identified a transcript corresponding to the distal 
promoter in tracheal RNA using a primer extension method. However no other study 
has addressed the activity of this distal promoter. In this preliminary study we have used 
RT-PCR to look for transcripts corresponding to an active MUC5B distal promoter in 
clones of a mucus secreting colon cancer cell line, normal human bronchial epithelial 
(NHBE) cells grown at air liquid interface (ALI) and fetal lung tissue samples.  
 
In an effort to identify distal promoter activity, three different RT-PCR assays were 
performed. Two assays were designed to amplify any 5′ UTR that may correspond to a 
distal promoter transcript, while the third assay was designed as a control for MUC5B 
expression; assay 1 aimed to amplify from the 5′ region of the reported transcript to 
exon 1; assay 2 from the same region to exon 2; the control assay from exon 1 to exon 
2.  
 
Access was available to cDNAs from the following resources; various subclones of the 
mucus secreting HT29-MTX cell line, at both exponential and stationary phase (n = 8); 
fetal lung tissues (n = 2 ); NHBE cells grown at air liquid interface (n = 1). The PCRs 
were conducted on these cDNAs and MUC5B expression was validated in all HT29-
MTX subclones, fetal lung tissue and NHBE ALI cells. However, no transcripts 
corresponding to expected transcripts from the putative MUC5B distal promoter (assays 
one and two) could be identified for any cDNA sample. Figure 4.9 shows a 
representative experiment and figure 4.10 depicts the MUC5B 5′ UTR sequence which 
has been annotated for all primers and important motifs.  
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Figure 4.9  MUC5B putative distal promoter RT-PCR product visualisation. a. RT-PCR products 
aimed to amplify from the 5′ region of the reported transcript to exon 1. b. RT-PCR products aimed to 
amplify from the 5′ region of the reported transcript to exon 2. c. MUC5B control RT-PCR, product 
visualisation corresponding to a transcript spanning from exon 1 to exon 2. The colonic cell line HT29 
was differentiated into the two clones 5M21 and 5M12 by treatment with 10-5 M methotraxate. 5M21 has 
a mucus secreting phenotype. 5M12 has a enterocytic phenotype. E refers to exponential phase. S refers 
to stationary phase. All RT-PCR products were visualised on 2% agarose gels, 
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CTGTGACGTAAATAAAACAACAGACCTGGACACCACCCTAGGGTCCCCATGGGGCCG 
      distal TATA box          distal TSS 
 
GACGAGGCCACACCACCCGACCTGGTGCTTCCTGCCTGGCGTCTGCGCCACGGAGCA 
   distal FOR primer  
 
TTCAGGACGCTGGTGACCAGGGAGCCAGGAGGTGGGAGCATCTGAGGTGCAGGTCAC 
   NAU 647 (PE REV)- Perrais et al 
 
ACGGGCAGGAGGTGTTTGCAAGAGGTATTGCAGCGCGGACGGAGTGTCCTGCAGATG 
 
···········891bp of proximal promoter sequence··········· 
 
AGCATGGTGCCCTGCGTGGCCTGGCCTGGCTTGGGGCCAAGGCTCCCTGCTACATAA 
                                                   proximal TATA box 
 
GCTGGGGCCCCCAGGGGAGCAAGCACCCGGCCCGGCTCCCTCCCTGCCCGTCCCCGT 
                         proximal TSS 
 
CCCCCCACCCGTGCCAGCCCCCAGGATGGGTGCCCCGAGCGCGTGCCGGACGCTGGT 
                                             exon 1 FOR primer  
 
GTTGGCTCTGGCGGCCATGCTCGTGGTGCCGCAGGCAGGTAAGAGCCCCCCACTCCG 
                    exon 1 REV primer 
 
CCCCCTCTCGATGCTGTCTTCACGGCGGGGGTCTCTGCAGGTCGCTTGCCTGGGAGC 
 
··············2,393bp of intron 1 sequence···············  
 
CATTCCCTCTTCCCACAGAGACCCAGGGCCCTGTGGAGCCGAGCTGGGAGAATGCAG 
 
 
GGCACACCATGGATGGCGGTATGTGGCCAGGTTCGGGGGTGGGGGGTTCCTGACCAG 
   exon 2 REV primer 
 
GCTGGAGGGGCTGGAATTTGGGCTGGGGCAGGCAGACGCCTCTCCAAGCAGCCATGC 
 
 
Figure 4.10  Annotated MUC5B sequence spanning from the putative distal TATA box to exon 2. 
Boxed sequences shaded in grey represent primers used for the RT-PCR, where FOR is forward and REV 
is reverse. Bold and underlined sequence represents exons. Proximal and putative distal transcription start 
sites (TSS) are highlighted in red. Proximal and putative TATA boxes are highlighted in yellow. 
Sequence highlighted in purple represents the reverse primer elongated by primer extension in order to 
establish the distal TSS in the Perrais et al study (Perrais et al 2001). 
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4.3.6 MUC5AC and MUC5B extended haplotypes 
 
Significant disease associations were reported in chapter 3 between a 3′ end MUC5AC 
SNP and in this results chapter we report significant associations between severe asthma 
and 5′ MUC5B promoter SNPs, and some evidence of significant association between 
severe asthma and MUC5AC 3′ haplotypes. A previous study has identified a significant 
occurrence of an extended haplotype spanning from MUC2 to MUC5B in people of 
European ancestry (Rousseau et al. 2007), and it was therefore postulated that the 
significant associations reported in this thesis could possibly reflect a single risk 
haplotype with respect to respiratory disease, thus extended haplotypes spanning from 
MUC5AC to MUC5B will be studied in this section with respect to disease status. 
 
Extended haplotypes were inferred from all MUC5AC and MUC5B markers, except for 
the indels, the frequencies for which are shown in table 4.7.Three extended haplotypes 
dominate (E1, E2 and E3), although E1 is very frequent making up 46% and 45% of the 
haplotypes seen cases and controls respectively. This confirms the findings of the 
Rousseau et al (Rousseau et al. 2007) study though it should be noted that the extended 
haplotypes examined in this project are smaller since they do not include MUC2 marker 
data. 
 
The high expressing MUC5B promoter haplotype H1 (shading in blue in table 4.7), 
occurs on four of the extended haplotypes and it is noteworthy that in each case the H1 
carrying haplotype is at a greater frequency in the control sample, the most extreme 
examples of this being E9 and E17. This finding is consistent with the results reported 
in section 4.3.3.2 whereby the H1 haplotype is at significantly increased levels in the 
severe asthmatic control group. 
 
The distribution of the MUC5AC haplotypes examined in section 4.3.1.4 showed some 
evidence of significant difference between cases and controls in the severe asthmatic 
cohort and from viewing these data graphically (figure 4.3) it appeared that the HA and 
HC distributions were the cause of this association.  
 138 
It is evident that both the HA and HC MUC5AC haplotypes (orange and red 
respectively) mainly occur with the H3 MUC5B haplotype (shaded pink in table 4.7). 
Only the extended haplotype E17 includes both the HA and H1 haplotypes, both of 
which have been shown previously in this chapter to be at increased numbers in the 
control sample set. Thus the statistically significant MUC5AC and MUC5B haplotype 
associations reported with asthma in this chapter are likely to be independent. 
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Table 4.7  Extended haplotypes ranging from MUC5AC to MUC5B, in asthmatic cases and controls 
 
 
All previously described MUC5AC and MUC5B variants have been included in the haplotype 
construction except for the MUC5B promoter indel since it is monomorphic in this data set. Haplotypes 
were inferred using PHASE. Blocks shaded pink and blue refer to the MUC5B H3 and H1 haplotypes 
respectively. Blocks shaded orange, green and red refer to the MUC5AC haplotypes HA, HB and HC. The 
case sample set includes asthmatic individuals from both the matched and severe disease cohorts. The 
control sample set includes the non-asthmatic controls from both the severe and matched disease cohorts. 
The difference in haplotype distributions between asthmatic cases and controls was not shown to be 
statistically significant when examined by PHASE case-control (p value = 0.4).  
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E1 G C C T A C C A G G C G T 116 119 
E2 G T T C G T G A G G C G T 34 16 
E3 A C C T G C G A G G C G T 24 32 
E4 A C C T G C G A G G C G C 9 6 
E5 A C C T G C G G A G C G C 9 5 
E6 G C C T A C C A G G C G C 9 10 
E7 G C C T A C C A G G C A T 8 10 
E8 G C C T A C C G G G C G T 8 8 
E9 A C C T G C G G G A G G C 5 15 
E10 G T T C G T G G G A G G C 5 6 
E11 A C C T G C G A G G C A T 4 2 
E12 G C C T A C C G G G C G C 3 0 
E13 G C C C G T G A G G C G T 3 6 
E14 G T T C G T G G A G C G C 3 6 
E15 A C C T G C G G G G C G C 2 0 
E16 A C C T G C C A G G C G T 2 0 
E17 G C C T A C C G G A G G C 2 9 
E18 G C C C G T G G G A G G C 2 3 
E19 G C C T G C C A G G C G T 1 0 
E20 G C C T A C C G A G C G C 1 2 
E21 G T T C G T G A A G C G T 1 0 
E22 G T T C G T G G G G C G T 1 1 
E23 G T T C G T G A G G C G C 0 3 
E24 G C C T A C C G A G C G T 0 1 
E25 G C C T A C G A G G C G T 0 1 
E26 A C C C G T G A G G C G C 0 1 
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4.3.7 LD across MUC5AC and MUC5B 
 
It was also of interest to examine whether there was a different pattern of LD between 
cases and controls. Measures of pairwise LD were calculated using data from only the 
MUC5AC and MUC5B SNPs with minor alleles greater than 10 per cent. The pairwise 
D′ measures shown in table 4.8 were calculated separately for case and control groups, 
which represent an amalgamation of both the matched and severe asthmatic disease 
cohorts. 
 
The first analysis was performed using the standard procedure LDmax, and the results 
are shown in table 4.8a. In general, complete LD is seen across MUC5AC. Breakdown 
of LD between the MUC5AC markers rs35968147 and rs34666042 is however seen in 
both the cases and controls. This apparent breakdown is rather unexpected since the rare 
alleles of these two SNPs appear together on one of the most frequent haplotypes, HC 
(see table 4.3).  
 
D′ values less than one are usually interpreted as evidence of historic recombination. 
However, this assumes correct haplotype inference and for the markers to be in HWE. 
Since these SNPs have minor allele frequencies greater than 10 per cent and no 
significant deviation from HWE, this unexpected finding is unlikely to have resulted 
from a frequency issue and in this case it seems to be a product of the EM algorithm 
used by LDmax in order to infer phase.  
 
In order to examine these inconsistencies, an unconventional approach was taken by 
applying the PHASE inferred individual haplotypes to the software HaploXT which is 
generally used for families. As can be seen in table 4.8b, the breakdown of LD between 
rs35968147 and rs34666042 is no longer an issue in the HaploXT pairwise results. Thus 
the pairwise LD measures generated by HaploXT appear to be more reliable. Significant 
association can be seen between the MUC5B markers and several of the MUC5AC 
SNPs, however there is no obvious suggestion that this differs between cases and 
controls.  
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Table 4.8  Pairwise LD measures for MUC5AC and MUC5B markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pairwise D′ measures of LD for cases and controls have been calculated for markers across MUC5AC and 
MUC5B using two different methods, LDmax and HaploXT. Pairwise measures of D′ shown to be 
statistically significant with p values less than 0.05 are in bold. Cases include the asthmatic affected 
groups from both the severe and matched cohorts. Controls include the non-affected groups from both the 
severe and matched asthmatic cohorts.  
 rs34666042 1.000         
rs34831688 1.000 1.000        
rs35968147 0.998 0.664 1.000       
rs2075844 1.000 1.000 1.000 1.000      
rs28728088 1.000 1.000 1.000 1.000 1.000     
rs1132440 1.000 1.000 1.000 1.000 1.000 1.000    
rs885455 0.070 0.127 0.046 0.151 0.232 0.094 0.224   
rs2735738 0.120 0.309 0.271 0.183 0.320 0.184 0.313 0.737  
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088 rs1132440 rs885455  
 
 rs34666042 1.000         
rs34831688 1.000 1.000        
rs35968147 1.000 0.722 1.000       
rs2075844 1.000 1.000 1.000 1.000      
rs28728088 1.000 1.000 1.000 1.000 1.000     
rs1132440 0.915 1.000 1.000 1.000 1.000 1.000    
rs885455 0.178 0.001 0.018 0.038 0.431 0.058 0.422   
rs2735738 0.243 0.424 0.338 0.332 0.376 0.186 0.351 0.792  
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088 rs1132440 rs885455  
 
MUC5AC MUC5B 
M
U
C5
A
C
M
U
C5
B
LDmax Controls 
Cases 
a. 
b. 
Cases 
Controls HaploXT 
MUC5AC MUC5B 
M
U
C5
A
C
M
U
C5
B
  rs34666042 1.000         
rs34831688 1.000 1.000        
rs35968147 1.000 1.000 1.000       
rs2075844 1.000 1.000 1.000 1.000      
rs28728088 1.000 1.000 1.000 1.000 1.000     
rs1132440 0.914 1.000 1.000 1.000 1.000 1.000    
rs885455 0.364 0.008 0.008 0.008 0.483 0.008 0.498   
rs2735738 0.549 0.130 0.130 0.130 0.675 0.130 0.684 0.814  
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088 rs1132440 rs885455  
 
  rs34666042 1.000         
rs34831688 1.000 1.000        
rs35968147 1.000 1.000 1.000       
rs2075844 1.000 1.000 1.000 1.000      
rs28728088 1.000 1.000 1.000 1.000 1.000     
rs1132440 1.000 1.000 1.000 1.000 1.000 1.000    
rs885455 0.267 0.163 0.163 0.163 0.375 0.163 0.370   
rs2735738 0.357 0.297 0.297 0.297 0.475 0.297 0.471 0.715  
  rs2075843 rs34666042 rs34831688 rs35968147 rs2075844 rs28728088 rs1132440 rs885455  
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4.4 Discussion  
 
This chapter has explored variation within the genes that code for the respiratory 
mucins, in relation to asthma. However the most noteworthy finding involves variation 
within the MUC5B promoter, whereby the high expressing H1 haplotype is shown to be 
significantly underrepresented in the severe asthmatic cases as opposed to their controls, 
a pattern of association opposite from that hypothesised. It appears to be counter-
intuitive that the H1 expressing haplotype should be at a significantly lower frequency 
within a sample set of hypersecretory disease cases. However it should be remembered 
that although mucus hypersecretion is likely to exacerbate asthmatic symptoms, the 
cause of asthma is likely to be allergy related and therefore under some circumstances, 
higher airway mucus levels may even confer protection against the development of 
asthma by preventing penetration of insults and allergens into the epithelial cells with a 
greater efficiency. 
 
The rare alleles of variants rs7115457 and rs7118568, define the H1 haplotype. These 
two variants were shown to be significantly associated with severe asthma, associations 
that are likely to be dependent since the SNPs are completely linked. Variant rs7115457 
is located within the putative nuclear factor-kappa B (NFκB) binding site located at -
238/-229 within the MUC5B promoter. NFκB is said to be a prominent transcription 
factor in chronic airway disease (Barnes 2006). Its active form is located in the nucleus 
where it binds directly to NFκB promoter motifs. NFκB binding sites can be found on 
various target inflammatory genes and since the respiratory mucins genes are known to 
be upregulated by inflammation, the predicted NFκB motifs within the MUC5B 
promoter are likely to be functional.  
 
NFκB is thought to be activated by various stimulants such as, cytokines, viral 
infections and oxidants such as ozone (Barnes 2006), all of which are known to 
exacerbate asthmatic symptoms. Variation within the NFκB binding sites of the 
MUC5B promoter may therefore confer susceptibility to asthma or increase asthmatic 
severity since the variants could alter binding of NFκB to its motif. For instance, during 
chronic inflammatory airway disease the epithelial surface is immersed in inflammatory 
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cytokines which will in turn lead to the activation of NFκB. In essence this could be the 
causal event of MUC5B aberrant expression in the goblet cells during chronic airway 
disease. The extent of this aberrant MUC5B expression may however by dependent on 
variation within the NFκB regulatory motif in the promoter. 
 
At the outset of this project it was hypothesised that activation of the putative distal 
promoter may be the causal event of MUC5B aberrant expression in the goblet cells, 
and therefore preliminary experiments were conducted to characterise and validate the 
putative MUC5B distal promoter proposed by Perrais et al (Perrais et al. 2001). 
However all attempts to isolate transcripts corresponding to an active distal promoter 
proved unsuccessful and correspondence with the laboratory who had proposed this 
second promoter proved unsatisfactory. It was subsequently concluded that no evidence 
supported the activity of a distal promoter and therefore investigations were not 
furthered. 
 
Although the significant association between the MUC5AC SNP rs1132440 identified in 
chapter 3 could not be confirmed with either asthmatic cohort, the negative results may 
be a result of reduced power since both disease cohorts are much smaller than the three 
thousand samples genotyped in chapter 3. 
 
A potentially very interesting finding was made during the analyses in this section with 
regard to calculating measures of pairwise LD. It appears that some of the breakdowns 
in LD identified in the LDmax output, may in fact by spurious and a direct result of the 
EM algorithm used to infer haplotypes prior to LD measure calculation. This issue 
could pose a great problem since the EM algorithm is also used by Haploview outputs, 
made publically available by the HapMap project. 
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Chapter 5 
Exploring copy number variation in MUC5AC 
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5 Exploring copy number variation in MUC5AC  
 
5.1 Introduction 
 
This chapter considers the possibility that the MUC5AC gene is affected by copy 
number variation (CNV). This introductory section aims to illustrate how wide-spread 
CNV is thought to be throughout the human genome.  
 
5.1.1 Genome-wide methods for the detection of CNV 
 
Copy number variation or rather a copy number variant, is defined as a DNA segment 
of 1kb or greater that is detected at different numbers of copies when comparing at least 
two genomes. A CNV can either be a duplication or deletion but defining which of 
these categories it belongs to is difficult since the CNV detected is relative to a 
reference genome (Scherer et al. 2007). A CNV becomes a copy number polymorphism 
(CNP) if the frequency of the variant reaches 1% or greater in a population. 
Overlapping CNVs are generally merged to produce CNV regions (CNVR). The 
publically available Database of Genomic Variants (DGV) contains all reported CNVRs 
which number 8410 at present (February 2010). 
 
Genome-wide microarrays have been very important for the advancement in 
understanding the extent of copy number diversity within the human genome. A method 
known as array comparative genomic hybridisation (aCGH) is widely used to detect 
CNV at the genome-wide level. Test and reference DNA samples are differentially 
labelled with fluorescence and simultaneously hybridised to the probes present on a 
microarray. The fluorescence ratio of each probe is measured in order to compare the 
DNA dosage for each sample at the specific genomic region represented by that probe. 
Therefore when defining a CNV it can only be said that the test genome has more or 
less of the DNA segment in comparison to the reference genome, the actual structure of 
the variant can not be defined by this method. 
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Various probes have been used for aCGH such as, large-insert clones (40-200kb), and 
oligonucleotides (25-80bp). Large-insert clone arrays have the best coverage of the 
genome and the hybridisations are generally the most reliable i.e. low-noise (Carter 
2007). However since the DNA inserts are so large they provide low-resolution because 
it is difficult to refine the CNV boundaries and therefore CNV sizes are likely to be 
overestimated (Redon et al. 2006). Oligonucleotide probes give a much higher 
resolution, but this is accompanied by high-noise which increases the risk of false 
positive CNV calls. In order to reduce noise an adapted procedure has been developed 
known as representational oligonucleotide microarray analysis (ROMA). The test and 
reference DNA are first digested with a restriction enzyme and then the fragments are 
amplified by PCR. Small fragments are preferentially amplified and the selected 
oligonucleotide probes correspond to these amplified fragments (Carter 2007; Sebat et 
al. 2004).  
 
The experimental methods described above detect potential CNV by directly comparing 
the hybridisation intensities of reference and test DNA samples which are indicative of 
DNA dosage. However methods have also been developed in which the hybridisation of 
a single test DNA sample to a microarray is sufficient for CNV detection, such as 
genotyping array platforms. SNP arrays are primarily used for high-throughput 
genotyping. Both matched and mismatched probes of 25 bases are present on the array 
for each allele of a SNP. Thus the intensities at each probe will indicate which alleles 
are present for that specific SNP in the test sample. As with ROMA, the test DNA is 
digested and amplified prior to hybridisation. The intensity data can also be used to 
detect CNV, and special algorithms are used in order to make more reliable calls. 
Algorithms used such as PennCNV, make calls based on genotyping signal intensities, 
allele frequencies, distance between neighbouring SNPs, and allelic intensity ratios 
(Wang et al. 2007). 
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5.1.2 The surprising extent of CNV in the human genome  
  
Although CNV has been associated with disease (Breunis et al. 2008; Hollox et al. 
2008) whole genome microarray studies have identified CNV as a considerable source 
of genetic diversity in the genomes of healthy individuals (Iafrate et al. 2004; Jakobsson 
et al. 2008; Levy et al. 2007; Perry et al. 2008; Redon et al. 2006; Sebat et al. 2004). A 
comprehensive study (Redon et al. 2006) examining a HapMap collection of 270 
individuals from four populations (Yoriba, Japanese, Han Chinese and European), has 
suggested that as much as 12% of the human genome is affected by CNV. This study 
also highlights that many genes are encompassed by the 1447 discrete CNVRs 
identified.  
 
The extent of CNV in the healthy genome is surprising. However it must be 
remembered that such alterations in genome architecture will not always alter function. 
Many CNVs will have a neutral affect on gene expression levels since duplication or 
deletion events may not even affect a gene. Even in the case of genes, a deletion will not 
be detrimental if the remaining gene copy is sufficient for normal function and if a gene 
is duplicated, expression levels will only increase if appropriate regulatory elements are 
acting on the duplicate and if the new chromatin context allows expression (Henrichsen 
et al. 2009).  
 
 
5.1.3 Does CNV affect MUC5AC? 
 
The aim of this chapter is to explore the possibility that CNV affects MUC5AC. The 
notion that MUC5AC falls within, or at least partially within a CNVR was introduced in 
chapter 1. In chapter 1 genotype data for rs1132440, a SNP in exon 19 of the MUC5AC 
3′ region, was analysed in the 1946 longitudinal birth cohort and was shown to be 
significantly associated with five non-independent respiratory outcomes. However the 
causative genetic component remains unclear since deviations from HWE highlighted 
an excess of rs1132440 heterozygotes in the hayfever and allergy affected sample sets. 
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Unexpected numbers of heterozygotes could be indicative of CNV since the variant 
alleles would no longer be present at only two copies and as can be seen in figure 5.1 
various copy number scenarios will result in ‘heterozygote’ genotyping. It was therefore 
proposed that copy number affects the MUC5AC gene, rs1132440 falls within this 
CNVR and that MUC5AC CNV may be the true causal genetic component with respect 
to the risk of hayfever and allergy phenotypes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  True and artificial heterozygotes. Alternative types of possible diplotypes for rs1132440 if 
located within a CNV region. Three diploid genomes are depicted here with two, three or four copies of 
the entire or partial MUC5AC gene. For all three scenarios genotyping methods will infer heterozygosity.  
 
 
At present four genome-wide studies have reported CNVs and CNVRs within or 
including, the 11p15.5 MUC gene complex (see figure 5.2). In one study using a whole 
genome tile path approach, a CNVR that encompasses the whole 11p15.5 MUC gene 
complex, has been identified in a single individual (Redon et al. 2006). However this 
approach uses BAC clones as probes and thus the resolution of this method is low and 
we are unable to refine the CNV call. Another study has also identified a CNVR within 
the MUC5AC and MUC5B region using the array comparative genomic hybridisation 
approach with 60mer oligo probes (Perry et al. 2008). 
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MUC5AC
MUC5AC
MUC5AC
MUC5AC
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Figure 5.2  Representations of MUC5AC with the reported CNVRs. The top half of this figure shows 
a graphical representation of the MUC5AC gene including the sequence golden path (May 2004 
NCBI35/hg17) sequence gap (provided by Ralph Burgess, Undergraduate project student, G.E.E). The 
coloured blocks aligned beneath the gene diagram are from database of genomic variant (DGV) output, 
and indicate independently reported CNVRs within the MUC5AC region. (http://projects.tcag.ca/cgi-
bin/variation/gbrowse/hg18/).  
 
 
5.1.4 Sequencing strategy for CNV detection 
 
Here we introduce a sequencing strategy for the detection of CNV and report its 
application with respect to MUC5AC. DNA sequencing has been widely used 
throughout this project as a direct method for SNP discovery and typing. In sequence 
traces, overlapping peaks present at single loci are inferred as heterozygous genotypes, 
and it is the examination of these heterozygous peak patterns that forms the basis of this 
CNV detection approach.  
 
When amplifying regions of sequence that contain true heterozygous loci, equal 
quantities of fragments containing each allele will be amplified and therefore when 
sequenced we might expect to see equal peak sizes in the traces at the polymorphic 
position. Although the entire trace pattern is decidedly reproducible, the size of every 
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peak depends on the local sequence context and terminator dye incorporation rates, 
therefore peak sizes will vary throughout the trace. Consequently the peaks representing 
each allele at a heterozygous position will not necessarily be equal. However the 
relative peak heights are constant from sample to sample in sequence traces from 
amplified products of the same DNA segment (Dobbs and Gee 2002; Kwok 2010).  
 
 
5.2 Hypothesis and Aims 
 
This chapter aims to establish a novel method for the determination of copy number 
variant regions by studying the relative peak patterns at heterozygote loci. We 
hypothesise that the relative peak heights or rather the peak patterns for heterozygous 
loci will in fact vary from sample to sample if the polymorphic locus resides within a 
CNVR due to the unequal amplification of alleles. Thus sequencing and subsequent 
heterozygote peak examination will be used as a semi-quantitative method and first port 
of call, to highlight potential CNVR. 
 
 
5.3 Results 
 
5.3.1 MUC5AC fragments sequenced  
 
Two fragments were chosen in the MUC5AC 3′ region for subsequent sequencing. The 
first amplified fragment spans from exon 18 to exon 19 at the 3′ end of the gene. This 
region was chosen for sequencing since rs1132440 is located within exon 19. The 
second sequenced fragment spans from exon 13 to exon 14, and was chosen as a second 
3′ region fragment since a high number of SNPs have been reported here which 
increases the chance of obtaining heterozygous peaks. All primers were designed within 
exons rather than introns because exonic sequences are less likely to accumulate 
variants if the proposed duplication remains functional. 
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Sequencing and peak pattern examination of the two 3′ fragments were performed for 
176 samples composed of 84 severe asthmatics and 92 healthy controls (refer to 
materials and methods). Details of SNP discovery and typing data are given in chapter 4 
and therefore this results section will only discuss the heterozygote peak examination of 
sequence traces. 
 
 
5.3.2 Examining heterozygous peak patterns 
 
Heterozygote peaks were examined at six SNP loci; rs2075843, rs34666042, 
rs34831688 within the exon 13 to 14 fragment, and rs35968147, rs2075844, 
rs28728088 within the exon 18 to 19 fragment. Only samples heterozygous for at least 
one SNP could be included in this analysis and of these only clean sequence traces were 
considered, reducing the total number of samples examined to 96 (severe asthmatic and 
healthy controls). Unfortunately the peaks corresponding to rs1132440 heterozygotes 
could not be examined since this locus was too close to the end of the trace where peaks 
are low in quality.  
 
For all loci inspected, the heterozygote peak patterns clearly varied from sample to 
sample. Peak patterns were assessed for their degree of unevenness and were recorded 
as ‘even ’, ‘slightly uneven’ or ‘very uneven’ and a record made of which allele 
predominated. Figure 5.4a and b shows examples of heterozygote peaks classified as 
‘very uneven’ and figure 5.4c gives an example of ‘even’ peak pattern.   
 
As shown in the figure 5.3 example the observed asymmetric peak patterns were 
generally similar for all heterozygous loci within the same amplified product, as would 
be expected if this did indeed represent more copies of one allele than the other.  
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Figure 5.3  Sequence traces for two triple heterozygote individuals. These traces represent three loci 
within the same fragment spanning from exon 18 to exon 19. Corresponding traces are shown for two 
individuals, sample H06 in the top row (a) and sample C06 in the bottom row (b), note that both are from 
the “hypernormal” control sample set. The grey boxes identify SNP loci. 
 
 
The SNP rs2075844 showed the most exaggerated variation in heterozygote peak 
patterns and a sample with even peaks and one with very uneven peaks are shown in 
figure 5.4 as examples. In different individuals the relative peak heights at this locus 
varied from even (n = 23) to quite uneven (n = 28), and the peak patterns oscillate with 
respect to which allele peak is the highest; in the case of the ‘quite uneven’ peaks the A 
allele peak is higher in 16 samples, and the G allele peak is higher in 12 samples. 
 
If this CNV detection method is viable, one could infer from the peak patterns shown in 
figure 5.4 that these three individuals have different copy numbers of the sequence 
region that contains this locus. For instance we might predict that sample AW16 (a) has 
a duplicate copy of this region containing allele A at the rs2075844 SNP locus and vice 
versa for sample DS003 (b). Intuitively sample DS033 (c) appears to possess an even 
number of copies however as explained in the strategy section 1.1.4 all peak heights 
depend on local sequence context and terminator dye incorporation and therefore even 
peak patterns may not be indicative of an even number of copies. Thus no direct 
rs35968147 rs2075844 rs28728088
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inference can be made with regard to the numbers of possible copies, and inference of 
DNA dosage is merely relative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4  Sequence traces of the rs2075844 locus for three heterozygous samples. Samples AW16 
(a), DS003 (b), and DS033 (c) are shown here. Note that all three individuals are from the severe 
asthmatic sample set. 
 
 
5.3.3 The importance of repeats 
 
In order to inspect the robustness of this CNV detection method, both the amplification 
and sequencing steps were repeated for the entire severe asthmatic sample set (n = 84), 
with all reaction conditions kept constant. All genotypes were confirmed and 
heterozygous peak patterns were compared in only the samples that had very 
asymmetric or entirely even peak patterns and had clear sequence traces for both the 
first and second sequence runs. Two SNPs were studied in detail as being ones with the 
clearest variability.  A total of 20 comparisons were made between first and second run 
sequence traces, of these 8 were discrepant, 6 of which were very discrepant (see table 
5.1). These results thus show no evidence of concordance for experiment to experiment 
rs2075844
a. 
b. 
c. 
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results leading to the conclusion that examining peak heights in this region of the 
MUC5AC gene does not give an indication of copy number. 
 
However it should be noted that in discrepant samples in which there was 
heterozygosity at more than one position, the inconsistencies were true for each 
polymorphic locus within the same amplified product (see figure 5.5). Thus it might be 
implied that the observed variance in peak patterns is a product of the PCR 
amplification step.  
 
Table 5.1  Peak pattern descriptions of rs2075843 and rs2075844 heterozygous samples for two 
separate sequence runs. 
 
 rs2075843 
Sample 1st run 2nd run 
AW22 Very uneven A peak bigger Very uneven A peak bigger 
DS003 Very uneven A peak bigger Very uneven A peak bigger 
DS020 Very uneven G peak bigger Very uneven G peak bigger 
DS033 Very uneven G peak bigger Very uneven G peak bigger 
SA038 Even peaks Even Peaks 
SA137 Very uneven A peak bigger Even peaks 
 
 rs2075844 
Sample 1st run 2nd run 
AW01 Very uneven G bigger Very uneven A bigger 
AW02 Even peaks Even peaks 
AW14 Very uneven G peak bigger Uneven G peak bigger 
AW16 Very uneven A peak bigger Almost even  
AW23 Even peaks Uneven G bigger 
AW27 Very uneven A peak bigger Very uneven A peak bigger 
DS003 Very uneven G peak bigger Uneven G bigger 
DS020 Even peaks Even peaks 
DS030 Even peaks Even peaks 
DS033 Even peaks Even peaks 
SA035 Even peaks Uneven A bigger 
SA043 Even peaks Very uneven G peak bigger 
SA050 Even peaks Even peaks 
SA137 Very uneven G peak bigger Very uneven G peak bigger 
 
Samples whose peak patterns were very different between sequencing runs have been shaded in blue. 
Samples whose peak patterns differ but to a lesser degree are shaded in pink. 
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Figure 5.5  Comparison of first run and repeat sequence traces for two samples AW01 (a) and 
SA043 (b) heterozygous at for rs2075844 and rs28728088. 
rs2075844 rs28728088 
a. 
b. 
1st run 
Repeat 
1st run 
Repeat 
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5.4 Discussion 
 
This results chapter used a sequencing strategy in an attempt to examine whether the 
MUC5AC gene was affected by CNV, however this technique proved to be unreliable 
since the findings could not be replicated. An independent method of CNV detection, 
multiple ligation probe assay (MLPA), was used in preliminary experiments as part of a 
MSc project in the lab. DNA specific probes are ligated to genomic DNA and the 
ligated DNA/probe complex is then amplified. PCR product quantities are considered to 
be proportional to the number of copies to which the probe had bound to. MUC5AC 
CNV could not be detected by the MLPA method in an experiment which used 43 
samples. However the technique was not well suited to MUC5AC since probes could 
not be designed with the specified levels of GC richness, due to the high GC content of 
this gene. It should also be noted here that only high quality DNA could be used for 
MLPA, thus DNA from lymphoblastoid cell lines was used for this experiment, rather 
than DNA from our disease cohort.  
 
While neither CNV detection method was able to confirm MUC5AC CNV, both assays 
had drawbacks. We hope to follow up this study with other CNV detection techniques 
in an effort to conclusively confirm or disprove the presence of CNV. At present, blood 
and sputum samples are being collected from patients with severe asthma. We propose 
to use the high quality blood DNA for more comprehensive MLPA studies which will 
include high density probe coverage of the 11p15.5 MUC gene complex. Sputum 
samples will be analysed for different MUC5B isoforms and quantities by our 
collaborator Karine Rousseau (Manchester Mucin laboratory) to determine whether 
aberrant mucin isoforms are detected in the same patients.  
 
Unfortunately, MUC5AC CNV could neither be confirmed nor disproved by this study, 
and thus there is no evidence that the deviations from HWE reported in chapter 3, are 
due to variations in copy number.  
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The deviations from HWE could be a consequence of chance, however we would be 
unlikely to see the differences we do between the affecteds and unaffected groups since 
all samples were randomised and located together on the same plates.  
 
SNPs under primers would result in strand specific PCR or primer extension dropout 
that might produce spurious results if the SNP is more frequent in either the affected or 
the unaffected group. Since genetic variants under a primer would result in more 
homozygous typings, this is unlikely to have been an issue because the greatest 
deviation in the MUC5AC rs1132440 genotype distributions was an increase in the 
number of heterozygotes in the allergy and hayfever affected groups.  
 
We have no reason to suspect incorrect genotyping of the MUC5AC rs1132440 variant 
in chapter 3 because some samples were also typed by RFLP and all heterozygote 
examples were confirmed.  
 
If this region of MUC5AC is not affected by CNV then we are unsure why the 
sequencing peak heights are so unstable. From experience and personal correspondence 
with other researchers, it is unusual for heterozygous peak patterns to shift so 
dramatically in the opposite directions. The GC richness of the sequence could 
somehow be causing the heterozygote peak pattern discrepancies. If the degree of allele 
detection is reliant on the sequence context then this could pose a problem for CNV 
results in the literature. 
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6 Characterisation of the MUC5B promoter in 
the context of Africa. 
 
As the continent of the origin of modern humans, Africa has the deepest human history 
and thus harbours much more human genetic diversity than anywhere else in the world. 
Nevertheless, studies of autosomal genes on Africans remain limited and most SNP 
discovery projects until very recently have been heavily biased towards non-African 
populations. Very little mucin research has involved participants of African ancestry 
and thus the primary aim of this study was to initiate the characterisation of potentially 
functional variants within the MUC5B promoter region in several African populations, 
with particular emphasis on those of Ethiopian origin. 
 
In the introductory section of this chapter, the history of African populations will be 
explored in relation to genetic diversity and the recent African origin theory. 
 
 
6.1 Introduction 
 
6.1.1 The theory of Recent African Origin  
 
Charles Darwin was the first to propose that “our early progenitors lived on the African 
continent” (Descent of man 1871- Chapter VI - On the Affinities and Genealogy of 
Man). It is now generally accepted that all non-Africans are descendants of 
anatomically modern humans originating in Africa. This is known as the recent African 
origin theory (RAO). 
 
Genetic analysis of contemporary human populations has significantly aided in 
deciphering the origins of modern humans. Studies involving mitochondrial DNA 
(mtDNA) and the Y-chromosome have proved to be invaluable for studying the past 
due to their inability to recombine. Simple phylogenies can be constructed based on 
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sequential mutations. Phylogenetic analysis has identified that the most recent common 
ancestor of the patrilineal Y chromosome and matrilineal mitochondrial DNA lines, 
originated in Africa (Cann et al. 1987; Underhill et al. 2000; Vigilant et al. 1991). 
 
The population of modern humans that migrated out of Africa is likely to have been 
small and thus it is postulated that a bottleneck accompanied the out-of-Africa 
migratory event. By comparing genetic variation between African and non-African 
populations, evidence has accumulated in favour of a RAO and subsequent bottleneck. 
Studies have shown that African populations have greater levels of allelic and 
haplotypic diversity and more private allelic variants than non-African populations, 
which only contain a proportion of the African diversity (Campbell and Tishkoff 2008; 
Tishkoff et al. 1996; Tishkoff et al. 1998; Tishkoff et al. 2000). This extensive African 
diversity is mirrored by linguistic diversity: approximately 2000 ethnolinguistic groups 
have been identified within the African continent (Campbell and Tishkoff 2008). 
 
Studies of linkage disequilibrium (LD) have also been used to reflect the age and 
demographic history of African and non-African populations. Older populations show a 
greater breakdown in LD, whereas relatively ‘young’ populations or populations, that 
have undergone a recent bottleneck event, will have increased levels of LD. It has been 
shown that the extent of LD increases with increasing distance from East Africa 
(Jakobsson et al. 2008), consistent with the notion that East Africans are of the most 
ancient of all human populations. 
 
 
6.1.2 The importance of East Africa 
 
While it is generally accepted by the scientific community that anatomically modern 
humans originated in Africa, the anticipated migratory routes out-of-Africa remain 
ambiguous. One proposed route suggests that modern humans first left from Ethiopia 
and migrated to East Asia and Oceania via the Bab-el-Mandeb of the Red sea. Several 
genetic studies support a migratory route originating from East Africa. It has been 
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shown that a mtDNA haplogroup originally thought to be an ancient East Asian marker, 
actually originated in East Africa (Quintana-Murci et al. 1999) and is at high 
frequencies in contemporary Ethiopian populations. 
 
The most ancestral Y-chromosome has been identified in Ethiopians, East African 
Sudanese and the South African Khoisan (Tishkoff and Williams 2002). It is thought 
that the Khoisan may have once inhabited Eastern Africa (Passarino et al. 1998). If this 
is the case then Y-chromosomal data certainly points to an East African patrilineal 
origin.  
 
 
6.1.3 Back migrations into Ethiopia 
 
Back migrations have also played a prominent role in the history of Ethiopia which is in 
fact thought to have been the first state developed in sub-Saharan Africa (Cavalli-Sforza 
et al. 1994). Past migrations into Ethiopia have caused the Ethiopian gene pool to 
become a mixture of non-African as well as African genes (Cavalli-Sforza et al. 1994). 
Past major external influences into Ethiopia have come from the Sudanese and Semitic 
peoples. Levine states that the Sudanese influence occurred in two waves, the first in 
approximately the third millennium B.C and the second in the first millennium. It is this 
second wave that is thought to have greatly influenced the Western Ethiopian Anuak 
ethnic group (Levine 2000), who will discussed later in this introductory section. 
 
Just as the Bab-el-Mandeb is thought to have provided the route out-of-Africa for the 
first Modern Humans, it is also thought to have been the route by which the peoples of 
Arabia back migrated into Ethiopia. Levine suggests that a small continuous wave of 
Arabian influence has occurred in Ethiopia for the past 3 millennia involving Jews, 
Syrian Christians and Arabian Muslims (Levine 2000). 
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6.1.4 Ethiopian ethnic groups 
 
Eighty-five different ethnic groups reside in Ethiopia (Ethiopian census 2007 – see web 
citations on page 206), and although admixture has occurred, it is still possible to 
identified distinct populations due to linguistic, cultural and geographic disparities. In 
this project five of these groups have been analysed; the Afar, Amhara, Anuak, Maale 
and Oromo. 
 
 
6.1.4.1 Afar 
 
The Afar people are herders (Murdock  1959) and constitute 1.7% of the overall 
Ethiopian population and 90% of this ethnic group inhabit the Afar region (see figure 
6.1) (Ethiopian census 2007 – see web citations on page 206). Many of the Afar live in 
the Danakil depression (Murdock  1959) which is the lowest point in Africa (CIA world 
factbook – see web citations on page 206) and is recorded as having the world’s highest 
average temperature (NASA – see web citations on page 206). The relative humidity of 
the depression is 70% (Leroux 2010), a high value considering that rainfall within this 
region is very scarce (Leroux 2010).  
 
As can be seen in figure 6.2 Afar is a Cushitic language which branches from the Afro-
Asiatic family (Ethnolgue – see web citations on page 206). Cushitic languages are 
spoken by farmers and pastoralist herders in the majority of Ethiopia and are also 
spoken in the republic of Sudan (Cavalli-Sforza et al. 1994), and in other parts of the 
horn of Africa. 
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6.1.4.2 The Amhara 
 
The Amhara ethnic group live mainly in the highlands of the Amhara region (see figure 
6.1) where they mainly subsist on agriculture, producing crops like cotton, different 
cereals and oil plants. The Amhara constitute a high percentage of the Ethiopian 
population (26.9%) (Ethiopian census 2007 – see web citations on page 206). As can be 
seen in figure 6.2, Amharic is a Semitic language which branches from the Afro-Asiatic 
language family (Ethnologue – see web citations on page 206). Semitic languages are 
spoken in Northern Ethiopia, in all of Arabia and the middle East (Cavalli-Sforza et al. 
1994). 
 
 
6.1.4.3 The Anuak 
 
The Anuak mostly live in settlements on the river banks of the Baro river in the 
Gambella region (13suns - see web citations on page 206) (see figure 6.1) and make up 
only a small percentage of the overall Ethiopian population, 0.12% (Ethiopian census 
2007 – see web citations on page 206). During the rainy season the Anuak subsist on 
agriculture, producing crops such as cotton, sorghum and various fruit and vegetables. 
Fishing is prominent during the dry season and hunting is also practised (Murdock  
1959; Woube 1998) 13suns – see web citations on page 206). During the rainy season, 
humidity levels are between 72-78% (Woube 1998). As can be seen in figure 6.2 Anuak 
is a Nilotic language which comes from the Nilo-Saharan family (Ethnologue – see web 
citations on page 206).  
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Figure 6.1  Map of Ethiopia’s administrative regions. The region/state boundaries displayed on this  
map are based on those defined by the United Nations emergencies unit for Ethiopia and the United 
Nations Office for Coordination of Humanitarian Affairs (UN OCHA-Ethiopia). 
http://www.africa.upenn.edu/eue_web/eue_mnu.htm and http://www.ocha-eth.org/Maps/Maps.htm. Note 
that SNNPR refers to Southern Nations Nationalities and Peoples’ Regional States, and that Addis Ababa 
and Dire Dawa are chartered cities. 
 
 
6.1.4.4 The Maale 
 
The Maale (also spelt Male, Marle, Malle) are a minority ethnic group making up only 
0.13% of the Ethiopian population, and mostly reside within the Southern Nations 
Nationalities and Peoples’ Regional States (SNNPR) (see figure 6.1) (census 2007). As 
can be seen in figure 6.2 Maale is an Omotic language which branches from the Afro-
Asiatic language family (Ethnologue – see web citations on page 206). This language is 
spoken in only a small region of Ethiopia (Cavalli-Sforza et al. 1994).  
 
 
Anuak 
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6.1.4.5 The Oromo 
 
The Oromo people, previously called the Galla, are pastoralists (Murdock  1959) and 
mostly inhabit the highlands of the Oromia region (see figure 6.1) and are the largest 
ethnic group in Ethiopia, making up 34.5% of the population of the country (Ethiopian 
census 2007 – see web citations on page 206). As can be seen in figure 6.2 Oromo is a 
Cushitic language which branches from the Afro-Asiatic language family (Ethnologue – 
see web citations on page 206). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2  African language tree. Language tree of a subset of African language families, extended to 
show only languages that correspond specifically to this project. Figure kindly provided by Bryony Jones, 
PhD student, GEE. 
 
 
6.1.5 Other African populations considered in this project 
 
Seven other African populations have been studied within this project and are defined 
here by the country/place in which they were collected; Congo-Brazzaville, Ghana, 
Cameroon Grassfields-Somie, Cameroon Lake Chad, Malawi, Mozambique and Sudan. 
Volta-CongoNiger-Congo
(Atlantic-Congo) Benue-Congo
Narrow Bantu(Bantoid)
Nilo-Saharan
Central
Semitic
South
Shuwa Arabs
Sudanese Arabs
Amharic
Oromo
Afar
Maale
Anuak
Ghanaians
Somie
Chewa
Congolese
Sena
Afro-Asiatic
Omotic
Cushitic East
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The sample collection was made by The Centre for Genetic Anthropology (TCGA), to 
represent countries influenced by the Bantu expansion. Some 58% are speakers of a 
Bantoid language.  
 
Although the Malawi sample is entirely composed of an ethnic group called the Chewa 
(n = 50), the remaining populations are composed of mixed ethnicities. Because of this, 
the groups have been divided by country. However the Cameroon sample is divided into 
two geographic locations, Grassfields-Somie and Lake Chad, and it should be noted that 
these two sample sets are ethnically and linguistically very different. Of the Somie 
sample 59 out of 63 speak a Bantoid language, whereas no Bantoid derived languages 
are spoken by the Lake Chad individuals. 
 
 
6.2 Hypothesis and Aims 
 
The main aim of this study is to characterise MUC5B promoter variation in the context 
of African populations. The initial aim is to identify any novel variants and to 
investigate their potential to alter function, for instance whether they are located within 
a TFBS or within a region highly conserved between species. We also intend to explore 
the overall pattern of upstream MUC5B variation with respect to species conservation 
and measures of selection.  
 
The final aim of this chapter is to study MUC5B promoter variation between 
geographically distinct populations. Since the expression of MUC5B is orchestrated by 
environmental cues, we hypothesise that the past environments inhabited by populations 
are likely to have specifically shaped the MUC5B promoter variation of the population 
due to environmental selective pressures. One could predict that frequencies of the 
MUC5B promoter haplotype variants are likely to reflect environmental pressures since 
they have been shown to confer different expression levels (Kamio et al 2005; Loh et al 
2010).  
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6.3 Results 
 
In this results section, genetic data will be reported for the MUC5B proximal promoter 
(as described in chapter 4) and analysed in the context of Africa. The MUC5B promoter 
region spanning from -1097 to +97 nucleotides relative to the transcription start site was 
sequenced in a total of 748 African individuals from eight main geographic populations; 
Ethiopia, Congo, Ghana, Cameroon Grassfields-Somie, Cameroon Lake Chad, Malawi, 
Mozambique, and Sudan. The Ethiopian sample was subdivided into five ethnic groups, 
and studied in detail.  
 
 
6.3.1 Allelic variants 
 
A total of 15 allelic variants were identified in the African sample as a whole, eight of 
which had been previously described. Details of these variants, including minor allele 
frequencies, are shown in table 6.1 and are annotated in the sequence shown in figure 
6.4. It should be noted that population specific genotype distributions for all SNPs are in 
accordance with those predicted under HWE.  
 
14 out of 15 of the variations are present in the Ethiopians; eight and six of these were 
identified in the Mozambique and Cameroon Lake Chad sample sets respectively and 
only seven could be identified in the Congo-Brazzaville, Ghana, Cameroon Grassfields-
Somie, Malawi and Sudan samples.  
 
All previously reported SNPs (rs885455, rs885454, rs17235353, rs7115457, rs7118568, 
rs56235854, rs2735738) were present in both African and non-African (European 
and/or Japanese) populations, except for rs56366237 at position -560, which is African 
specific.  
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Seven allelic variants identified in this study have not been previously reported and 
have therefore been termed ‘novel’ variants. Six out of seven (-988, -946, -614, -420, -
221, -89) are private to Ethiopia, and one out of the seven (-194) has been identified 
only in the Congo, Ghana, Malawi, Mozambique and Sudan samples. The -194 novel 
appears to be a Niger-Congo specific allele as all carriers of the derived allele (except 
for one individual) speak languages that belong to the Niger-Congo family. All novel 
variants are however at low frequencies. 
 
Examination of all novel SNPs in relation to transcription factor binding sites, shows 
that variant -194 falls within the putative Sp1 binding site located at -196 to -185 (see 
figure 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3  Diagrammatic representation of the MUC5B proximal promoter with annotated 
transcription factor binding sites (TFBS) and identified allele variants. The TFBS’s denoted in this 
figure have either been predicted by rVista during this project or have been previously identified in the 
literature (Chen et al. 2001; Wu et al. 2007a). The human MUC5B promoter sequence and the 
homologous mouse Muc5b promoter sequence, were first aligned by zPicture and the generated 
alignment was then used as an input file for rVista.  
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Table 6.1  MUC5B proximal promoter African allelic variants.  
 
Ethnic Sample -988 (G) -946 (A) -919 (G) -906 (A) -659 to -660 (D) -614 (T) -560 (G) -420 (A) -237 (A) -221 (T) -217 (G) -194 (T) -100 (A) -89 (A) -78 (C)
group number ••• ••• rs885455 rs885454 rs17235353 ••• rs56366237 ••• rs7115457 ••• rs7118568 ••• rs56235854 ••• rs2735738
Ethiopia 380 0.013 0.001 0.238 0.038 0.021 0.011 0.017 0.011 0.125 0.011 0.139 ••• 0.030 0.007 0.332
Afar 76 0.027 ••• 0.187 0.067 0.013 0.020 0.007 0.020 0.073 0.007 0.087 ••• 0.013 ••• 0.293
Amhara 76 0.020 ••• 0.184 0.033 0.020 0.020 0.007 0.020 0.092 0.007 0.099 ••• 0.059 ••• 0.250
Anuak 76 ••• ••• 0.309 0.007 ••• ••• 0.066 ••• 0.250 ••• 0.296 ••• ••• 0.033 0.487
Malle 76 ••• ••• 0.276 0.033 0.026 0.013 ••• 0.013 0.105 0.040 0.105 ••• 0.026 ••• 0.349
Oromo 76 0.020 0.007 0.237 0.053 0.046 ••• 0.007 ••• 0.105 ••• 0.112 ••• 0.053 ••• 0.283
Congo-Brazzaville 52 ••• ••• 0.423 0.115 ••• ••• 0.067 ••• 0.212 ••• 0.225 0.048 ••• ••• 0.373
Ghana 56 ••• ••• 0.375 0.116 ••• ••• 0.080 ••• 0.140 ••• 0.184 0.009 ••• ••• 0.325
Cameroon Grassfields-Somie 65 ••• ••• 0.344 0.109 0.008 ••• 0.065 ••• 0.177 ••• 0.223 ••• ••• ••• 0.354
Cameroon Lake Chad 63 ••• ••• 0.198 0.079 ••• ••• 0.016 ••• 0.083 ••• 0.117 ••• ••• ••• 0.331
Malawi 49 ••• ••• 0.439 0.133 ••• ••• 0.122 ••• 0.117 ••• 0.170 0.010 ••• ••• 0.298
Mozambique 51 ••• ••• 0.370 0.110 0.010 ••• 0.153 ••• 0.157 ••• 0.225 0.020 ••• ••• 0.392
Sudan 29 ••• ••• 0.328 0.069 ••• ••• 0.069 ••• 0.190 ••• 0.224 0.017 ••• ••• 0.414
Country
Position relative to transcription start site and rs identifier
 
Table of population specific minor allele frequencies (MAF) for all allelic variants identified in this project. ••• denotes a MAF of zero 
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-1097 
CCACGGAGCATTCAGGACGCTGGTGACCAGGGAGCCAGGAGGTGGGAGCATCTGAGGTGCA 
                                                -988 
GGTCACACGGGCAGGAGGTGTTTGCAAGAGGTATTGCAGCGCGGACGGRGTGTCCTGCAGA 
                             -946                       -919 
TGACGCTGTCTGTCCTGTAGATGACGCTCRTCAAGGAGGTTTACCACATAGCCCCCRGGAA 
        -906                                         rs885455 
GCCCACCCRACACCAGCCGGAGGTGCTAGGCTTCTGCGGCTCCCACCTGGGGCAGGCGGAG 
        rs885454 
GACCCCGGGCAGGTCCAGGACCCCCCGGAGCAGCTGCTTCCTCAACCCTGCCAGGGTTAAT 
 
GAGGAGGCCCCAGAGTGAGGTGGAGGCCAAATGGGACTCAGGGCCGGAGCCTCTGGCCTGG 
 
CTGGATCAGGGCTGGCATTGGACAAGCGCAGCTGACTCCCGATGTGCATGGCCAGGAGACA 
          -659/660                                      -614 
CTCTGGGCCTCAGTTTCCCCTTGAATGTGAACCTTGAAACAGATCAGCCCAGAGACYTCCC 
          rs17235353                             -560 
ACGGTCTTCAAGGGGCTCTGGTCAGCTGGGCTGGGGTCTCTGGAAATAGRGCCTCCTCCAG 
                                                 rs56366237 
GGACCCCCACAAGCCACCCAGACTGAGCATCCTGGCCATGTGCATGCCTGAGCTCAGCAGG 
 
AGCCTCCCGGcCTCCCCGTGGGCTAAGCAGTGGTGGGAGGGGAGCTCCAGCCTCGTGGGCC 
      -420 
CTCCCCRGGCCTCGGGGACCCATGGTCAGTGGCTGGGGGTGCTGCCCAGAGGCTGGGATTC 
 
CCTTCCAGCAGGAGCCGCAGTGGGGCTGAGTGTGAGGCAGGCTGGCTGACCACTGTTTCCA 
 
TGGACCCTGCGTCCAAGGCCAGCCCTGCCTTCCAGCGGCTTTGCCATCTAGGACGGGTGCC 
      -237           -221 -217                   -194 
AGGTGGRGTAGGCCCTTCTCTCYCTTSCGATTCTCAGAAGCTGCTGGGGKTGGGGGCGTCC 
      rs7115457           rs7118568               
TGGGCCTCAGGGCACAGAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCC 
                     -100       -89        -78   -72 
CCTCCCCGAGAGCAAACACACRTGGCTGGAGCRGGGAAGAGCAYGGTGCYCTGCGTGGCCT 
                     rs56235854            rs2735738 
GGCCTGGCTTGGGGCCAAGGCTCCCTGCTACATAAGCTGGGGCCCCCAGGGGAGCAAGCAC 
                                                           +1 
CCGGCCCGGCTCCCTCCCTGCCCGTCCCCGTCCCCCCACCCGTGCCAGCCCCCAGGATGGG 
                                 +97 
TGCCCCGAGCGCGTGCCGGACGCTGGTGTTGGCTC 
 
 
Figure 6.4  MUC5B proximal promoter sequence annotated with African alleles. Grey highlight indicates 
forward and reverse primers for the fragment A. Pink highlight indicates forward and reverse primers for 
fragment B. All previously identified SNPs highlighted in green. All novel SNPs identified by this project are 
highlighted in yellow. Transcription start site is highlighted in red and is described as position +1. The TATA 
box is highlighted in turquoise and the start of translation codon (ATG) is underlined and in bold.  
 171 
6.3.2 MUC5B promoter haplotype 
 
Haplotypes were inferred for all previously reported SNPs with a certainty of 0.9 or 
greater using PHASE. All novel rare alleles were manually allocated to haplotypic 
backgrounds by identifying individuals who were both homozygous for a particular 
haplotype and carriers of the rare novel allele. It was thereafter assumed that the novel 
rare allele always fell on that particular haplotypic background since it is unlikely that 
the mutation will have occurred more than once. The previously identified MUC5B 
promoter haplotypes and their identifiers (Kamio et al. 2005) were used as the basis for 
naming the African haplotypes. Additional haplotypes seen in the African populations 
that had not been seen in the Japanese population (Kamio et al. 2005) were given new 
identifiers.  
 
A total of 23 MUC5B promoter haplotypes were identified in the African sample as a 
whole, of which 20 were found within the Ethiopian population and between 8 and ten 
could be identified in each of the other African sample sets (see table 6.2). It should be 
remembered that only 6 MUC5B promoter haplotypes were identified in the healthy 
European controls typed in chapter 2. Table 6.2 describes all haplotypes and includes 
haplotype frequencies for each African population. Many haplotypes are however rare 
and therefore the population specific pie charts shown in figure 6.6 represent only the 
percentages of the three major haplotypes (H3, H1 and H8) plus a category described as 
‘other’ which contains all rarer haplotypes. 
 
The phylogenetic tree shown in figure 6.5 was created in order to display the 
relationships between haplotypes (Network 4.516). On examination of the tree it is 
apparent that several of the mutations have to have occurred more than once (labelled 
with stars), and since this is rather unlikely it suggests that several of the haplotypes 
have occurred by recombination. 
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Figure 6.5  MUC5B promoter haplotype network. All African haplotypes have been included in this 
network. The circumference of each node is relative to the haplotype frequency. The orange node 
identifies the chimpanzee haplotype. Haplotype identifiers are indicated in black font, while red font 
signifies the mutation. Mutation identifiers are named with respect to their location relative to the 
transcription start site.  Mutations that are shown to occur more than once on the tree are labelled with 
stars. Network 4.516 was used to construct the network.  
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Table 6.2  Sequence details and frequencies of the MUC5B proximal promoter haplotypes identified in eight African sample sets. 
Blue shading represents the ancestral/chimpanzee H5 haplotype. Pink shading represents the most frequent haplotype H3. White cells signify single step mutations.  ••• 
represent frequencies of zero. Alleles in lower case represent those variants discovered for the first time by this project. 
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H5 a g G G I c A g G c C g G g C 0.035 0.010 0.010 ••• ••• ••• 0.034 0.038 
H5a a g G G I c G g G c C g G g C 0.004 0.042 0.030 0.016 ••• 0.049 0.068 0.038 
H4 a g G A I c A g G c C g G g C 0.024 ••• ••• ••• ••• ••• ••• 0.019 
H10a a g G G I c G g G c G g G g C ••• ••• ••• 0.016 ••• ••• ••• ••• 
H1 a g G G I c A g A c G g G g C 0.124 0.208 0.160 0.186 0.073 0.122 0.148 0.173 
H3 a g A G I c A g G c C g G g T 0.551 0.448 0.510 0.500 0.564 0.488 0.489 0.538 
H3a a g A G I c A g G c C g A g T 0.031 ••• ••• ••• ••• ••• ••• ••• 
H3b a a A G I c A g G c C g G g T 0.001 ••• ••• ••• ••• ••• ••• ••• 
H3c g g A G I c A g G c C g G g T 0.013 ••• ••• ••• ••• ••• ••• ••• 
H3d a g A G I t A a G c C g G g T 0.011 ••• ••• ••• ••• ••• ••• ••• 
H3e a g A G I c A g G c C t G g T ••• 0.052 0.010 ••• ••• 0.012 0.023 0.019 
H15 a g A G D c A g G c C g G g T 0.005 ••• ••• 0.008 ••• ••• 0.011 ••• 
H8 a g A G I c A g G c C g G g C 0.114 0.072 0.090 0.113 0.200 0.049 0.045 0.077 
H8a a g A G I c A g G c C g G a C 0.007 ••• ••• ••• ••• ••• ••• ••• 
H8b a g A G I c A g G t C g G g C 0.011 ••• ••• ••• ••• ••• ••• ••• 
H8c a g A G I c G g G c C g G g C ••• ••• ••• ••• ••• 0.012 ••• ••• 
H14 a g A G I c A g G c G g G g C 0.001 ••• ••• ••• 0.009 ••• ••• ••• 
H14a a g A G I c G g G c G g G g C 0.013 0.010 0.030 0.032 0.018 0.037 0.068 0.038 
H13 a g A G I c A g A c G g G g C 0.003 0.010 ••• ••• 0.018 ••• ••• ••• 
H7 a g G G D c A g G c C g G g T 0.005 ••• ••• ••• ••• ••• ••• ••• 
H6 a g G G I c A g G c C g G g T 0.035 0.021 0.030 0.016 0.027 0.085 ••• 0.019 
H2 a g G A D c A g G c C g G g T 0.008 ••• ••• ••• ••• ••• ••• ••• 
H9 a g G A I c A g G c C g G g T 0.005 0.125 0.130 0.113 0.091 0.146 0.114 0.038 
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The shading in table 6.2 illustrates the possible relationships between the haplotypes. 
The blue shading signifies the ancestral (chimpanzee) haplotype H5 or haplotypes 
relating to H5, and pink shading denotes the most frequent haplotype H3 or haplotypes 
relating to H3. Cells left unfilled represent single step mutations. In table 6.2 the 
haplotypes shaded with one colour and interspersed with single unfilled cells, can be 
accounted for by single step mutations on the background of pre-existing haplotypes, 
whereas haplotypes containing blocks with 2 colours can be accounted for by 
recombination events. For instance H3a, H3b, H3c, H3e and H15 can all be accounted 
for by single step mutations occurring on the H3 haplotypic background, and haplotypes 
H8 and H6 appear to be the direct recombinants between H3 and H5 but it is not 
possible to accurately describe the recombination blocks.  
 
As can be seen in the pie charts of figure 6.6 H3 has the highest frequency in all African 
populations as is the case in European samples (Kamio et al. 2005)(chapter 4). The 
percentage of the high expressing haplotype H1 does not appear to vary much between 
most of the African populations but does seem to be at a lower frequency in the 
Cameroon Lake Chad sample set. As will be seen in the next section however, there are 
differences between ethnic groups within the Ethiopian sample. H8 seems to be at an 
increased frequency in western Africa, where the eastern and south eastern populations, 
Ethiopia, Malawi and Mozambique have more rare haplotypes, exhibiting greater 
haplotypic diversity. 
 
The tabulation of haplotype counts amongst the eight African populations shown in 
figure 6.7b has been used to create the correspondence analysis 2-dimensional map 
shown in figure 6.7a. correspondence analysis has been used in this instance to 
represent the interrelationships between single haplotype distributions across 
populations and the haplotype composition of each population. The correspondence 
analysis map first and second dimensions capture 59.81% and 15.04% of the inertia 
respectively. The most noteworthy observation of this correspondence analysis is that 
the first axis clearly separates Ethiopia from any other population, largely attributable to 
the existence of more derived haplotypes due to one step mutations from old 
haplotypes. 
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Figure 6.6  Pie charts to depict haplotype percentages for each African population. Each pie chart 
represents the three major haplotypes H3, H1 and H8, plus a group containing all ‘other’ haplotypes.   
 
 H1 
H3 
H8 
Other 
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Figure 6.7  a. Correspondence analysis 2D map representing the interrelationships between the 
African populations and the MUC5B promoter haplotypes shown in the contingency table (b). CO 
Congo, GH Ghana, SO Grassfields-Somie, LC Lake Chad, MA Malawi, MO Mozambique, SU 
Sudan, ET Ethiopia. Blue filled circles represent the row coordinates and red filled squares represent the 
column coordinates. Correspondence analysis performed by Statistica version 9.
 CO GH SO LC MA MO SU ET 
Haplotype        H1 20 16 23 8 10 13 9 93 
H2    0 0 0 0 0 0 0 6 
H3 43 51 62 62 40 43 28 414 
H3a 0 0 0 0 0 0 0 23 
H3b 0 0 0 0 0 0 0 1 
H3c 0 0 0 0 0 0 0 10 
H3d 0 0 0 0 0 0 0 8 
H3e 5 1 0 0 1 2 1 0 
H4 0 0 0 0 0 0 1 18 
H5 1 1 0 0 0 3 2 26 
H5a 4 3 2 0 4 6 2 3 
H6 2 3 2 3 7 0 1 26 
H7 0 0 0 0 0 0 0 4 
H8 7 9 14 22 4 4 4 86 
H8a 0 0 0 0 0 0 0 5 
H8b 0 0 0 0 0 0 0 8 
H8c 0 0 0 0 1 0 0 0 
H9 12 13 14 10 12 10 2 4 
H10a 0 0 2 0 0 0 0 0 
H13 1 0 0 2 0 0 0 2 
H14 0 0 0 1 0 0 0 1 
H14a 1 3 4 2 3 6 2 10 
H15 0 0 1 0 0 1 0 4 
2D Plot of Row and Column Coordinates; Dimension:  1 x  2
Input Table (Rows x Columns): 23 x 8
Standardization: Row and column profiles
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6.3.3 Ethiopia in detail 
 
In this section genetic differences between the five Ethiopian ethnic groups will be 
examined by analysing further the MUC5B proximal promoter data described above.  
 
 
6.3.3.1 Haplotype distributions 
 
In order to explore genetic differences between the five Ethiopian ethnicities, the 
MUC5B promoter haplotype distributions for each ethnic group (see table 6.3) were 
firstly examined by the exact test of population differentiation implemented by Arlequin 
(see materials and methods section for details). Statistically significant differences in 
haplotype frequencies were identified between the Anuak and all other ethnic groups 
with p values ranging from 0.01 to 0.00001.  
 
The vast difference between the Anuak and all other ethnic groups can be seen in the 
correspondence analysis shown in figure 6.9. In this two-dimensional map the first and 
second dimensions capture 56.82% and 20.72% of the total inertia. It is the first axis 
that clearly separates the Anuak from all other ethnicities.  
 
Because of the previous association identified between asthma and the H1 haplotype, 
the percentage of H1 haplotypes versus all other haplotypes were compared between the 
ethnic groups. A statistically significant Pearsons chi squared p value < 0.0001 was 
obtained and from figure 6.8 it is evident that the Anuak group have a significantly 
greater percentage of the H1 haplotype than the other ethnic group. 
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Figure 6.8  Pie charts to show H1 haplotype percentage versus all other haplotypes for five 
Ethiopian ethnicities. 
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Table 6.3  Sequence details and frequencies of the MUC5B proximal promoter haplotypes identified in the five Ethiopian ethnic groups. 
 
Population specific frequencies are included for each of the five ethnic groups. Number of chromosomes included in these descriptions are as follows; Afar = 148, Amharic =  
152, Anuak = 152, Malle = 150 and Oromo = 150. ••• represent frequencies of zero. Haplotypes and SNPs not polymorphic in Ethiopia have not been included. Alleles in 
lower case represent variants found for the first time by this project.
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H1 a g G G I c a g A c G G g C 0.074 0.092 0.243 0.107 0.100 0.124 
H2 a g G A D c a g G c C G g T 0.014 ••• ••• 0.007 0.020 0.008 
H3 a g A G I c a g G c C G g T 0.595 0.605 0.487 0.527 0.540 0.551 
H3a a g A G I c a g G c C A g T 0.014 0.059 ••• 0.027 0.053 0.031 
H3b a a A G I c a g G c C G g T ••• ••• ••• ••• 0.007 0.001 
H3c g g A G I c a g G c C G g T 0.027 0.020 ••• ••• 0.020 0.013 
H3d a g A G I t a a G c C G g T 0.020 0.020 ••• 0.013 ••• 0.011 
H4 a g G A I c a g G c C G g C 0.047 0.026 ••• 0.020 0.027 0.024 
H5 a g G G I c a g G c C G g C 0.020 0.026 0.020 0.067 0.040 0.035 
H5a a g G G I c g g G c C G g C ••• ••• 0.020 ••• ••• 0.004 
H6 a g G G I c a g G c C G g T 0.027 0.020 0.020 0.060 0.047 0.035 
H7 a g G G D c a g G c C G g T ••• 0.013 ••• 0.013 ••• 0.005 
H8 a g A G I c a g G c C G g C 0.135 0.092 0.118 0.120 0.107 0.114 
H8a a g A G I c a g G c C G a C ••• ••• 0.033 ••• ••• 0.007 
H8b a g A G I c a g G t C G g C 0.007 0.007 ••• 0.040 ••• 0.011 
H9 a g G A I c a g G c C G g T 0.007 0.007 0.007 ••• 0.007 0.005 
H13 a g A G I c a g A c G G g C ••• ••• 0.007 ••• 0.007 0.003 
H14 a g A G I c a g G c G G g C 0.007 ••• ••• ••• ••• 0.001 
H14a a g A G I c g g G c G G g C 0.007 0.007 0.046 ••• 0.007 0.013 
H15 a g A G D c a g G c C G g T ••• 0.007 ••• ••• 0.020 0.005 
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 AF AM AN ML OR 
Haplotype           H1 11 14 37 16 15 
H2 2 0 0 1 3 
H3 88 92 74 79 81 
H3a 2 9 0 4 8 
H3b 0 0 0 0 1 
H3c 4 3 0 0 3 
H3d 3 3 0 2 0 
H4 7 4 0 3 4 
H5 3 4 3 10 6 
H5a 0 0 3 0 0 
H6 4 3 3 9 7 
H7 0 2 0 2 0 
H8 20 14 18 18 16 
H8a 0 0 5 0 0 
H8b 1 1 0 6 0 
H9 1 1 1 0 1 
H13 0 0 1 0 1 
H14 1 0 0 0 0 
H14a 1 1 7 0 1 
H15 0 1 0 0 3 
Figure 6.9  a. Correspondence analysis 2D map representing the interrelationships between the five 
Ethiopian ethnic groups and the MUC5B promoter haplotypes shown in the contingency table (b).  
AF Afar, AM Amhara, AN Anuak, ML Maale, OR Oromo. Blue filled circles represent the row 
coordinates and red filled squares represent the column coordinates. Correspondence analysis performed 
by Statistica version 9. 
2D Plot of Row and Column Coordinates; Dimension:  1 x  2
Input Table (Rows x Columns): 20 x 5
Standardization: Row and column profiles
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6.3.3.2 H1 status and elevation 
 
There is evidence that the different MUC5B promoter haplotypes vary in function 
(Kamio et al. 2005) and MUC5B promoter haplotypes have also been shown to be 
significantly associated with respiratory disease in Europe (chapter 4) and Japan (Kamio 
et al. 2005). It therefore seems possible that the difference in haplotype frequencies 
between the ethnic groups has resulted from selection as opposed to demography.  
 
Since the respiratory mucins are critical for lung function and elevation is known to 
affect lung function, we hypothesise that different functional MUC5B promoter variants 
will be favoured at different elevation levels. For instance at higher elevations the air is 
drier and thus mucin compositions that maximise water retention may be selected for in 
order to maintain airway hydration. Elevation levels within Ethiopia vary greatly 
ranging from -125 metres in the Danakil depression to 4,533 metres in Ras Dejen (CIA 
World factbook – see web citations on page 206) and therefore the Ethiopian data set 
provided an opportunity to examine MUC5B promoter haplotypes with respect to 
ancestral homeland elevation. 
 
At the outset of this project the idea had been to study the presence or absence of H1 at 
different elevation levels within the Ethiopian sample as a whole. For each individual, 
data were available for the location of DNA sample collection and birthplace. In this 
analysis, birthplace elevation values (obtained from Heavens Above – see web citations 
on page 206) were used since they are likely to relate more closely to the geographic 
location of the ancestors of the participants. However, initial observations made this 
analysis problematic. The overall Ethiopian sample set is stratified with respect to 
haplotype frequencies due to its composition of five ethnic groups. It was therefore 
important to determine whether there were significant differences in birthplace elevation 
levels between the different ethnic groups and as can be seen in figure 6.10 this tends to 
be the case especially for the Anuak and Maale ethnic groups whereby all individual 
birthplace elevation levels are highly clustered. This means that any analyses involving 
birthplace elevation and genetic data, in this Ethiopian sample set, will be confounded 
by ethnicity. 
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This problem was circumvented by including only the Amhara and Oromo samples in 
the analysis. As can be seen from the scatter plots in figure 6.10, birth place elevation 
levels within these two ethnic groups are varied, making it possible to analyse H1 
presence or absence in relation to elevation. In order to maximise sample number, the 
Amhara and Oromo have been pooled together (n = 124) since no significant difference 
could be identified between these two populations in the previous haplotypic analysis.  
 
Firstly, each individual was assigned as either a H1 carrier or H1 non-carrier, which 
simply refers to a typing of at least one H1 haplotype or no H1 haplotype respectively. 
Initially the 2 by 2 contingency table shown in table 6.4 was constructed to express the 
H1 status distribution with respect to a high and low birth elevation, defined using the 
cut off point of 2,400 metres, which is medically recognised as high altitude (Medicine 
Net – see web citations on page 206). The distribution of these data was not 
significantly different (Pearsons chi squared 2-sided p value of 0.555). 
 
 
Table 6.4  Contingency table of the H1 haplotype distribution amongst individuals born at high and 
low elevation levels. 
 
H1 Status High Low Total 
H1 carrier 9 14 23 
H1 non-carrier 33 68 101 
Total 42 82 124 
 
Data includes a pooled sample of the Amhara and Oromo ethnic groups (n = 124). The high and low 
categories have been defined by a cut off point of 2,400 metres. H1 carrier status is not significantly 
different between the high and low elevation sample sets.  (Pearsons chi squared 2-sided p value of 
0.555).  
 
 
However significance may have been dampened by the categorisation of birthplace 
elevation levels and therefore a Mann Whitney U statistical test was used to compare 
the distributions of raw elevation measures between H1 carrier and H1 non-carrier 
sample sets (see figure 6.11). Once again no significant association between H1 status 
and elevation could be identified (p value of 0.824).  
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Figure 6.10  Scatter plot of birth elevation levels within each ethnic group. Each data point represents 
the birth elevation level of a single individual. The red dotted line represents the cut off point of 2,400 
metres, used to categorize high and low elevations. 
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Figure 6.11  Scatter plot of 
the raw birthplace elevation 
levels within H1 carrier and 
H1 non-carrier sample sets. 
Amhara and Oromo pooled data 
set. These data were examined 
with a Mann Whitney U test (p 
value of 0.824).  
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6.3.3.3 The high incidence of H1 in the Anuak 
 
The most noteworthy observation of this study is the high incidence of H1 in the Anuak 
sample. The Anuak have also been noted to be significantly different with respect to 
other regulatory genetic markers studied in our laboratory, the lactase enhancer and 
UGT1A1 promoter TATA box (unpublished - Bryony Jones and Laura Horsfall). This 
difference may be entirely attributable to the demographic history of the Anuak, whom 
we know are linguistically different from the other Ethiopian ethnic groups tested 
within this study since they speak a language descended from the Nilo-Saharan family 
and all other populations speak languages that belong to the Afro-Asiatic family. 
However the geography of Ethiopia varies greatly from high mountainous plateaus to 
inhospitable lowlands and deserts (Levine 2000). The Anuak are the only group in this 
study that live in a lowland environment on the river banks, and functional genetic 
variants that may be favourable in such an environment might reach higher frequencies 
under selective pressures. 
 
Disease prevalence within Ethiopia is also known to vary geographically. For instance, 
malaria is generally rife in lowland regions such as Gambella where the Anuak originate 
from, but the highlands (>2,500 metres) are malaria free (WHO). The Gambella region 
in which the Anuak live has also been reported to have the highest rate of TB and HIV, 
with prevalence levels only comparable with the three main urban areas, Addis Ababa, 
Dire Dawa and Harari, plus the Afar region in the case of HIV (WHO Ethiopian TB and 
HIV reports – see web citations on page 206). 
 
The CIA world fact book (see web citations on page 206) states that meningococcal 
meningitis is a major respiratory infectious disease that affects Ethiopia, spreading 
between people via respiratory droplets. There are three clinical manifestations, 
meningeal syndrome, septicaemia and pneumonia. It is a very serious disease which 
often results in morbidity or mortality. The bacterium responsible Neisseria 
meningitidis inhabits the nose and throat mucosal membrane. Epidemic levels often 
accompany the dry seasons or droughts and asymptomatic carriers of the bacteria (5-
10% of the population) are thought to play a large role in spreading the disease. 
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Respiratory inflammation and infection are considered to be risk factors and the highest 
incidence of this disease occurs throughout the African ‘meningitis belt’ shown in 
figure 6.12 (WHO meningococcal meningitis fact sheet – see web citations on page 
206). 
 
As can be seen in figure 6.12 the ‘meningitis belt’ extends from Senegal to western 
Ethiopia. Western Ethiopia includes the Gambella region which is inhabited by the 
Anuak, and it is tempting to speculate that the high frequency of the H1 haplotype 
within this ethnic group could in fact be in response to the selective pressures of 
meningococcal meningitis. The higher levels of MUC5B produced by the high 
expressing H1 haplotype might possibly confer protective properties against 
meningococcal meningitis and that the Anuak may harbour a greater number of 
asymptomatic carriers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12  African ‘meningitis belt’. Map of Africa displaying the ‘meningitis belt’, the area across 
sub-Saharan Africa that harbours the highest burden of meningococcal meningitis 
(http://ehp.niehs.nih.gov/docs/2009/117-1/belt-large.jpg).  
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6.3.3.4 Nucleotide diversity, tests of neutrality and conservation profiles  
 
In order to investigate the possible effects of selection on the MUC5B promoter, 
nucleotide diversity has been measured and tests of neutrality have been conducted on 
the Ethiopian data set. These data have also provided an opportunity for examining the 
properties of the curiously high level of promoter polymorphism with respect to 
nucleotide sequence conservation profiles. 
 
The expected diversity level of any stretch of sequence is defined as θ (theta) (see 
materials and methods section 2.4.5). Estimates of θ can be calculated by several 
different methods which utilise different observations of diversity such as number of 
segregating sites, number of singletons, level of homozygosity, number of alleles or 
measures of π (described below). Under neutral evolution or rather neutrality, all 
estimates of θ should be equal. 
 
A measure of nucleotide diversity (π) (see materials and methods section 2.4.5.1) was 
calculated for the 1194 nucleotide promoter sequence in each population using analysis 
software DnaSP (see materials and methods). Measures of π represent the probability 
that two copies of a specific nucleotide will be the same if selected randomly from a 
population. Values of zero indicate that all sites are monomorphic. All π values obtained 
were similar for the five Ethiopian ethnic groups with 11.3 x 10¯4, 11.3 x 10¯4, 16.2 x 
10¯4, 12.4 x 10¯4 and 12.1 x 10¯4 for Afar, Amharic, Anuak, Maale and Oromo 
populations respectively. Although it should be noted that the Anuak have the largest π 
value. 
 
Since π was similar for all ethnicities, nucleotide diversity measures were calculated for 
the Ethiopian population as a whole, using sliding windows of 100 nucleotides to cover 
the entire input sequence in one nucleotide steps. The π value of each window was 
plotted at the central point of that window (figure 6.13a). Peaks in the plotted π values 
represent regions of increased nucleotide diversity, whereas troughs indicate a lack of 
heterozygosity. 
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Figure 6.13a shows the π sliding window plot for the Ethiopian population as a whole. 
The sequence close to the transcription start site exhibits high levels of diversity as does 
the sequence between approximately -800 to -1000bp relative to the transcription start 
site.  
 
In order to inspect where these high levels of diversity are with respect to potentially 
functional regions, a primate conservation profile was constructed for the MUC5B 
proximal promoter (figure 6.13a). Below the diversity plot is a histogram representing 
sequence conservation between the human, chimpanzee, orangutan and rhesus monkey 
MUC5B proximal promoter sequences, created by phylogenetic shadowing (see 
materials and methods section). There are two main peaks of conservation. By 
comparing the two aligned plots in figure 6.13a, it can be seen that the peak furthest 
from the TSS (approximately -550 to -800), corresponds to a region of little sequence 
diversity in humans. This is what is expected for regions that are functional, purifying 
selection having acted upon this region. However the second highly conserved region 
corresponds to sequence of high diversity in the Ethiopian population, implying that 
while this region contains functionally important elements, which had been conserved 
over primate evolution, selective pressures have favoured diversity in this Ethiopian 
human population. 
 
It should however be noted that the high level of diversity closest to the TSS is 
interrupted by a steep drop in diversity. This narrow band of low diversity aligns with 
the highest point of conservation, implying that within this short narrow band of 
sequence (approximately -159 to -139) variants are not tolerated and therefore this 
segment of promoter sequence could be considered essential for MUC5B expression. 
This narrow band of sequence lies in between the two putative Sp1 binding sites (-196 
to -185 and -124 to -114). The high degree of accumulated diversity either side of this 
narrow band could indicate that these variants somehow modulate the functional 
activity of the highly conserved region. As can be seen in figure 6.13b, this narrow band 
of sequence exhibits a high level of homology (65%) even when the species 
comparisons are extended to also include the marmoset, horse, dog and mouse. 
However, a potential TFBS has yet to be identified in this region.
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                  -196                                                               -114 
 
Human       GGGTGGGGGCGTCCTGGGCCTCAG-GGCACAGAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCCCCTCCCCG 
Chimp       GGGTGGGGGCTTCCTGGGCCTCAG-GGCACAGAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCCCCTCCCCG 
Rhesus      GGGTGGGGGCGTCCTGGGCCTCAG-GGCACAGAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCCCCTCCCCG 
Marmoset    GGGCGGGGGCATCTTGG-CCTTAG-AGCACAGAGCTGCAAATCTTTCCTGCTCCAGGCCTCTTCCCTGCCACAGCCCCTCCCCG 
Dog         GGGCG-GGGGTCCCGTGAAGCTGG-G-CCCACAGCCGCAAATCCTTCCTTGTCC-GGCGACTTTCCTGCCTCAGCCCCTCCCCA 
Horse       GGGGAAGGGGTCCTGCATCTCTGG-GGCCCAGAGCCACAAATCCTTCCTCCTCA-GGGCTCTTTCCTGCCATGGCCCCTCCCCG 
Orangutan   GGGTGGGGGCGTCCTGGACCTCAG-GGCACAAAGCTGCAAATCCTTCCTGATCCAGGCCTCTCCCCTGCCACAGCCCCTCCCCG 
Mouse       CCACAAGGGGTGGGAGCACTCTGGTGGCACAGTGATGTAAATCCTTCCTTCTCCATGGCCTCTTCCTGCCATGGCCCCTCCCCA 
                 ***              *   * **  *    ***** *****  **   *       ******   ********** 
 
Figure 6.13  Nucleotide diversity and species conservation of 
the MUC5B proximal promoter. a. Aligned plots of  nucleotide 
diversity (π) and sequence conservation profiles for the MUC5B 
proximal promoter. The plot of π values constructed using a 
sliding window approach (DnaSP), depicts regions of high 
(peaks) and low (troughs) sequence diversity within the MUC5B 
promoter sequence for the whole Ethiopian sample. The 
histogram below shows a conservation profile for the human, 
chimpanzee, orangutan and rhesus monkey MUC5B promoter 
sequences, whereby peaks represent regions of high sequence 
conservation and troughs represent regions of low sequence 
conservation (eShadow). The x axis refers to the nucleotide 
position relative to the transcription start site (TSS). The y axis is 
a measure of percentage variation, whereby 0 % signifies 
complete conservation. b. Multiple species alignment (clustalW2) 
for the sequence region corresponding to the narrow band of high 
conservation and low sequence diversity at approximately -159 to 
-139. Grey highlighted sequence corresponds to the putative Sp1 
binding sites (-196 to -185 and -124 to -114). Pink highlighted 
sequence corresponds to the narrow band.  
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6.3.3.5 Test of neutrality- Tajima’s D 
 
Tajima’s D is a statistical method used to compare estimates of θ based on π with those 
calculated from the number of segregating sites. Under conditions of neutrality Tajima’s 
D will be zero. However significantly positive values of D may represent balancing 
selection and significantly negative values may be indicative of positive selection 
(Jobling et al. 2004).  
 
Values of D were calculated for the Ethiopian group as a whole and for all ethnic groups 
individually using DnaSP version 5.10.00. No values significantly deviated from those 
expected under neutrality, though the Anuak was the only population to give a positive 
result (1.2), all other ethnic groups having negative Tajima’s D values.  
 
Tajima’s D values were also calculated in sliding windows of 100 nucleotides and 
plotted in the line graphs shown in figure 6.14. It is clear from this figure that the 
patterns of Tajima’s D values across the MUC5B promoter sequence are noticeably 
different in the Anuak as compared to the other ethnic groups. The most noteworthy 
observation of the Anuak Tajima’s D plot is the positive double peaks at approximately 
-300 to -150 and -150 to -30 nucleotides relative to the transcription start site. The steep 
drop to a Tajima’s D value of zero at approximately -150 corresponds to the narrow 
band of high conservation and low nucleotide diversity discussed previously (section 
6.3.3.4). Either side of this region are two positive Tajima’s D peaks which represent 
balancing selection or rather a maintenance of multiple alleles. Thus balancing selection 
may explain the high sequence diversity (high π values) seen either side of the narrow 
band. It should therefore be noted that while the overall Tajima’s D value for the 
promoter sequence of the Anuak was not significantly positive, the pattern observed in 
the sliding window plot is suggestive of balancing selection for these two small regions. 
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Figure 6.14  Plots of Tajima’s D values for the MUC5B promoter sequence. Values of D were 
calculated for sliding windows of 100 nucleotides in length. The value of D for each window was plotted 
at the windows centre point. Steps between each window was 25 nucleotides. The y axis refers to the D 
value and the x axis denotes nucleotide position within the sequence relative to the TSS. 
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6.4 Discussion 
 
This study is the first to characterise MUC5B promoter variation within the context of 
Africa. Approximately 1kb of the sequence directly upstream of the MUC5B TSS has 
been characterised in 748 individuals of African ethnicity, originating from eight main 
geographic locations. All seven allelic variants previously identified in European 
(chapter 4) and Japanese (Kamio et al. 2005) data sets  have also been identified within 
Africa. However eight additional variants have been discovered within the African 
populations that were not shown to exist in the non-African samples, which therefore 
shows that the non-African populations contain only a subset of the African MUC5B 
promoter diversity. These results highlight the importance of genetic studies involving 
African populations, since African diversity will represent the full spectrum of human 
genetic variation.  
 
Allelic diversity within the MUC5B promoter region appears to be rather extensive. 
Preliminary characterisation of the MUC5AC proximal promoter in the Ethiopian 
sample set (n = 378) gives a very different picture. In the case of MUC5AC we have 
identified just two SNPs within the 1kb region upstream of the TSS, rs28469016 and 
rs17859812 with minor allele frequencies of 0.04 and 0.39 respectively. Thus the low 
level of MUC5AC upstream diversity indicates that the extensive promoter variability is 
not a generalisation for the predominantly expressed respiratory mucins. Although, no 
functional studies have been performed on the MUC5AC promoter and we can not 
therefore exclude that this arbitrary 1kb upstream region is not the complete promoter of 
the gene. It is interesting to speculate that the MUC5B promoter variation allows 
variable MUC5B expression because it is an evolutionary adaptation with some 
haplotypes being favoured in one environment and some in another. Future functional 
studies will however be required to elucidate whether the novel variants identified 
during this project have an effect on MUC5B expression levels.  
 
Of all the African specific allelic variants, the SNP located at position -194 relative to 
the TSS, is perhaps the most interesting since it is located within a putative Sp1 binding 
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site. As discussed in section 6.3.3.4, the region containing the two Sp1 binding sites 
appears to possess the greatest sequence conservation between primates. Sp1 is a zinc 
finger transcription factor and the two Sp1 motifs located within the MUC5B proximal 
promoter (-196/-185 and -124/-114) have been shown to be functional. In a study using 
site-directed mutagenesis followed by transfection studies, the Sp1 TFBS at -124/-114 
was shown to be essential for basal transcription of MUC5B (Wu et al. 2007a). The 
importance of this site is reflected by the complete conservation of the TFBS between 
human, chimpanzee, orangutan, rhesus monkey, marmoset, dog, horse and mouse 
sequences. Increased Sp1 binding at the -196/-185 site was shown to responsible for 
phorbol 12-myristate 13-acetate (PMA) induced MUC5B expression (Wu et al. 2007a). 
PMA is a protein kinase C activator used in cell cultures as an inflammatory stimulant, 
and has been shown to be a potent enhancer of MUC5B expression in primary human 
bronchial cell cultures grown at air liquid interface (ALI). Binding of Sp1 to this site 
may therefore be important for the upregulation of MUC5B by environmental 
respiratory responses. The -194 variant is likely to be functional since it is located 
within this environmental response motif and this nucleotide position is conserved 
between the human, chimpanzee, Orangutan, Rhesus monkey, marmoset, dog and horse 
genome.  
 
On comparing MUC5B promoter nucleotide diversity with a primate conservation 
profile, an interesting pattern was observed for the region approximately 270 
nucleotides upstream of the TSS (see figure 6.13a). Within this region two peaks of 
high sequence diversity correspond to highly conserved sequence, an unusual pattern 
since high conservation indicates functionality, implying that diversifying selection or 
some kind of adaptive selection, has acted upon this region of the human promoter. 
However the sliding window nucleotide diversity (π) plot shown in figure 6.13a is based 
only on the Ethiopian sample set and therefore further investigations with regard to 
possible diversifying selection would benefit from the inclusion of π measurements for 
various populations around the world.  
 
The sliding window plots created for nucleotide diversity (π) are very effective for 
studying the patterns of diversity across a length of sequence since the an overall 
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calculation of π for the whole sequence will not be truly representative of sequence 
segments that confer different functions. For instance, the first 100bp upstream of a 
genes TSS is of great importance for basal transcription of the gene and therefore 
sequence variants within this region are more likely to be damaging (Buckland et al. 
2005). The sliding windows are also very beneficial for calculations such as Tajima’s D 
since they highlight sequence regions that are more susceptible to selective pressures.  
 
The elevated incidence of the high expressing H1 haplotype within the Ethiopian Anuak 
ethnic group was an interesting but quite unexplained finding. However it is not clear 
why this divergence between the Anuak and other ethnic groups has occurred and 
therefore further studies will be needed to determine whether demographic histories or 
environmental selective pressures have caused the H1 haplotype to reach an elevated 
frequency in the Anuak. It could be interesting to explore and compare the frequency of 
this high expressing haplotype in other linguistically similar populations since the 
Anuak were the only group in this study that speak a Nilo Saharan language. The 
ultimate goal for the future will be to collect samples of Anuak ethnicity that have been 
phenotyped for a particular respiratory disease such as TB or phenotyped for Neisseria 
meningitidis carrier status. These sample sets will form a case-control cohort which will 
be typed for the MUC5B proximal promoter haplotypes. Significant associations could 
then be explored with respect to MUC5B promoter variation and respiratory disease 
susceptibility.  
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7 General Discussion 
 
The principal aim of this project was to examine genetic variation within MUC5AC and 
MUC5B in relation to respiratory disease and demography. Since these genes code for 
the major components of airway mucus, they are prime candidates for genetic studies on 
susceptibility and severity of inflammatory respiratory disease. 
 
The first results chapter of this thesis reports significant associations between a 
synonymous SNP in the 3′ end of MUC5AC and five allergy related respiratory 
outcomes, bronchitis, wheeze, allergy, hayfever and asthma, in a European longitudinal 
birth cohort. Since these outcomes are not independent because their symptoms are 
overlapping, it is not surprising that several show significance. It is important to 
highlight here that the allergy and hayfever outcomes showed the highest level of 
significance with this MUC5AC variant. It should however be noted that this MUC5AC 
exonic SNP does not alter an amino acid and is therefore not considered to be causative, 
but was chosen at the outset of this project due to a paucity of validated SNPs. The 
original plan had been to select MUC5AC markers likely to be functional or that would 
give greater coverage as tagging SNPs, to type on the 1946 cohort. However this aim 
could not be fulfilled during the course of this project since there has been a slow 
progression of MUC5AC research in the literature and a slow accumulation of 
interesting SNPs in the database. It therefore appeared to be more beneficial to explore 
the causes of the deviations from HWE that had become evident when the datasets were 
segregated into affected and unaffected groups with respect to allergy and hayfever, 
since these results are indicative of CNV which had the potential to be the undiscovered 
genetic factor causing the significant associations between MUC5AC and allergic 
phenotypes. However the notion of CNV could not be supported experimentally.  
 
In any genetic association study like this, there is a risk of false positive results. This 
risk is amplified when testing multiple loci simultaneously and the significant 
associations we see would not stand up to Bonferroni correction. However this issue is 
of less concern in this project than for example in genomewide studies, since all the 
research is hypothesis driven, for instance, the multiple MUC5AC/inflammatory gene-
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gene interaction studies reported in chapter 3, considered only polymorphisms with 
evidence of functional effect and of genes encoding proteins with likely biological 
effect on MUC5AC. 
 
As an independent test for the robustness of the associations reported between 
MUC5AC and the various allergy related respiratory outcomes, a permutation test was 
used which confirmed the significant associations. Since the sample set under 
investigation was longitudinal, information was also available for various lifestyle and 
environmental factors such as social class, smoking history, sex and region of birth. 
These factors are potentially ‘confounders’ since they have the ability to influence the 
outcomes under study and may cause false positive associations. They were therefore 
included in the regression models as a method to adjust for these potential confounders.  
 
The mucin genes directly upstream and downstream of MUC5AC, MUC2 and MUC5B, 
were also typed for variants in the longitudinal cohort and tested for association with 
various respiratory outcomes. However, very little evidence was obtained for any 
association of MUC2 or MUC5B even though LD across this region was confirmed.  
 
The same MUC5AC variant (rs1132440) has also been typed in two small asthmatic 
cohorts in the second results chapter, but no association could be detected in either case-
control disease cohort. This is hardly surprising since the effect size is much smaller 
than the longitudinal birth cohort which therefore has more power. The reduced power 
of these asthmatic cohorts may have lead to false negative results especially when 
considering that associations with asthma had only reached borderline significance in 
the large longitudinal cohort. It is however curious that some evidence of association 
was noted between the MUC5AC 3′ end haplotypes and severe asthma.  
 
Although the disease cohorts are considerably smaller than the longitudinal cohort, they 
have the added benefit of being collected in a clinical setting. While the longitudinal 
cohort provides a wealth of data of relevance to respiratory history and possible 
confounders, outcomes are self declared, whereas all asthmatic disease cohort 
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participants have been clinically diagnosed which reduces the problem of phenotypic 
heterogeneity. 
 
Even though there was no significant association of MUC5B exonic SNPs and 
respiratory outcomes in the longitudinal cohort the confirmation that promoter SNPs are 
associated with altered expression of MUC5B (Kamio et al. 2005; Loh  et al. 2010) led 
us to test these as functional variants in the two small asthmatic disease cohorts. This 
project reports here for the first time, significant associations between MUC5B 
promoter variants and severe asthma. The MUC5B H1 haplotype which appears to 
direct high expression both in vivo (Loh  et al. 2010) and in vitro (Kamio et al. 2005), is 
significantly underrepresented in the severe asthmatic cases as compared to the non-
asthmatic control samples, implying that the H1 haplotype confers protection against 
the development of asthma. This association is somewhat counter-intuitive since one 
might expect an increase in the incidence of high expressing haplotypes in 
hypersecretory disease sample sets. However, previous in vivo studies on the MUC5B 
promoter have been based only on constitutive expression levels in fetuses (Loh  et al. 
2010) and therefore may not be true for the adult respiratory epithelium particularly 
after environmental challenge. In order to further understand facultative expression 
levels of the different MUC5B promoter haplotypes, one might perform similar RT-
PCR experiments on surgical biopsy tissue from adults with asthma and controls, 
though such tissue is hard to obtain. It would also be interesting to culture cells grown at 
air liquid interface, from individuals (asthmatic and not) with the various MUC5B 
haplotypes and compare MUC5B expression levels upon exposure to various challenges 
or rather known asthmatic triggers. It could be suggested that a subtle enhancement of 
MUC5B production may give the airway mucus greater protective properties and 
produce a mucosal barrier that is more efficient at excluding inflammatory stimulators, 
while perhaps over-production clogs the airways 
 
It should be noted that the MUC5B rs7115457 variant which determines the H1 
haplotype and is significantly associated with severe asthma (chapter 4), is located 
within a suggested NFκB transcription binding site (Chen et al. 2001). If the genetic 
variant abolishes the NFκB binding site then we might expect the facultative promoter 
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dynamics to become rather complicated when challenged by environmental insults. For 
instance, by reducing the binding of NFκB to the promoter, other transcription factors 
may be able to bind to the DNA more efficiently. It should be remembered that the 
transcription factors driving expression of a gene do not act independently but instead 
act in concert with each other and environmental cues, in a complexed dynamic process. 
Thus the MUC5B haplotype expression data collected from constitutive in vivo fetal 
studies and in vitro reporter construct assays may not be representative of the complex 
dynamics of the adult MUC5B promoter response. Nevertheless the observation of 
difference in expression in fetuses implies that this SNP can be functional in vivo.  
 
In the final results chapter, the distribution of the H1 MUC5B promoter haplotype was 
also shown to be significantly different between Ethiopian ethnic groups. The western 
Ethiopian Anuak peoples have a significantly greater incidence of H1 compared to four 
other Ethiopian ethnicities. The Anuak live on lowland river banks in western Ethiopia 
which is a distinct geographic region from all other groups examined and it is therefore 
interesting to speculate that environmental specific protective properties of this 
haplotype have lead to high levels of H1 through positive selection. Meningococcal 
meningitis and tuberculosis endemics are known to be particularly prevalent in the 
region inhabited by the Anuak and since infection is likely to drive selection it is 
interesting to speculate that the high incidence of H1 may be a consequence of adaptive 
protection against respiratory infection. 
 
Characterisation of the MUC5B promoter in an African sample set (n = 745) has 
identified a total of 15 variants within the 1kb sequence upstream of the transcription 
start site, 7 of which have not been previously identified and are reported here for the 
first time in this study. This would appear to be a very high level of diversity, and 
contrast with a preliminary study of the MUC5AC promoter in an Ethiopian sample (n = 
378), whereby only two SNPs were discovered within the upstream one kilobase 
sequence. However the functional significance of these novel regulatory SNPs is not 
known and therefore functional studies such as luciferase assays, electrophoretic 
mobility shift assays, chromosome immunoprecipitation or in vivo heterozygote exonic 
SNP tagging methods using RNA transcripts, will need to follow.  
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Perhaps the most interesting novel SNP is the variant at position -194 since it falls 
within an experimentally determined Sp1 binding site. It is also noteworthy that the 
high levels of nucleotide diversity within the few hundred bases directly upstream of the 
TSS, corresponds to high levels of primate species conservation which indicates a 
region of functional importance. The accumulation and maintenance of variants within 
this functional region is indicative of balancing selection which might suggest that 
MUC5B promoter diversity has been beneficial. This phenomenon is typical of genes 
that respond to infectious agents, since different pathogens are prevalent in different 
geographic regions and thus changes are often in parallel with alterations in 
environment over time. Also pathogens are continuously evolving and it is therefore 
advantageous for genetic diversity to exist within the population in order to maximise 
the chance of survival for at least a small number of individuals. 
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8 Appendices 
 
Appendix 1- Genotyping of non-mucin genetic markers – 
conducted by Lynne Vinall  
 
IL1β rs16944 
 
Genotyped using standard PCR conditions with RFLP with BsobI.  
 
PCR primers 
Forward 5′ GATTGGCTAGGGTAACAGCACC 3′ (1946-IL1B-C) 
Reverse 5′ GGGACAAAGTGGAAGACACACA 3′ 
 
 
IL1RN (tandem repeat) 
 
Standard PCR conditions were used for this assay and visualisation of the PCR product 
by agarose gel electrophoresis was used to infer allele sizes. 
 
PCR primer 
Forward 5′ CTCAGCAACACTCCTA 3′ 
Reverse 5′ TCCTGGTCTGCAGGTAA 3′ 
 
 
TNF-α rs1800629 
 
A tetra primer arms PCR was used for this assay and visualisation of the PCR product 
by agarose gel electrophoresis was used to infer SNP genotypes. The four primers, 
A,B,C and D were added at a ratio of 20:1:1:2 respectively.  
 
Outer PCR primers 
Forward – TNFA-C 5′ACCCAAACACAGGCCTCAGGACTCAACA 3′ 
Reverse – TNFA-D 5′AGTTGGGGACACGCAAGCATGAAGGATA 3′ 
 
Inner PCR primers 
Forward – TNFA-A 5′TGGAGGCAATAGGTTTTGAGGGGCAGGA 3′ 
Reverse – TNFA-B 5′ TAGGACCCTGGAGGCTGAACCCCGTACC 3′ 
 
 
EGFR SNP (rs2227983) and EGFR microsatellite 
 
The EGFR SNP and microsatellite/CA repeat were genotyped as a multiplex.  
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Primers for SNP PCR product 
Forward 5′ CAAGGTCATGGAGCACAGG 3′ (CY5) 
Reverse 5′ CTGACATTCCGGCAAGAGAC 3′ 
 
Primers for the CA repeat 
Forward 5′ CTCAAGGTTGGAATTGTGC 3′ 
Reverse 5′ GCTGTTTGAAGAATTTGAGC 3′ (CY5) 
 
RFLP using AlwNI was used to genotype the SNP. The CA repeat could be genotyped 
on the basis of PCR product size.  
 
The SNP digest product and the CA repeat PCR product were visualised together on the 
ALF Express™  
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Original 
Variable 
Question asked Original outcome codes Recoded  
Variable  
Recoded outcome codes 
ALLG89 Have you ever had an allergy (1946-1989)? 0 – No 
1 – Yes, once 
2 – Yes, recurring 
EVALLERG 0 – Never (original code 0) 
1 – Ever (original codes 1 or 2) 
ASTH89 Have you ever had asthma (1946-1989)? 0 – No 
1 – Yes, once 
2 – Yes, recurring 
EVASTHM 0 – Never (original code 0) 
1 – Ever (original codes 1 or 2) 
BRONC89 Have you ever had bronchitis (1989-1999)?  0 – No 
1 – Yes, once 
2 – Yes, recurring 
BRONC89R 0 – Never (original code 0) 
1 – Ever (original codes 1 or 2) 
HAY89 
 
Have you ever had hay fever (1946-1989) 0 – No 
1 – Yes, once 
2 – Yes, recurring 
EVHAY 
- 
0 – Never (original code 0) 
1 – Ever (original codes 1 or 2) 
- 
HAYF In the last ten years (1989-1999), did you have 
hay fever? 
1 – Yes 
2 – No 
  
LRIP Have you ever had a lower respiratory infection 
(i.e. bronchitis, broncho pneumonia or 
pneumonia) in early childhood (0 to 24 mths)? 
0 – No attacks of LRI  
1 – One attack; no treatment sought 
2 – One attack; saw private doctor 
or was hospital out-patient  
3 – One attack; was in-patient at 
hospital/nursing home  
4 – More than one attack; no 
treatment sought 
5 – More than one attack; saw 
private doctor or was hospital out-
patient  
6 – More than one attack; was in-
patient at hospital/nursing home  
LRIPY 0 – Never (original code 0)  
1– Ever (original codes 1-6) 
Has your chest ever sounded wheezy or whistling 
(1946-1989)? 
0 – No 
1 – Yes 
WZY89 
Did you get this most days (or nights)? 0 – No 
1 – Yes 
WZY89C 0 – No or  not most days or nights  
1 – Yes, most days or nights   
FEVM89 Max FEV1 reading when participant was 43 yrs 
old. 
- FEVM89C  Outliers removed: 0.01 – 1.00 
litres 
FEVM99 Max FEV1 reading when participant was 53 yrs - FEVM99D Outliers removed: 0.00 - 0.07, 
Appendix 2 
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Table 1  Respiratory measures and outcomes studied in the 1946 birth cohort. Questionnaire data was converted to outcome codes for analysis. 
Some of these codes were recoded, both are shown in the table. Table adapted from Andrew Loh’s thesis (Loh  2007).  
 
 
 
 
 
 
 
old. 0.31 - 1.00, 9.70 – 9.99 litres  
FEVM89C 
– 
FEVM99D 
Difference in Max FEV1 over 10 years  
(1989-1999). 
- DELTA - 
ALLERGY In the last ten years (1989-1999), have you had 
any allergies? 
1 – Yes 
2 – No 
- - 
ASTHMA In the last ten years (1989-1999), did you have 
asthma? 
1 – Yes 
2 – No 
-  
BRONC During the past 3 years (1997-1999), did you 
have any chest illness, such as bronchitis or 
pneumonia, which kept you off work or indoors for 
a week or more? 
1 – Yes 
2 – No 
- - 
Has your chest ever sounded wheezy or whistling 
(1946-1999)? 
1 – Yes 
2 – No 
WZY 
Did you get this most days (or nights)? 1 – Yes 
2 – No 
WZYC 0 – No or  not most days or nights  
1 – Yes, most days or nights   
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Original Variable Question asked Original outcome codes Recoded  
Variable  
Recoded outcome codes 
CIG89C Do you smoke cigarettes? Question was 
asked in 1966, 1971, 1977, 1982 and 
1989. 
1 – Currently smoking  
2 – Ex-smoker   
3 – Never smoked  
CIG89CR Never (code 3) → 0 
Ever (codes 1 or 2) → 1 
CIG99C Do you smoke cigarettes? Question 
asked in 1966, 1971, 1977, 1982, 1989 
and 1999. 
1 – Currently smoking  
2 – Ex-smoker   
3 – Never smoked 
CIG99CR  Never (code 3) → 0 
Ever (codes 1 or 2) → 1 
FSC50C Participant’s father’s social class at age 
4, inferred from father’s occupation 
1– Professional  
2 – Intermediate 
3 – Skilled (non-manual)  
4 – Skilled (manual)  
5 – Partly skilled  
6 – Unskilled  
FSC50R Non-manual job (codes 1- 3) → 0 
Manual job (codes 4-6) → 1 
REG46AR Participant’s region of birth 1 – Scotland  
2 – North  
3 – Central  
4 – London + S.Eastern  
- - 
SCL89C Participant’s own social class at age 43, 
inferred from subject’s occupation 
1– Professional  
2 – Intermediate 
3 – Skilled (non-manual)  
4 – Skilled (manual)  
5 – Partly skilled  
6 – Unskilled  
SCL89CR Non-manual job (codes 1- 3) → 0 
Manual job (codes 4-6) → 1  
SEXX Sex of participant 1 – Male 
2 – Female 
SEXXR Male – 0 
Female – 1 
SCL99C Participant’s own social class at age 53, 
inferred from subject’s occupation 
1– Professional  
2 – Intermediate 
3 – Skilled (non-manual)  
4 – Skilled (manual)  
5 – Partly skilled  
6 – Unskilled  
SCL99CR Non-manual job (codes 1- 3) → 0 
Manual job (codes 4-6) → 1 
Table 2  Potential confounder variables studied in the 1946 birth cohort. Questionnaire data was converted to outcome codes for analysis. Some 
of these codes were recoded, both are shown in the table. Table adapted from Andrew Loh’s thesis (Loh  2007)
 204 
Appendix 3 
 
 
ggggagtctggcccaccctccagaccatcctcaaggcccactggcccaggcatccccgcc 
 
cacccctcccaccgtgccgtgctgcagcgggtctaccggcctggatgtgaaagagagctt 
 
ggagaccccagagacctcggaaccttcagctttggaagtgacgtcggtggggtgggtggg 
                                          -2019            -2002 
gggggcacaggctctggagtcccggaagtgagcggggagctaYgctgagatctgggagaY 
                                     rs11042646       rs55974837 
     -1996                                            -1947 
cccctKcccccacccaggtacagggccaggcagaagcccgaggtgtgccctgagKtaaag 
     rs35619543                                       rs12804004 
aaaccgtcacaaagaacaaagggagaaggcgggttccagcctccaccacagccctcgcgc 
 
tctgaggagccacctgggggcctcagccatgaggggtgacaggtggcaaaacgggccagc 
 
tccgttcacgtcgctgtgcagctgtctccgccctccatctccagaacgttctcacattcc 
                       -1738 
caagctgaaaccctgtccccatgMaacaccagctcaccatcccctctgccagcccctggc 
                       rs868902 
gcccaccgtccacactccgtctctgcgggtttcatgactccaggggcagcacacgagtgg 
 
cccctcctgcctttgtcctctgtgtccacctgcctcactctgcacagtgtccccagcttc 
                         -1556 
ccccatggagcagcctgggccagccYctccttttcacggctgaaccgtattccaccgcac 
                         rs868903 
ggatcagcctcacgatgctgacccagtcctccgcccagggacacatgggcagcttctgcc 
                        -1437 
tttgtcagtgatgctgctgtggacWtgggtgtgcaaatgtccctcaggacccgccttcag 
                        rs868904 
ttcttctggggacagacccagagtggagttgctggtcacccccaccagcagggcacaggg 
 
ctccgggtccccacgtctctgccaacacttcctacttcctgtgtttcttgatccccgcca 
 
tcctattgagcgtgagacaggtcagaagctttgaagatgggctttcgtcttgtcccagaa 
 
atcccacctctaagaatttaacttcagaaagacaaacgcgggggagctggtgcagggccc 
 
gtgacggggactgtgacgtaaataaaacaacagacctggacaccaccctagggtccccat 
            DISTAL TATA BOX 
 
 
Putative MUC5B distal promoter annotated sequence. The nucleotides highlighted in 
green have been identified in the matched asthmatic cohort. The putative TATA box has 
been highlighted in yellow. 
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Appendix 4 
 
a
b
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Web citations 
 
Ethiopian census 2007 (Summary and statistical report of 2007 population and housing 
census) - http://www.csa.gov.et/pdf/Cen2007_firstdraft.pdf 
Goddard Space Flight NASA - 
http://www.gsfc.nasa.gov/scienceques2001/20020524.htm 
CIA World factbook - https://www.cia.gov/library/publications/the-world-
factbook/geos/et.html 
Ethnologue - http://www.ethnologue.com/web.asp 
13suns - http://www.13suns.com/ 
Heavens Above (Ethiopian elevation levels) - http://www.heavens-
above.com/selecttown.asp?CountryID=ET 
Medicine Net - http://www.medterms.com/script/main/art.asp?articlekey=8578 
WHO Ethiopian TB report -  
http://apps.who.int/globalatlas/predefinedReports/TB/PDF_Files/eth.pdf 
WHO meningococcal meningitis fact sheet - 
http://www.who.int/csr/disease/meningococcal/en/index.html 
WHO Ethiopian HIV report - 
http://apps.who.int/globalatlas/predefinedReports/EFS2008/short/EFSCountryProfiles2
008_ET.pdf)       
Genome completion estimate - http://www.strategicgenomics.com/Genome/index.htm 
Ensembl Assembly and Genebuild - 
http://www.ensembl.org/Homo_sapiens/Info/StatsTable 
Hugo Gene Nomenclature Committee (HGNC)  - www.genenames.org 
Formulae - http://www.statisticssolutions.com/methods-chapter/statistical-tests/mann-
whitney-u-test/ 
 
OMIM - http://www.ncbi.nlm.nih.gov/omim/ 
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